KR20000068177A - 퓨린 유도체 및 항응혈제로서 그의 용도 - Google Patents
퓨린 유도체 및 항응혈제로서 그의 용도 Download PDFInfo
- Publication number
- KR20000068177A KR20000068177A KR1019997001289A KR19997001289A KR20000068177A KR 20000068177 A KR20000068177 A KR 20000068177A KR 1019997001289 A KR1019997001289 A KR 1019997001289A KR 19997001289 A KR19997001289 A KR 19997001289A KR 20000068177 A KR20000068177 A KR 20000068177A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- amino
- optionally
- halo
- substituted
- Prior art date
Links
- 239000003146 anticoagulant agent Substances 0.000 title abstract description 7
- 229940127219 anticoagulant drug Drugs 0.000 title abstract description 7
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title abstract description 3
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 251
- 238000000034 method Methods 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 230000001732 thrombotic effect Effects 0.000 claims abstract description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 447
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 279
- -1 ureido, cyano, guanidino Chemical group 0.000 claims description 230
- 125000000217 alkyl group Chemical group 0.000 claims description 208
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 90
- 229910052739 hydrogen Inorganic materials 0.000 claims description 82
- 239000001257 hydrogen Substances 0.000 claims description 82
- 125000003118 aryl group Chemical group 0.000 claims description 71
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 57
- 125000001188 haloalkyl group Chemical group 0.000 claims description 51
- 125000003545 alkoxy group Chemical group 0.000 claims description 50
- 150000002431 hydrogen Chemical class 0.000 claims description 47
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 47
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 45
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 44
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 38
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 38
- 125000001424 substituent group Chemical group 0.000 claims description 37
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 26
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 21
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 208000007536 Thrombosis Diseases 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 11
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 5
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 4
- 150000004678 hydrides Chemical class 0.000 claims description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 4
- XWONPVXAQKMKDM-UHFFFAOYSA-N chembl72527 Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)O)N=2)=C1 XWONPVXAQKMKDM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 55
- IKOPFZLRBYCQSH-UHFFFAOYSA-N chembl305809 Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C(N)=N)O)N=2)=C1 IKOPFZLRBYCQSH-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 45
- 108010074860 Factor Xa Proteins 0.000 description 35
- 108090000190 Thrombin Proteins 0.000 description 26
- 229960004072 thrombin Drugs 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 108010000499 Thromboplastin Proteins 0.000 description 23
- 102000002262 Thromboplastin Human genes 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 239000012131 assay buffer Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 150000003254 radicals Chemical class 0.000 description 18
- 239000012224 working solution Substances 0.000 description 18
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000015271 coagulation Effects 0.000 description 10
- 238000005345 coagulation Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 229960000187 tissue plasminogen activator Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 229940093499 ethyl acetate Drugs 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 125000003107 substituted aryl group Chemical group 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 6
- 239000000010 aprotic solvent Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 102100027378 Prothrombin Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940073584 methylene chloride Drugs 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229940039716 prothrombin Drugs 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 108010054964 H-hexahydrotyrosyl-alanyl-arginine-4-nitroanilide Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- JJZJHXMYCPDNAZ-UHFFFAOYSA-N FC(F)(F)C1=CC(C(=O)N(C)C)=CC(OC=2N=CC=CN=2)=C1 Chemical compound FC(F)(F)C1=CC(C(=O)N(C)C)=CC(OC=2N=CC=CN=2)=C1 JJZJHXMYCPDNAZ-UHFFFAOYSA-N 0.000 description 3
- 108010074105 Factor Va Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- FKDXDPKETBQBJL-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-n,n-dimethylbenzamide Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C=CC=2)C(=O)N(C)C)=N1 FKDXDPKETBQBJL-UHFFFAOYSA-N 0.000 description 2
- HVURHSWXCLZXDV-UHFFFAOYSA-N 3-[2-(2-amino-5-carbamimidoylphenoxy)-9-benzyl-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)N)N=2)=C1 HVURHSWXCLZXDV-UHFFFAOYSA-N 0.000 description 2
- OYNGDRKTHQUQNU-UHFFFAOYSA-N 3-[2-(2-amino-5-cyanophenoxy)-9-benzyl-8-methylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound NC1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N OYNGDRKTHQUQNU-UHFFFAOYSA-N 0.000 description 2
- UGJGTEOWLFBMGU-UHFFFAOYSA-N 3-[5-amino-4-(benzylamino)-6-(5-cyano-2-phenylmethoxyphenoxy)pyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)C(N)=C(NCC=3C=CC=CC=3)N=2)=C1 UGJGTEOWLFBMGU-UHFFFAOYSA-N 0.000 description 2
- JRWBVZWICNIFBM-UHFFFAOYSA-N 3-[6-(benzylamino)-2-methylsulfanyl-5-nitropyrimidin-4-yl]oxy-4-phenylmethoxybenzonitrile Chemical compound [O-][N+](=O)C=1C(OC=2C(=CC=C(C=2)C#N)OCC=2C=CC=CC=2)=NC(SC)=NC=1NCC1=CC=CC=C1 JRWBVZWICNIFBM-UHFFFAOYSA-N 0.000 description 2
- XHMKZFKAMGRQCV-UHFFFAOYSA-N 3-[6-(benzylamino)-2-methylsulfanyl-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound [O-][N+](=O)C=1C(OC=2C=C(C=CC=2)C(=O)N(C)C)=NC(SC)=NC=1NCC1=CC=CC=C1 XHMKZFKAMGRQCV-UHFFFAOYSA-N 0.000 description 2
- SEYDIAFHKCDPSK-UHFFFAOYSA-N 3-[6-(benzylamino)-2-methylsulfonyl-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 SEYDIAFHKCDPSK-UHFFFAOYSA-N 0.000 description 2
- GSLQKOAZKZWYLC-UHFFFAOYSA-N 3-[[2-(2-amino-5-carbamimidoylphenoxy)-8-methyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C(=CC=C(C=3)C(N)=N)N)N=2)=C1 GSLQKOAZKZWYLC-UHFFFAOYSA-N 0.000 description 2
- FSQMPCDVHKXAAP-UHFFFAOYSA-N 3-[[2-(2-amino-5-cyanophenoxy)-8-methyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound NC1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N FSQMPCDVHKXAAP-UHFFFAOYSA-N 0.000 description 2
- FIOCQLJNFKYRBV-UHFFFAOYSA-N 3-[[3,5-diamino-2-(2-amino-5-cyanophenoxy)-6-benzyl-2H-pyrimidin-4-yl]oxy]-N,N-dimethylbenzamide Chemical compound NC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N FIOCQLJNFKYRBV-UHFFFAOYSA-N 0.000 description 2
- TULKODADVOEVTR-UHFFFAOYSA-N 3-hydroxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(O)=C1 TULKODADVOEVTR-UHFFFAOYSA-N 0.000 description 2
- GHAWBARMICSLQS-UHFFFAOYSA-N 4,6-dichloro-2-methylsulfanyl-5-nitropyrimidine Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(Cl)=N1 GHAWBARMICSLQS-UHFFFAOYSA-N 0.000 description 2
- KOIUPWQSMUFAHI-UHFFFAOYSA-N 4-phenylmethoxy-3-pyrimidin-2-yloxybenzonitrile Chemical compound C(C1=CC=CC=C1)OC1=C(OC2=NC=CC=N2)C=C(C=C1)C#N KOIUPWQSMUFAHI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 108010054265 Factor VIIa Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229940039715 human prothrombin Drugs 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940102396 methyl bromide Drugs 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 2
- 229940043349 potassium metabisulfite Drugs 0.000 description 2
- 235000010263 potassium metabisulphite Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108010014806 prothrombinase complex Proteins 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VUAOGLPPRVZFCH-UHFFFAOYSA-N tert-butyl 2-cyano-5-pyrimidin-2-yloxybenzoate Chemical compound C(C)(C)(C)OC(=O)C=1C=C(OC2=NC=CC=N2)C=CC=1C#N VUAOGLPPRVZFCH-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229960003766 thrombin (human) Drugs 0.000 description 2
- 108010065972 tick anticoagulant peptide Proteins 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- DMNNGTXKFARCTR-UHFFFAOYSA-N 2-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzamide Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C(N)=O)=N1 DMNNGTXKFARCTR-UHFFFAOYSA-N 0.000 description 1
- FHZBSPUEJTZWMC-UHFFFAOYSA-N 2-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzoic acid Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C(O)=O)=N1 FHZBSPUEJTZWMC-UHFFFAOYSA-N 0.000 description 1
- IHCLRYRVYBBYDO-UHFFFAOYSA-N 2-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzamide Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C(N)=O)=N1 IHCLRYRVYBBYDO-UHFFFAOYSA-N 0.000 description 1
- JNBPDBGHFXOTSH-UHFFFAOYSA-N 2-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzoic acid Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C(O)=O)=N1 JNBPDBGHFXOTSH-UHFFFAOYSA-N 0.000 description 1
- BYNZEGUYEARUFL-UHFFFAOYSA-N 2-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzamide Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C(N)=O)=N1 BYNZEGUYEARUFL-UHFFFAOYSA-N 0.000 description 1
- MSWKGDOJEWNPTH-UHFFFAOYSA-N 2-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzoic acid Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C(O)=O)=N1 MSWKGDOJEWNPTH-UHFFFAOYSA-N 0.000 description 1
- RILGBTLQQXDBPN-UHFFFAOYSA-N 2-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-cyanobenzamide Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)C(=O)N)N RILGBTLQQXDBPN-UHFFFAOYSA-N 0.000 description 1
- WTQRSMLDZMIJCE-UHFFFAOYSA-N 2-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-cyanobenzoic acid Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)C(=O)O)N WTQRSMLDZMIJCE-UHFFFAOYSA-N 0.000 description 1
- VMZIKCYILYWVCX-UHFFFAOYSA-N 2-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-cyanobenzamide Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)C(=O)N)N VMZIKCYILYWVCX-UHFFFAOYSA-N 0.000 description 1
- FLBAAKAEHAGJHV-UHFFFAOYSA-N 2-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-cyanobenzoic acid Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)C(=O)O)N FLBAAKAEHAGJHV-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JETXINPXYACJTF-UHFFFAOYSA-N 2-[2-(2-tert-butyl-5-carbamimidoylphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-(2,3-dihydro-1h-indol-3-yl)propanoic acid Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CC4C5=CC=CC=C5NC4)C(O)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(C)(C)C)N=2)=C1 JETXINPXYACJTF-UHFFFAOYSA-N 0.000 description 1
- QAALHCGXLRSSFS-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-chlorophenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-phenylpropanoic acid Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CC=4C=CC=CC=4)C(O)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)Cl)N=2)=C1 QAALHCGXLRSSFS-UHFFFAOYSA-N 0.000 description 1
- UNURTWPYQGNKQS-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-ethoxyphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-4-methylpentanoic acid Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(N=C(C)N2C(CC(C)C)C(O)=O)C2=N1 UNURTWPYQGNKQS-UHFFFAOYSA-N 0.000 description 1
- MWKBIPQVDAUWFY-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-hydroxyphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]propanoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)O)N=C2N(C(C(O)=O)C)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 MWKBIPQVDAUWFY-UHFFFAOYSA-N 0.000 description 1
- VHDAHNDNGALFMW-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-hydroxyphenoxy)-8-methyl-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-9-yl]butanedioic acid Chemical compound CN1CCN=C1c1cccc(Oc2nc(Oc3cc(ccc3O)C(N)=N)nc3n(C(CC(O)=O)C(O)=O)c(C)nc23)c1 VHDAHNDNGALFMW-UHFFFAOYSA-N 0.000 description 1
- RIPKTNINCOJCAW-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-methoxyphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-methylbutanoic acid Chemical compound COC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(N=C(C)N2C(C(C)C)C(O)=O)C2=N1 RIPKTNINCOJCAW-UHFFFAOYSA-N 0.000 description 1
- GOBNIAQKNKLMNW-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-methoxyphenoxy)-8-methyl-6-[3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]phenoxy]purin-9-yl]pentanedioic acid Chemical compound COC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(CCC(=O)OC(C)(C)C)C=CC=2)=C(N=C(C)N2C(CCC(O)=O)C(O)=O)C2=N1 GOBNIAQKNKLMNW-UHFFFAOYSA-N 0.000 description 1
- PQAAJGLTEGAAIP-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-methylphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-(4-sulfanylphenyl)propanoic acid Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CC=4C=CC(S)=CC=4)C(O)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C)N=2)=C1 PQAAJGLTEGAAIP-UHFFFAOYSA-N 0.000 description 1
- QPIRXFKMRLQAOO-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-phenoxyphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-methylpentanoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)N=C2N(C(C(O)=O)C(C)CC)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 QPIRXFKMRLQAOO-UHFFFAOYSA-N 0.000 description 1
- BRVWYUDNZRVNFP-UHFFFAOYSA-N 2-[2-(5-carbamimidoyl-2-phenylmethoxycarbonylphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-hydroxybutanoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C(=O)OCC=2C=CC=CC=2)N=C2N(C(C(O)=O)C(O)C)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 BRVWYUDNZRVNFP-UHFFFAOYSA-N 0.000 description 1
- LFUHYQOVOMQHJJ-UHFFFAOYSA-N 2-[3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-methylphenyl]guanidine Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(NC(N)=N)C=C(C)C=2)=N1 LFUHYQOVOMQHJJ-UHFFFAOYSA-N 0.000 description 1
- MMXAFKJZWHYWOG-UHFFFAOYSA-N 2-[3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxyphenyl]guanidine Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(NC(N)=N)C=CC=2)=N1 MMXAFKJZWHYWOG-UHFFFAOYSA-N 0.000 description 1
- UWXWXXWUJMACBS-UHFFFAOYSA-N 2-[3-[2-(2-amino-5-cyanophenoxy)-8,9-diethylpurin-6-yl]oxyphenyl]guanidine Chemical compound NC1=C(OC2=NC(=C3N=C(N(C3=N2)CC)CC)OC2=CC(=CC=C2)NC(=N)N)C=C(C=C1)C#N UWXWXXWUJMACBS-UHFFFAOYSA-N 0.000 description 1
- CJYIYJRLPNZFFQ-UHFFFAOYSA-N 2-[3-[2-(2-amino-5-cyanophenoxy)-9-benzyl-8-methylpurin-6-yl]oxyphenyl]guanidine Chemical compound NC1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)NC(=N)N)C=C(C=C1)C#N CJYIYJRLPNZFFQ-UHFFFAOYSA-N 0.000 description 1
- RYWLYSGBVLURCY-UHFFFAOYSA-N 2-[3-[4,5-diamino-6-[4-cyano-3-(dimethylamino)phenoxy]pyrimidin-2-yl]oxyphenyl]guanidine Chemical compound C1=C(C#N)C(N(C)C)=CC(OC=2C(=C(N)N=C(OC=3C=C(NC(N)=N)C=CC=3)N=2)N)=C1 RYWLYSGBVLURCY-UHFFFAOYSA-N 0.000 description 1
- QGKGPWTXBJUFEL-UHFFFAOYSA-N 2-[3-[4,5-diamino-6-[5-cyano-2-(dimethylamino)phenoxy]pyrimidin-2-yl]oxyphenyl]guanidine Chemical compound CN(C)C1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(NC(N)=N)C=CC=2)=NC(N)=C1N QGKGPWTXBJUFEL-UHFFFAOYSA-N 0.000 description 1
- QUEBQGGALSIMQX-UHFFFAOYSA-N 2-[3-[4-amino-6-[4-cyano-3-(dimethylamino)phenoxy]-5-nitropyrimidin-2-yl]oxyphenyl]guanidine Chemical compound C1=C(C#N)C(N(C)C)=CC(OC=2C(=C(N)N=C(OC=3C=C(C=CC=3)N=C(N)N)N=2)[N+]([O-])=O)=C1 QUEBQGGALSIMQX-UHFFFAOYSA-N 0.000 description 1
- RXDBFICQMZJXHC-UHFFFAOYSA-N 2-[3-[4-amino-6-[5-cyano-2-(dimethylamino)phenoxy]-5-nitropyrimidin-2-yl]oxyphenyl]guanidine Chemical compound CN(C)C1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)N=C(N)N)=NC(N)=C1[N+]([O-])=O RXDBFICQMZJXHC-UHFFFAOYSA-N 0.000 description 1
- XTKWHFKCWFZPIU-UHFFFAOYSA-N 2-[3-[6-(benzylamino)-2-(5-cyano-2-nitrophenoxy)-5-nitropyrimidin-4-yl]oxyphenyl]guanidine Chemical compound NC(N)=NC1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)[N+]([O-])=O)N=2)[N+]([O-])=O)=C1 XTKWHFKCWFZPIU-UHFFFAOYSA-N 0.000 description 1
- STEPXZYQFQYNJQ-UHFFFAOYSA-N 2-[3-[6-(benzylamino)-2-methylsulfanyl-5-nitropyrimidin-4-yl]oxy-5-methylphenyl]guanidine Chemical compound [O-][N+](=O)C=1C(OC=2C=C(NC(N)=N)C=C(C)C=2)=NC(SC)=NC=1NCC1=CC=CC=C1 STEPXZYQFQYNJQ-UHFFFAOYSA-N 0.000 description 1
- YSPKMGSVCLSPQS-UHFFFAOYSA-N 2-[3-[6-(benzylamino)-2-methylsulfanyl-5-nitropyrimidin-4-yl]oxyphenyl]guanidine Chemical compound [O-][N+](=O)C=1C(OC=2C=C(NC(N)=N)C=CC=2)=NC(SC)=NC=1NCC1=CC=CC=C1 YSPKMGSVCLSPQS-UHFFFAOYSA-N 0.000 description 1
- DUVPNYVNLRKGAC-UHFFFAOYSA-N 2-[3-[6-(benzylamino)-2-methylsulfonyl-5-nitropyrimidin-4-yl]oxy-5-methylphenyl]guanidine Chemical compound NC(N)=NC1=CC(C)=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 DUVPNYVNLRKGAC-UHFFFAOYSA-N 0.000 description 1
- OBXYRBKIKOGDAU-UHFFFAOYSA-N 2-[3-[6-(benzylamino)-2-methylsulfonyl-5-nitropyrimidin-4-yl]oxyphenyl]guanidine Chemical compound [O-][N+](=O)C=1C(OC=2C=C(NC(N)=N)C=CC=2)=NC(S(=O)(=O)C)=NC=1NCC1=CC=CC=C1 OBXYRBKIKOGDAU-UHFFFAOYSA-N 0.000 description 1
- XGUFZWFQYJCKCT-UHFFFAOYSA-N 2-[3-[9-benzyl-6-(5-cyano-2-phenoxyphenoxy)-8-methylpurin-2-yl]oxy-5-methylphenyl]guanidine Chemical compound N1=C(OC=2C=C(C=C(C)C=2)N=C(N)N)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC(C#N)=CC=C1OC1=CC=CC=C1 XGUFZWFQYJCKCT-UHFFFAOYSA-N 0.000 description 1
- TYCFGARSLMKVSM-UHFFFAOYSA-N 2-[3-[[1,5-diamino-4-benzyl-6-(5-cyano-2-phenoxyphenoxy)-2H-pyrimidin-2-yl]oxy]-5-methylphenyl]guanidine Chemical compound N(C(=N)N)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)OC2=CC=CC=C2)N)C=C(C=1)C TYCFGARSLMKVSM-UHFFFAOYSA-N 0.000 description 1
- ORNJSLBUNBNKKD-UHFFFAOYSA-N 2-[3-[[1-amino-4-benzyl-6-(5-cyano-2-phenoxyphenoxy)-5-nitro-2H-pyrimidin-2-yl]oxy]-5-methylphenyl]guanidine Chemical compound N(C(=N)N)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)OC2=CC=CC=C2)N)C=C(C=1)C ORNJSLBUNBNKKD-UHFFFAOYSA-N 0.000 description 1
- YZBODTFMNGQGSP-UHFFFAOYSA-N 2-[3-[[2-(2-amino-5-cyanophenoxy)-8-methyl-7H-purin-6-yl]oxy]phenyl]guanidine Chemical compound NC1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)NC(=N)N)C=C(C=C1)C#N YZBODTFMNGQGSP-UHFFFAOYSA-N 0.000 description 1
- NFAOLWQKIFQWJW-UHFFFAOYSA-N 2-[3-[[3,5-diamino-2-(2-amino-5-cyanophenoxy)-6-benzyl-2H-pyrimidin-4-yl]oxy]phenyl]guanidine Chemical compound NC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)NC(=N)N)N)C=C(C=C1)C#N NFAOLWQKIFQWJW-UHFFFAOYSA-N 0.000 description 1
- PYQMFHACSXZLPP-UHFFFAOYSA-N 2-[3-[[6-[4-cyano-3-(dimethylamino)phenoxy]-8-methyl-7h-purin-2-yl]oxy]phenyl]guanidine Chemical compound C1=C(C#N)C(N(C)C)=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C=C(NC(N)=N)C=CC=3)N=2)=C1 PYQMFHACSXZLPP-UHFFFAOYSA-N 0.000 description 1
- ZIMSGNXYOOLNIY-UHFFFAOYSA-N 2-[3-[[6-[5-cyano-2-(dimethylamino)phenoxy]-8-ethyl-7h-purin-2-yl]oxy]phenyl]guanidine Chemical compound N=1C(OC=2C(=CC=C(C=2)C#N)N(C)C)=C2NC(CC)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 ZIMSGNXYOOLNIY-UHFFFAOYSA-N 0.000 description 1
- AJKOCIFPOSOOJC-UHFFFAOYSA-N 2-[3-[[6-[5-cyano-2-(dimethylamino)phenoxy]-8-methyl-7h-purin-2-yl]oxy]phenyl]guanidine Chemical compound CN(C)C1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(NC(N)=N)C=CC=2)=NC2=C1NC(C)=N2 AJKOCIFPOSOOJC-UHFFFAOYSA-N 0.000 description 1
- YBMOWRRAJSJAJY-UHFFFAOYSA-N 2-[4-(benzylamino)-5-nitro-6-(3-nitrophenoxy)pyrimidin-2-yl]oxy-4-cyano-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(C#N)C=C1OC1=NC(NCC=2C=CC=CC=2)=C([N+]([O-])=O)C(OC=2C=C(C=CC=2)[N+]([O-])=O)=N1 YBMOWRRAJSJAJY-UHFFFAOYSA-N 0.000 description 1
- PJCXNJMOSYIHJR-UHFFFAOYSA-N 2-[4-(benzylamino)-6-[3-(carbamoylamino)phenoxy]-5-nitropyrimidin-2-yl]oxy-4-cyanobenzoic acid Chemical compound NC(=O)NC1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)C(O)=O)N=2)[N+]([O-])=O)=C1 PJCXNJMOSYIHJR-UHFFFAOYSA-N 0.000 description 1
- UUCNWJKROVLIPC-UHFFFAOYSA-N 2-[4-(benzylamino)-6-[3-(dimethylcarbamoyl)phenoxy]-5-nitropyrimidin-2-yl]oxy-4-cyano-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(C#N)C=C1OC1=NC(NCC=2C=CC=CC=2)=C([N+]([O-])=O)C(OC=2C=C(C=CC=2)C(=O)N(C)C)=N1 UUCNWJKROVLIPC-UHFFFAOYSA-N 0.000 description 1
- QQZHELKTDJDOEI-UHFFFAOYSA-N 2-[4-(benzylamino)-6-[3-(dimethylcarbamoyl)phenoxy]-5-nitropyrimidin-2-yl]oxy-4-cyanobenzoic acid Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)C(O)=O)N=2)[N+]([O-])=O)=C1 QQZHELKTDJDOEI-UHFFFAOYSA-N 0.000 description 1
- XVQIGAOIVJAHGT-UHFFFAOYSA-N 2-[6-(3-aminophenoxy)-8,9-diethylpurin-2-yl]oxy-4-carbamimidoyl-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(N)C=CC=2)=C(N=C(CC)N2CC)C2=N1 XVQIGAOIVJAHGT-UHFFFAOYSA-N 0.000 description 1
- AAIYARHNCAWHCN-UHFFFAOYSA-N 2-[6-(3-aminophenoxy)-8,9-diethylpurin-2-yl]oxy-4-cyano-N,N-diethylbenzamide Chemical compound C(C)N(C(=O)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC)CC)OC2=CC(=CC=C2)N)C=C(C=C1)C#N)CC AAIYARHNCAWHCN-UHFFFAOYSA-N 0.000 description 1
- RDADEGAKXAXBKW-UHFFFAOYSA-N 2-[6-(3-aminophenoxy)-9-benzyl-8-methylpurin-2-yl]oxy-4-carbamimidoyl-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(N)C=CC=2)=C(N=C(C)N2CC=3C=CC=CC=3)C2=N1 RDADEGAKXAXBKW-UHFFFAOYSA-N 0.000 description 1
- XOPPQTNNHLMTLC-UHFFFAOYSA-N 2-[6-[3-(carbamoylamino)phenoxy]-8,9-diethylpurin-2-yl]oxy-4-cyanobenzoic acid Chemical compound C(=O)(O)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC)CC)OC2=CC(=CC=C2)NC(=O)N)C=C(C=C1)C#N XOPPQTNNHLMTLC-UHFFFAOYSA-N 0.000 description 1
- OQXJYKPHDHPAIB-UHFFFAOYSA-N 2-[6-amino-2-[3-(diaminomethylideneamino)phenoxy]-5-nitropyrimidin-4-yl]oxy-4-cyanobenzamide Chemical compound NC(=N)NC1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)C(N)=O)C(=C(N)N=2)[N+]([O-])=O)=C1 OQXJYKPHDHPAIB-UHFFFAOYSA-N 0.000 description 1
- BVJMFZJBGIDGPC-UHFFFAOYSA-N 2-[6-amino-2-[3-(diaminomethylideneamino)phenoxy]-5-nitropyrimidin-4-yl]oxy-4-cyanobenzoic acid Chemical compound NC(=N)NC1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)C(O)=O)C(=C(N)N=2)[N+]([O-])=O)=C1 BVJMFZJBGIDGPC-UHFFFAOYSA-N 0.000 description 1
- VFNBHFNEAAGWDC-UHFFFAOYSA-N 2-[9-(1-amino-3-hydroxy-1-oxopropan-2-yl)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-2-yl]oxy-4-carbamimidoylbenzoic acid Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CO)C(N)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(O)=O)N=2)=C1 VFNBHFNEAAGWDC-UHFFFAOYSA-N 0.000 description 1
- LUKGJINFYQNZOF-UHFFFAOYSA-N 2-[9-benzyl-6-[3-(carbamoylamino)phenoxy]-8-methylpurin-2-yl]oxy-4-carbamimidoylbenzoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C(O)=O)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC=CC(NC(N)=O)=C1 LUKGJINFYQNZOF-UHFFFAOYSA-N 0.000 description 1
- VOXCOBSTIIAUJE-UHFFFAOYSA-N 2-[9-benzyl-6-[3-(carbamoylamino)phenoxy]-8-methylpurin-2-yl]oxy-4-cyanobenzoic acid Chemical compound C(=O)(O)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)NC(=O)N)C=C(C=C1)C#N VOXCOBSTIIAUJE-UHFFFAOYSA-N 0.000 description 1
- NGYMSIGSAOKFRX-UHFFFAOYSA-N 2-[9-benzyl-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-2-yl]oxy-4-carbamimidoyl-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(N=C(C)N2CC=3C=CC=CC=3)C2=N1 NGYMSIGSAOKFRX-UHFFFAOYSA-N 0.000 description 1
- PXKYESDODHUOEL-UHFFFAOYSA-N 2-[9-benzyl-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-2-yl]oxy-4-carbamimidoylbenzoic acid Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(O)=O)N=2)=C1 PXKYESDODHUOEL-UHFFFAOYSA-N 0.000 description 1
- ZFTBXZVCOULZSB-UHFFFAOYSA-N 2-[9-benzyl-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-2-yl]oxy-4-cyanobenzoic acid Chemical compound C(=O)(O)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N ZFTBXZVCOULZSB-UHFFFAOYSA-N 0.000 description 1
- MFVHXLQNUIIJMS-UHFFFAOYSA-N 2-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-carbamimidoylbenzamide Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C(N)=N)C(N)=O)N=2)=C1 MFVHXLQNUIIJMS-UHFFFAOYSA-N 0.000 description 1
- MIUROZYENOKTNL-UHFFFAOYSA-N 2-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-carbamimidoylbenzoic acid Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C(N)=N)C(O)=O)N=2)=C1 MIUROZYENOKTNL-UHFFFAOYSA-N 0.000 description 1
- RLCSNYSPRSPYHH-UHFFFAOYSA-N 2-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-cyanobenzamide Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C#N)C(N)=O)N=2)=C1 RLCSNYSPRSPYHH-UHFFFAOYSA-N 0.000 description 1
- KARPFQPSLNSUIZ-UHFFFAOYSA-N 2-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-cyanobenzoic acid Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C#N)C(O)=O)N=2)=C1 KARPFQPSLNSUIZ-UHFFFAOYSA-N 0.000 description 1
- RACZCLUTKDGYNM-UHFFFAOYSA-N 2-[[3-amino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-4-cyanobenzamide Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)C(=O)N)N)C=CC=1 RACZCLUTKDGYNM-UHFFFAOYSA-N 0.000 description 1
- RVNTVKZZIVIAKX-UHFFFAOYSA-N 2-[[3-amino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-4-cyanobenzoic acid Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)C(=O)O)N)C=CC=1 RVNTVKZZIVIAKX-UHFFFAOYSA-N 0.000 description 1
- GLFJYQHBWRQCIN-UHFFFAOYSA-N 2-[[6-(3-aminophenoxy)-8-methyl-7H-purin-2-yl]oxy]-4-cyano-N,N-diethylbenzamide Chemical compound C(C)N(C(=O)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)N)C=C(C=C1)C#N)CC GLFJYQHBWRQCIN-UHFFFAOYSA-N 0.000 description 1
- MQORJRLDVATIBN-UHFFFAOYSA-N 2-[[6-(3-aminophenoxy)-8-methyl-7h-purin-2-yl]oxy]-4-carbamimidoyl-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(N)C=CC=2)=C(NC(C)=N2)C2=N1 MQORJRLDVATIBN-UHFFFAOYSA-N 0.000 description 1
- NCOFSYMDEPUUQI-UHFFFAOYSA-N 2-[[6-[3-(carbamoylamino)phenoxy]-8-methyl-7H-purin-2-yl]oxy]-4-cyanobenzoic acid Chemical compound C(=O)(O)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)NC(=O)N)C=C(C=C1)C#N NCOFSYMDEPUUQI-UHFFFAOYSA-N 0.000 description 1
- XWKWBTSKOMTNPH-UHFFFAOYSA-N 2-[[8-tert-butyl-2-[3-(diaminomethylideneamino)phenoxy]-7h-purin-6-yl]oxy]-4-carbamimidoylbenzoic acid Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)C(O)=O)=C2NC(C(C)(C)C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 XWKWBTSKOMTNPH-UHFFFAOYSA-N 0.000 description 1
- DAMCKMPOCGOAHF-UHFFFAOYSA-N 2-[[8-tert-butyl-2-[3-(diaminomethylideneamino)phenoxy]-7h-purin-6-yl]oxy]-4-cyanobenzoic acid Chemical compound N=1C(OC=2C(=CC=C(C=2)C#N)C(O)=O)=C2NC(C(C)(C)C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 DAMCKMPOCGOAHF-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- LDQGEZOBRQNJFL-UHFFFAOYSA-N 2-carbamimidoyl-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-ethyl-7h-purin-6-yl]oxy]benzamide Chemical compound N=1C(OC=2C=C(C(C(N)=N)=CC=2)C(N)=O)=C2NC(CC)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 LDQGEZOBRQNJFL-UHFFFAOYSA-N 0.000 description 1
- MUWODACCFLODIF-UHFFFAOYSA-N 2-carbamimidoyl-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzamide Chemical compound N=1C(OC=2C=C(C(C(N)=N)=CC=2)C(N)=O)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 MUWODACCFLODIF-UHFFFAOYSA-N 0.000 description 1
- BKTLUMKBFBGWIQ-UHFFFAOYSA-N 2-carbamimidoyl-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzoic acid Chemical compound N=1C(OC=2C=C(C(C(N)=N)=CC=2)C(O)=O)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 BKTLUMKBFBGWIQ-UHFFFAOYSA-N 0.000 description 1
- HSVXHUCUSNMLEO-UHFFFAOYSA-N 2-cyano-5-[5,6-diamino-2-[3-(diaminomethylideneamino)phenoxy]pyrimidin-4-yl]oxybenzamide Chemical compound NC(=N)NC1=CC=CC(OC=2N=C(OC=3C=C(C(C#N)=CC=3)C(N)=O)C(N)=C(N)N=2)=C1 HSVXHUCUSNMLEO-UHFFFAOYSA-N 0.000 description 1
- YJIFBNIAEQCOFX-UHFFFAOYSA-N 2-cyano-5-[5,6-diamino-2-[3-(diaminomethylideneamino)phenoxy]pyrimidin-4-yl]oxybenzoic acid Chemical compound NC(=N)NC1=CC=CC(OC=2N=C(OC=3C=C(C(C#N)=CC=3)C(O)=O)C(N)=C(N)N=2)=C1 YJIFBNIAEQCOFX-UHFFFAOYSA-N 0.000 description 1
- DBXOQTJYSLIWEG-UHFFFAOYSA-N 2-cyano-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-ethyl-7h-purin-6-yl]oxy]benzamide Chemical compound N=1C(OC=2C=C(C(C#N)=CC=2)C(N)=O)=C2NC(CC)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 DBXOQTJYSLIWEG-UHFFFAOYSA-N 0.000 description 1
- WSGMFDLCIJCYCW-UHFFFAOYSA-N 2-cyano-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzamide Chemical compound N=1C(OC=2C=C(C(C#N)=CC=2)C(N)=O)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 WSGMFDLCIJCYCW-UHFFFAOYSA-N 0.000 description 1
- REZNSMDZHVQNBS-UHFFFAOYSA-N 2-cyano-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzoic acid Chemical compound N=1C(OC=2C=C(C(C#N)=CC=2)C(O)=O)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 REZNSMDZHVQNBS-UHFFFAOYSA-N 0.000 description 1
- UVKPXRRYLKCLQR-UHFFFAOYSA-N 2-cyano-5-[[3,5-diamino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-2H-pyrimidin-4-yl]oxy]benzamide Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=C(C=C2)C#N)C(=O)N)N)C=CC=1 UVKPXRRYLKCLQR-UHFFFAOYSA-N 0.000 description 1
- YGFXNTXMTFDFBY-UHFFFAOYSA-N 2-cyano-5-[[3,5-diamino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-2H-pyrimidin-4-yl]oxy]benzoic acid Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=C(C=C2)C#N)C(=O)O)N)C=CC=1 YGFXNTXMTFDFBY-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- CHROPCMKBZZQJH-UHFFFAOYSA-N 2-phenylmethoxybenzonitrile Chemical compound N#CC1=CC=CC=C1OCC1=CC=CC=C1 CHROPCMKBZZQJH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UPUJXWDDFBSLJC-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-(dimethylamino)benzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)N(C)C)=N1 UPUJXWDDFBSLJC-UHFFFAOYSA-N 0.000 description 1
- UAWJXXWYMZWXEO-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-chlorobenzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)Cl)=N1 UAWJXXWYMZWXEO-UHFFFAOYSA-N 0.000 description 1
- OHHMJGJRLNYIBG-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-ethoxybenzonitrile Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(SC)=NC(N)=C1[N+]([O-])=O OHHMJGJRLNYIBG-UHFFFAOYSA-N 0.000 description 1
- LMEIYAIQSYEIMM-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(SC)=NC(N)=C1[N+]([O-])=O LMEIYAIQSYEIMM-UHFFFAOYSA-N 0.000 description 1
- BHCXNBHWKUNDBZ-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-methylbenzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C)=N1 BHCXNBHWKUNDBZ-UHFFFAOYSA-N 0.000 description 1
- HTJPRIPPOQTYIS-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-nitrobenzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)[N+]([O-])=O)=N1 HTJPRIPPOQTYIS-UHFFFAOYSA-N 0.000 description 1
- NINYSEWTGNOKGK-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-phenoxybenzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)OC=2C=CC=CC=2)=N1 NINYSEWTGNOKGK-UHFFFAOYSA-N 0.000 description 1
- HWGZNPGXTJCPSJ-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-bromobenzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C=C(Br)C=2)C#N)=N1 HWGZNPGXTJCPSJ-UHFFFAOYSA-N 0.000 description 1
- PLMPAPFMRJKUOI-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-ethoxybenzonitrile Chemical compound N#CC1=CC(OCC)=CC(OC=2C(=C(N)N=C(SC)N=2)[N+]([O-])=O)=C1 PLMPAPFMRJKUOI-UHFFFAOYSA-N 0.000 description 1
- WWXWZZSUHNFAJD-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-methoxybenzonitrile Chemical compound N#CC1=CC(OC)=CC(OC=2C(=C(N)N=C(SC)N=2)[N+]([O-])=O)=C1 WWXWZZSUHNFAJD-UHFFFAOYSA-N 0.000 description 1
- IPTWSOIMRVLBSW-UHFFFAOYSA-N 3-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-phenoxybenzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C=C(OC=3C=CC=CC=3)C=2)C#N)=N1 IPTWSOIMRVLBSW-UHFFFAOYSA-N 0.000 description 1
- QJCVAGNGWAMLOM-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-(dimethylamino)benzonitrile Chemical compound CN(C)C1=CC=C(C#N)C=C1OC1=NC(S(C)(=O)=O)=NC(N)=C1[N+]([O-])=O QJCVAGNGWAMLOM-UHFFFAOYSA-N 0.000 description 1
- ZRHUXVNGKRTGST-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-chlorobenzonitrile Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)Cl)=N1 ZRHUXVNGKRTGST-UHFFFAOYSA-N 0.000 description 1
- MRRMJVCEVLZYRX-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-ethoxybenzonitrile Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(S(C)(=O)=O)=NC(N)=C1[N+]([O-])=O MRRMJVCEVLZYRX-UHFFFAOYSA-N 0.000 description 1
- QDELEACEINIUTJ-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(S(C)(=O)=O)=NC(N)=C1[N+]([O-])=O QDELEACEINIUTJ-UHFFFAOYSA-N 0.000 description 1
- YWOHUEJRYGHWOE-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1OC1=NC(S(C)(=O)=O)=NC(N)=C1[N+]([O-])=O YWOHUEJRYGHWOE-UHFFFAOYSA-N 0.000 description 1
- RLTJVQKRDPXOCF-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-nitrobenzonitrile Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)[N+]([O-])=O)=N1 RLTJVQKRDPXOCF-UHFFFAOYSA-N 0.000 description 1
- IHBBZIPODUDENZ-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-phenoxybenzonitrile Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)OC=2C=CC=CC=2)=N1 IHBBZIPODUDENZ-UHFFFAOYSA-N 0.000 description 1
- KBCAWGLIACIFHW-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-5-bromobenzonitrile Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C=C(Br)C=2)C#N)=N1 KBCAWGLIACIFHW-UHFFFAOYSA-N 0.000 description 1
- OWSQEIXBAZCNSA-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-5-ethoxybenzonitrile Chemical compound N#CC1=CC(OCC)=CC(OC=2C(=C(N)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 OWSQEIXBAZCNSA-UHFFFAOYSA-N 0.000 description 1
- QJUXZQFHHGPQMB-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-5-methoxybenzonitrile Chemical compound N#CC1=CC(OC)=CC(OC=2C(=C(N)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 QJUXZQFHHGPQMB-UHFFFAOYSA-N 0.000 description 1
- WEBPWYWTGHGHQS-UHFFFAOYSA-N 3-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-5-phenoxybenzonitrile Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C=C(OC=3C=CC=CC=3)C=2)C#N)=N1 WEBPWYWTGHGHQS-UHFFFAOYSA-N 0.000 description 1
- HILPXZXZDFDGKR-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-(dimethylamino)benzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)N(C)C)=N1 HILPXZXZDFDGKR-UHFFFAOYSA-N 0.000 description 1
- UMTMQNUNHMWIOL-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-ethoxybenzonitrile Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(SC)=NC(Cl)=C1[N+]([O-])=O UMTMQNUNHMWIOL-UHFFFAOYSA-N 0.000 description 1
- ITKSWESHLZDKNY-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(SC)=NC(Cl)=C1[N+]([O-])=O ITKSWESHLZDKNY-UHFFFAOYSA-N 0.000 description 1
- ILGGZMIPUJAOBX-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-methylbenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C)=N1 ILGGZMIPUJAOBX-UHFFFAOYSA-N 0.000 description 1
- YIDKCNAYLZKACB-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-nitrobenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)[N+]([O-])=O)=N1 YIDKCNAYLZKACB-UHFFFAOYSA-N 0.000 description 1
- MFKYKKDXZHLYHM-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-phenoxybenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)OC=2C=CC=CC=2)=N1 MFKYKKDXZHLYHM-UHFFFAOYSA-N 0.000 description 1
- QFXQHURZWATZKR-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-phenylmethoxybenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)OCC=2C=CC=CC=2)=N1 QFXQHURZWATZKR-UHFFFAOYSA-N 0.000 description 1
- HFLFTLZEFFPGRH-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-ethoxybenzonitrile Chemical compound N#CC1=CC(OCC)=CC(OC=2C(=C(Cl)N=C(SC)N=2)[N+]([O-])=O)=C1 HFLFTLZEFFPGRH-UHFFFAOYSA-N 0.000 description 1
- LGALENSWKNRWKX-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-methoxybenzonitrile Chemical compound N#CC1=CC(OC)=CC(OC=2C(=C(Cl)N=C(SC)N=2)[N+]([O-])=O)=C1 LGALENSWKNRWKX-UHFFFAOYSA-N 0.000 description 1
- QOXQOHXKIWTEKI-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-nitroaniline Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C=C(N)C=2)[N+]([O-])=O)=N1 QOXQOHXKIWTEKI-UHFFFAOYSA-N 0.000 description 1
- CQAZHRBLGBUZEF-UHFFFAOYSA-N 3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-phenoxybenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C=C(OC=3C=CC=CC=3)C=2)C#N)=N1 CQAZHRBLGBUZEF-UHFFFAOYSA-N 0.000 description 1
- IUGUJVOSJPQAIS-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-(dimethylamino)benzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)N(C)C)N IUGUJVOSJPQAIS-UHFFFAOYSA-N 0.000 description 1
- VCJPPDZYSBNXMQ-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-chlorobenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)Cl)N VCJPPDZYSBNXMQ-UHFFFAOYSA-N 0.000 description 1
- LULCRVMRMFLPPE-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-ethoxybenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)OCC)N LULCRVMRMFLPPE-UHFFFAOYSA-N 0.000 description 1
- OYYLSHHIVUSJAG-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-methoxybenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)OC)N OYYLSHHIVUSJAG-UHFFFAOYSA-N 0.000 description 1
- UHPXPPJZTKWPFN-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-methylbenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)C)N UHPXPPJZTKWPFN-UHFFFAOYSA-N 0.000 description 1
- NNKLPIZBYMWOBW-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-nitrobenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)[N+](=O)[O-])N NNKLPIZBYMWOBW-UHFFFAOYSA-N 0.000 description 1
- SMANTOYPOLPADD-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-phenoxybenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)OC1=CC=CC=C1)N SMANTOYPOLPADD-UHFFFAOYSA-N 0.000 description 1
- NPVKHNHLTZZFOQ-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-5-bromobenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=CC(=C1)C#N)Br)N NPVKHNHLTZZFOQ-UHFFFAOYSA-N 0.000 description 1
- VTMFMOFDLBKGNX-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-5-ethoxybenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=CC(=C1)C#N)OCC)N VTMFMOFDLBKGNX-UHFFFAOYSA-N 0.000 description 1
- XNECHCKTZSHJLB-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-5-methoxybenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=CC(=C1)C#N)OC)N XNECHCKTZSHJLB-UHFFFAOYSA-N 0.000 description 1
- SGRSREVRELOTHK-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-5-phenoxybenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=CC(=C1)C#N)OC1=CC=CC=C1)N SGRSREVRELOTHK-UHFFFAOYSA-N 0.000 description 1
- OPZWRONWQJUKKW-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-(dimethylamino)benzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)N(C)C)N OPZWRONWQJUKKW-UHFFFAOYSA-N 0.000 description 1
- LEKYMALFYCEPQQ-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-chlorobenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)Cl)N LEKYMALFYCEPQQ-UHFFFAOYSA-N 0.000 description 1
- ZAKBRDRGJNFXEO-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-ethoxybenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)OCC)N ZAKBRDRGJNFXEO-UHFFFAOYSA-N 0.000 description 1
- LMOUUFMBVHLGGQ-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-methoxybenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)OC)N LMOUUFMBVHLGGQ-UHFFFAOYSA-N 0.000 description 1
- FJUACJUIUXUJAW-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-methylbenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)C)N FJUACJUIUXUJAW-UHFFFAOYSA-N 0.000 description 1
- VZHSBCLFPLWILO-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-nitrobenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)[N+](=O)[O-])N VZHSBCLFPLWILO-UHFFFAOYSA-N 0.000 description 1
- XCHNKGASMQFKQO-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-phenoxybenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)OC1=CC=CC=C1)N XCHNKGASMQFKQO-UHFFFAOYSA-N 0.000 description 1
- CQLYEWCRMJOPTC-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-5-bromobenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=CC(=C1)C#N)Br)N CQLYEWCRMJOPTC-UHFFFAOYSA-N 0.000 description 1
- YGTIIOILCIVFFZ-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-5-ethoxybenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=CC(=C1)C#N)OCC)N YGTIIOILCIVFFZ-UHFFFAOYSA-N 0.000 description 1
- WGQMNVCSOPZXMW-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-5-methoxybenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=CC(=C1)C#N)OC)N WGQMNVCSOPZXMW-UHFFFAOYSA-N 0.000 description 1
- PLSGFYZPQXYHBI-UHFFFAOYSA-N 3-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-5-phenoxybenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=CC(=C1)C#N)OC1=CC=CC=C1)N PLSGFYZPQXYHBI-UHFFFAOYSA-N 0.000 description 1
- NEPUFMNQRHZERC-UHFFFAOYSA-N 3-[2-(2-amino-5-carbamimidoylphenoxy)-8,9-diethylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)N)N=C2N(CC)C(CC)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 NEPUFMNQRHZERC-UHFFFAOYSA-N 0.000 description 1
- QZCWNJCNGMMFMJ-UHFFFAOYSA-N 3-[2-(2-amino-5-carbamimidoylphenoxy)-9-[1-amino-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CC=4N=CNC=4)C(N)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)N)N=2)=C1 QZCWNJCNGMMFMJ-UHFFFAOYSA-N 0.000 description 1
- SUQOPVVJRTWBLY-UHFFFAOYSA-N 3-[2-(2-amino-5-cyanophenoxy)-6-(benzylamino)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)N)N=2)[N+]([O-])=O)=C1 SUQOPVVJRTWBLY-UHFFFAOYSA-N 0.000 description 1
- ORRFXSGHMBINJJ-UHFFFAOYSA-N 3-[2-(2-amino-5-cyanophenoxy)-8,9-diethylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound NC1=C(OC2=NC(=C3N=C(N(C3=N2)CC)CC)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N ORRFXSGHMBINJJ-UHFFFAOYSA-N 0.000 description 1
- UIODCZVXCHRDBA-UHFFFAOYSA-N 3-[2-(5-carbamimidoyl-2-phenoxyphenoxy)-8,9-diethylpurin-6-yl]oxybenzoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)N=C2N(CC)C(CC)=NC2=C1OC1=CC=CC(C(O)=O)=C1 UIODCZVXCHRDBA-UHFFFAOYSA-N 0.000 description 1
- GUSCQIOCJUVHIM-UHFFFAOYSA-N 3-[2-(5-carbamimidoyl-2-phenoxyphenoxy)-9-[1-carboxy-4-(diaminomethylideneamino)butyl]-8-methylpurin-6-yl]oxybenzoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)N=C2N(C(CCCNC(N)=N)C(O)=O)C(C)=NC2=C1OC1=CC=CC(C(O)=O)=C1 GUSCQIOCJUVHIM-UHFFFAOYSA-N 0.000 description 1
- GSVMRENNYNXHLP-UHFFFAOYSA-N 3-[2-(5-carbamimidoyl-2-phenoxyphenoxy)-9-[5-(diaminomethylideneamino)-1-ethoxy-1-oxopentan-2-yl]-8-methylpurin-6-yl]oxybenzoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)N=C2N(C(CCCNC(N)=N)C(=O)OCC)C(C)=NC2=C1OC1=CC=CC(C(O)=O)=C1 GSVMRENNYNXHLP-UHFFFAOYSA-N 0.000 description 1
- MAIPWVVKCJZALB-UHFFFAOYSA-N 3-[2-(5-cyano-2-phenoxyphenoxy)-8,9-diethylpurin-6-yl]oxybenzoic acid Chemical compound O(C1=CC=CC=C1)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC)CC)OC2=CC(=CC=C2)C(=O)O)C=C(C=C1)C#N MAIPWVVKCJZALB-UHFFFAOYSA-N 0.000 description 1
- JVCZROVXZBVIRR-UHFFFAOYSA-N 3-[4,5-diamino-6-(2-amino-5-cyanophenoxy)pyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)N)C(N)=C(N)N=2)=C1 JVCZROVXZBVIRR-UHFFFAOYSA-N 0.000 description 1
- FXVWPKJAGKJCCM-UHFFFAOYSA-N 3-[4,5-diamino-6-(2-chloro-5-cyanophenoxy)pyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)Cl)C(N)=C(N)N=2)=C1 FXVWPKJAGKJCCM-UHFFFAOYSA-N 0.000 description 1
- IPSQGKIWVDVUBX-UHFFFAOYSA-N 3-[4,5-diamino-6-(3-amino-4-cyanophenoxy)pyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C=C(N)C(C#N)=CC=3)C(N)=C(N)N=2)=C1 IPSQGKIWVDVUBX-UHFFFAOYSA-N 0.000 description 1
- MAVIQAVFEVOLKR-UHFFFAOYSA-N 3-[4,5-diamino-6-(3-bromo-5-cyanophenoxy)pyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C=C(C=C(Br)C=3)C#N)C(N)=C(N)N=2)=C1 MAVIQAVFEVOLKR-UHFFFAOYSA-N 0.000 description 1
- VTKPZMDHKUXNBM-UHFFFAOYSA-N 3-[4,5-diamino-6-(3-cyano-5-phenoxyphenoxy)pyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C=C(C=C(OC=4C=CC=CC=4)C=3)C#N)C(N)=C(N)N=2)=C1 VTKPZMDHKUXNBM-UHFFFAOYSA-N 0.000 description 1
- PHONOYBYORWYCQ-UHFFFAOYSA-N 3-[4,5-diamino-6-(4-cyano-3-methylphenoxy)pyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C=C(C)C(C#N)=CC=3)C(N)=C(N)N=2)=C1 PHONOYBYORWYCQ-UHFFFAOYSA-N 0.000 description 1
- ZNCRDYJHQHARQQ-UHFFFAOYSA-N 3-[4,5-diamino-6-(5-cyano-2-methylphenoxy)pyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)C)C(N)=C(N)N=2)=C1 ZNCRDYJHQHARQQ-UHFFFAOYSA-N 0.000 description 1
- NPUDPIHFRKPMFN-UHFFFAOYSA-N 3-[4-(benzylamino)-5-nitro-6-(3-phenylmethoxyphenoxy)pyrimidin-2-yl]oxy-4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1OC1=NC(NCC=2C=CC=CC=2)=C([N+]([O-])=O)C(OC=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 NPUDPIHFRKPMFN-UHFFFAOYSA-N 0.000 description 1
- AYIQHRWCNDFGPG-UHFFFAOYSA-N 3-[4-(benzylamino)-6-(3-ethoxyphenoxy)-5-nitropyrimidin-2-yl]oxy-4-tert-butylbenzonitrile Chemical compound CCOC1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)C(C)(C)C)N=2)[N+]([O-])=O)=C1 AYIQHRWCNDFGPG-UHFFFAOYSA-N 0.000 description 1
- BMEQDIBMLUSVHI-UHFFFAOYSA-N 3-[4-(benzylamino)-6-(5-cyano-2-phenylmethoxyphenoxy)-5-nitropyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)C(=C(NCC=3C=CC=CC=3)N=2)[N+]([O-])=O)=C1 BMEQDIBMLUSVHI-UHFFFAOYSA-N 0.000 description 1
- TXDKDNJOZHDMQZ-UHFFFAOYSA-N 3-[4-(benzylamino)-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitropyrimidin-2-yl]oxy-4-phenylmethoxybenzonitrile Chemical compound CN1CCN=C1C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)N=2)[N+]([O-])=O)=C1 TXDKDNJOZHDMQZ-UHFFFAOYSA-N 0.000 description 1
- DAGKGUHKQITUCU-UHFFFAOYSA-N 3-[4-[3-(2-aminoethyl)phenoxy]-6-(benzylamino)-5-nitropyrimidin-2-yl]oxy-4-chlorobenzonitrile Chemical compound NCCC1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)Cl)N=2)[N+]([O-])=O)=C1 DAGKGUHKQITUCU-UHFFFAOYSA-N 0.000 description 1
- UZCJONCUSXEWKC-UHFFFAOYSA-N 3-[4-amino-6-(2-chloro-5-cyanophenoxy)-5-nitropyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)Cl)C(=C(N)N=2)[N+]([O-])=O)=C1 UZCJONCUSXEWKC-UHFFFAOYSA-N 0.000 description 1
- ASILNOGMMRFBFR-UHFFFAOYSA-N 3-[4-amino-6-(3-bromo-5-cyanophenoxy)-5-nitropyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C=C(C=C(Br)C=3)C#N)C(=C(N)N=2)[N+]([O-])=O)=C1 ASILNOGMMRFBFR-UHFFFAOYSA-N 0.000 description 1
- BPCLKZCACVLJFK-UHFFFAOYSA-N 3-[4-amino-6-(3-cyano-5-phenoxyphenoxy)-5-nitropyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C=C(C=C(OC=4C=CC=CC=4)C=3)C#N)C(=C(N)N=2)[N+]([O-])=O)=C1 BPCLKZCACVLJFK-UHFFFAOYSA-N 0.000 description 1
- NJYHIMRZDKSOSV-UHFFFAOYSA-N 3-[4-amino-6-(4-cyano-3-methylphenoxy)-5-nitropyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C=C(C)C(C#N)=CC=3)C(=C(N)N=2)[N+]([O-])=O)=C1 NJYHIMRZDKSOSV-UHFFFAOYSA-N 0.000 description 1
- GFCUDCHVWHKBKQ-UHFFFAOYSA-N 3-[4-amino-6-(4-cyano-3-nitrophenoxy)-5-nitropyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C=C(C(C#N)=CC=3)[N+]([O-])=O)C(=C(N)N=2)[N+]([O-])=O)=C1 GFCUDCHVWHKBKQ-UHFFFAOYSA-N 0.000 description 1
- INQCPBCHJWLGFM-UHFFFAOYSA-N 3-[4-amino-6-(5-cyano-2-methylphenoxy)-5-nitropyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)C)C(=C(N)N=2)[N+]([O-])=O)=C1 INQCPBCHJWLGFM-UHFFFAOYSA-N 0.000 description 1
- FRHWTUIDOLCBEC-UHFFFAOYSA-N 3-[4-amino-6-(5-cyano-2-nitrophenoxy)-5-nitropyrimidin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)[N+]([O-])=O)C(=C(N)N=2)[N+]([O-])=O)=C1 FRHWTUIDOLCBEC-UHFFFAOYSA-N 0.000 description 1
- OXMANQQFWORDDO-UHFFFAOYSA-N 3-[5,6-diamino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyrimidin-4-yl]oxy-4-ethoxybenzonitrile Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC(N)=C1N OXMANQQFWORDDO-UHFFFAOYSA-N 0.000 description 1
- FXIOJFCERCXDCO-UHFFFAOYSA-N 3-[5,6-diamino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyrimidin-4-yl]oxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC(N)=C1N FXIOJFCERCXDCO-UHFFFAOYSA-N 0.000 description 1
- BIBZXNMDJQQHKN-UHFFFAOYSA-N 3-[5,6-diamino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyrimidin-4-yl]oxy-4-phenoxybenzonitrile Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)OC=3C=CC=CC=3)C(N)=C(N)N=2)=C1 BIBZXNMDJQQHKN-UHFFFAOYSA-N 0.000 description 1
- UIQSDHWQVDBFKZ-UHFFFAOYSA-N 3-[5,6-diamino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyrimidin-4-yl]oxy-5-ethoxybenzonitrile Chemical compound N#CC1=CC(OCC)=CC(OC=2C(=C(N)N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)N)=C1 UIQSDHWQVDBFKZ-UHFFFAOYSA-N 0.000 description 1
- IDXKKJSRDJRQTK-UHFFFAOYSA-N 3-[5,6-diamino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]pyrimidin-4-yl]oxy-5-methoxybenzonitrile Chemical compound N#CC1=CC(OC)=CC(OC=2C(=C(N)N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)N)=C1 IDXKKJSRDJRQTK-UHFFFAOYSA-N 0.000 description 1
- NHRMBGZKSHABEM-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(2-chloro-5-cyanophenoxy)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)Cl)N=2)[N+]([O-])=O)=C1 NHRMBGZKSHABEM-UHFFFAOYSA-N 0.000 description 1
- KWROIEYHSGEFJU-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(2-tert-butyl-5-cyanophenoxy)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)C(C)(C)C)N=2)[N+]([O-])=O)=C1 KWROIEYHSGEFJU-UHFFFAOYSA-N 0.000 description 1
- NFMLPBRMFAHRAA-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(5-cyano-2-ethoxyphenoxy)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(NCC=2C=CC=CC=2)=C([N+]([O-])=O)C(OC=2C=C(C=CC=2)C(=O)N(C)C)=N1 NFMLPBRMFAHRAA-UHFFFAOYSA-N 0.000 description 1
- QEWIDSOJDFBKPU-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(5-cyano-2-methoxyphenoxy)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(NCC=2C=CC=CC=2)=C([N+]([O-])=O)C(OC=2C=C(C=CC=2)C(=O)N(C)C)=N1 QEWIDSOJDFBKPU-UHFFFAOYSA-N 0.000 description 1
- FNWDBONJJSWRMP-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(5-cyano-2-methylphenoxy)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)C)N=2)[N+]([O-])=O)=C1 FNWDBONJJSWRMP-UHFFFAOYSA-N 0.000 description 1
- GGCFUCVWNFTSTO-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(5-cyano-2-nitrophenoxy)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)[N+]([O-])=O)N=2)[N+]([O-])=O)=C1 GGCFUCVWNFTSTO-UHFFFAOYSA-N 0.000 description 1
- UHCNSKLDDKINFY-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(5-cyano-2-phenoxyphenoxy)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)OC=3C=CC=CC=3)N=2)[N+]([O-])=O)=C1 UHCNSKLDDKINFY-UHFFFAOYSA-N 0.000 description 1
- NWCDWNBBYLZXAI-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(5-cyano-2-phenoxyphenoxy)-5-nitropyrimidin-4-yl]oxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)OC=3C=CC=CC=3)N=2)[N+]([O-])=O)=C1 NWCDWNBBYLZXAI-UHFFFAOYSA-N 0.000 description 1
- AXHSYAONQOIDCI-UHFFFAOYSA-N 3-[6-(benzylamino)-2-(5-cyano-2-phenylmethoxyphenoxy)-5-nitropyrimidin-4-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)N=2)[N+]([O-])=O)=C1 AXHSYAONQOIDCI-UHFFFAOYSA-N 0.000 description 1
- MVAKZEPWTDKRCK-UHFFFAOYSA-N 3-[6-(benzylamino)-2-methylsulfonyl-5-nitropyrimidin-4-yl]oxy-4-phenylmethoxybenzonitrile Chemical compound [O-][N+](=O)C=1C(OC=2C(=CC=C(C=2)C#N)OCC=2C=CC=CC=2)=NC(S(=O)(=O)C)=NC=1NCC1=CC=CC=C1 MVAKZEPWTDKRCK-UHFFFAOYSA-N 0.000 description 1
- KZBSIWUGDACBBA-UHFFFAOYSA-N 3-[6-amino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitropyrimidin-4-yl]oxy-4-ethoxybenzonitrile Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC(N)=C1[N+]([O-])=O KZBSIWUGDACBBA-UHFFFAOYSA-N 0.000 description 1
- TYAUWYMMJKKKGT-UHFFFAOYSA-N 3-[6-amino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitropyrimidin-4-yl]oxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC(N)=C1[N+]([O-])=O TYAUWYMMJKKKGT-UHFFFAOYSA-N 0.000 description 1
- ITCCHDGRUURHEB-UHFFFAOYSA-N 3-[6-amino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitropyrimidin-4-yl]oxy-4-phenoxybenzonitrile Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)OC=3C=CC=CC=3)C(=C(N)N=2)[N+]([O-])=O)=C1 ITCCHDGRUURHEB-UHFFFAOYSA-N 0.000 description 1
- FQFDTWFEINNXTR-UHFFFAOYSA-N 3-[6-amino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitropyrimidin-4-yl]oxy-5-ethoxybenzonitrile Chemical compound N#CC1=CC(OCC)=CC(OC=2C(=C(N)N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)[N+]([O-])=O)=C1 FQFDTWFEINNXTR-UHFFFAOYSA-N 0.000 description 1
- ZFIOLOGRQGUTCD-UHFFFAOYSA-N 3-[6-amino-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitropyrimidin-4-yl]oxy-5-methoxybenzonitrile Chemical compound N#CC1=CC(OC)=CC(OC=2C(=C(N)N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)[N+]([O-])=O)=C1 ZFIOLOGRQGUTCD-UHFFFAOYSA-N 0.000 description 1
- MCXZSRORMDMUQU-UHFFFAOYSA-N 3-[8,9-diethyl-6-(3-hydroxyphenoxy)purin-2-yl]oxy-4-methylbenzenecarboximidamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C)N=C2N(CC)C(CC)=NC2=C1OC1=CC=CC(O)=C1 MCXZSRORMDMUQU-UHFFFAOYSA-N 0.000 description 1
- FXSQRYZSECGKDA-UHFFFAOYSA-N 3-[8,9-diethyl-6-(3-phenylmethoxyphenoxy)purin-2-yl]oxy-4-methylbenzonitrile Chemical compound CC1=C(OC2=NC(=C3N=C(N(C3=N2)CC)CC)OC2=CC(=CC=C2)OCC2=CC=CC=C2)C=C(C=C1)C#N FXSQRYZSECGKDA-UHFFFAOYSA-N 0.000 description 1
- GFXIACUICVCKDN-UHFFFAOYSA-N 3-[8,9-diethyl-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-2-yl]oxy-4-hydroxybenzenecarboximidamide Chemical compound CCc1nc2c(Oc3cccc(c3)C3=NCCN3C)nc(Oc3cc(ccc3O)C(N)=N)nc2n1CC GFXIACUICVCKDN-UHFFFAOYSA-N 0.000 description 1
- ZIALTJVEVUTOBQ-UHFFFAOYSA-N 3-[9-(1-amino-1-oxo-3-phenylpropan-2-yl)-2-(5-carbamimidoyl-2-chlorophenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CC=4C=CC=CC=4)C(N)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)Cl)N=2)=C1 ZIALTJVEVUTOBQ-UHFFFAOYSA-N 0.000 description 1
- YCLLXPPNNSCANN-UHFFFAOYSA-N 3-[9-(1-amino-1-oxopropan-2-yl)-2-(5-carbamimidoyl-2-hydroxyphenoxy)-8-methylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)O)N=C2N(C(C(N)=O)C)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 YCLLXPPNNSCANN-UHFFFAOYSA-N 0.000 description 1
- SVFKDRKWYZRURX-UHFFFAOYSA-N 3-[9-(1-amino-3-methyl-1-oxopentan-2-yl)-2-(5-carbamimidoyl-2-phenoxyphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)N=C2N(C(C(N)=O)C(C)CC)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 SVFKDRKWYZRURX-UHFFFAOYSA-N 0.000 description 1
- CZDQACSTTLGWQX-UHFFFAOYSA-N 3-[9-(1-amino-4-methyl-1-oxopentan-2-yl)-2-(5-carbamimidoyl-2-ethoxyphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(N=C(C)N2C(CC(C)C)C(N)=O)C2=N1 CZDQACSTTLGWQX-UHFFFAOYSA-N 0.000 description 1
- HACZVJXHWMBEEX-UHFFFAOYSA-N 3-[9-[1-amino-1-oxo-3-(4-sulfanylphenyl)propan-2-yl]-2-(5-carbamimidoyl-2-methylphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CC=4C=CC(S)=CC=4)C(N)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C)N=2)=C1 HACZVJXHWMBEEX-UHFFFAOYSA-N 0.000 description 1
- BODXXYSIGGOKIE-UHFFFAOYSA-N 3-[9-[1-amino-3-(2,3-dihydro-1h-indol-3-yl)-1-oxopropan-2-yl]-2-(2-tert-butyl-5-carbamimidoylphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CC4C5=CC=CC=C5NC4)C(N)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(C)(C)C)N=2)=C1 BODXXYSIGGOKIE-UHFFFAOYSA-N 0.000 description 1
- PTTRDKVFRPSZCZ-UHFFFAOYSA-N 3-[9-[1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-2-(5-carbamimidoyl-2-phenoxyphenoxy)-8-methylpurin-6-yl]oxybenzoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)N=C2N(C(CCCNC(N)=N)C(N)=O)C(C)=NC2=C1OC1=CC=CC(C(O)=O)=C1 PTTRDKVFRPSZCZ-UHFFFAOYSA-N 0.000 description 1
- YIBGFXAOAJXXDA-UHFFFAOYSA-N 3-[9-benzyl-2-(2-chloro-5-cyanophenoxy)-8-methylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound ClC1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N YIBGFXAOAJXXDA-UHFFFAOYSA-N 0.000 description 1
- RVNHZLMAIFCFGI-UHFFFAOYSA-N 3-[9-benzyl-2-(2-tert-butyl-5-carbamimidoylphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(C)(C)C)N=2)=C1 RVNHZLMAIFCFGI-UHFFFAOYSA-N 0.000 description 1
- MNAQHAFPRKLCRU-UHFFFAOYSA-N 3-[9-benzyl-2-(3,5-diaminophenoxy)-8-methylpurin-6-yl]oxy-5-ethoxybenzenecarboximidamide Chemical compound NC(=N)C1=CC(OCC)=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C=C(N)C=C(N)C=3)N=2)=C1 MNAQHAFPRKLCRU-UHFFFAOYSA-N 0.000 description 1
- CXGPOXZVVDMNMM-UHFFFAOYSA-N 3-[9-benzyl-2-(3,5-diaminophenoxy)-8-methylpurin-6-yl]oxy-5-ethoxybenzonitrile Chemical compound N#CC1=CC(OCC)=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C=C(N)C=C(N)C=3)N=2)=C1 CXGPOXZVVDMNMM-UHFFFAOYSA-N 0.000 description 1
- AZARWURJRKZXSC-UHFFFAOYSA-N 3-[9-benzyl-2-(3-chloro-5-methoxyphenoxy)-8-methylpurin-6-yl]oxy-4-ethoxybenzenecarboximidamide Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(OC)C=C(Cl)C=2)=NC2=C1N=C(C)N2CC1=CC=CC=C1 AZARWURJRKZXSC-UHFFFAOYSA-N 0.000 description 1
- COGPFDHSQRLENH-UHFFFAOYSA-N 3-[9-benzyl-2-(3-chloro-5-methoxyphenoxy)-8-methylpurin-6-yl]oxy-4-ethoxybenzonitrile Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(OC)C=C(Cl)C=2)=NC2=C1N=C(C)N2CC1=CC=CC=C1 COGPFDHSQRLENH-UHFFFAOYSA-N 0.000 description 1
- OBTOZFAXCBPWMF-UHFFFAOYSA-N 3-[9-benzyl-2-(5-carbamimidoyl-2-chlorophenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)Cl)N=2)=C1 OBTOZFAXCBPWMF-UHFFFAOYSA-N 0.000 description 1
- IALDHTBXIPVOKN-UHFFFAOYSA-N 3-[9-benzyl-2-(5-carbamimidoyl-2-ethoxyphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(N=C(C)N2CC=3C=CC=CC=3)C2=N1 IALDHTBXIPVOKN-UHFFFAOYSA-N 0.000 description 1
- QCIXYQUKDLVLRU-UHFFFAOYSA-N 3-[9-benzyl-2-(5-carbamimidoyl-2-methoxyphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound COC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(N=C(C)N2CC=3C=CC=CC=3)C2=N1 QCIXYQUKDLVLRU-UHFFFAOYSA-N 0.000 description 1
- RGZDCCFLQHDYSR-UHFFFAOYSA-N 3-[9-benzyl-2-(5-carbamimidoyl-2-methylphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C)N=2)=C1 RGZDCCFLQHDYSR-UHFFFAOYSA-N 0.000 description 1
- RRPVXMWFATVQNB-UHFFFAOYSA-N 3-[9-benzyl-2-(5-carbamimidoyl-2-phenoxyphenoxy)-8-methylpurin-6-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)OC=3C=CC=CC=3)N=2)=C1 RRPVXMWFATVQNB-UHFFFAOYSA-N 0.000 description 1
- JEWOGQVJZHDXON-UHFFFAOYSA-N 3-[9-benzyl-2-(5-carbamimidoyl-2-phenoxyphenoxy)-8-methylpurin-6-yl]oxybenzoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC=CC(C(O)=O)=C1 JEWOGQVJZHDXON-UHFFFAOYSA-N 0.000 description 1
- MXYUYYXVTVMQJK-UHFFFAOYSA-N 3-[9-benzyl-2-(5-cyano-2-ethoxyphenoxy)-8-methylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound C(C)OC1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N MXYUYYXVTVMQJK-UHFFFAOYSA-N 0.000 description 1
- PIFPNOQRUQPYNI-UHFFFAOYSA-N 3-[9-benzyl-2-(5-cyano-2-methoxyphenoxy)-8-methylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound COC1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N PIFPNOQRUQPYNI-UHFFFAOYSA-N 0.000 description 1
- FWNDRMYTHMVLEN-UHFFFAOYSA-N 3-[9-benzyl-2-(5-cyano-2-methylphenoxy)-8-methylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound CC1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N FWNDRMYTHMVLEN-UHFFFAOYSA-N 0.000 description 1
- RQNHIJGZEDOQPY-UHFFFAOYSA-N 3-[9-benzyl-2-(5-cyano-2-phenoxyphenoxy)-8-methylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound O(C1=CC=CC=C1)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N RQNHIJGZEDOQPY-UHFFFAOYSA-N 0.000 description 1
- YDATUHRQVPIRBB-UHFFFAOYSA-N 3-[9-benzyl-2-(5-cyano-2-phenoxyphenoxy)-8-methylpurin-6-yl]oxybenzoic acid Chemical compound O(C1=CC=CC=C1)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)O)C=C(C=C1)C#N YDATUHRQVPIRBB-UHFFFAOYSA-N 0.000 description 1
- WEBYALKYIHKVNM-UHFFFAOYSA-N 3-[9-benzyl-2-(5-cyano-2-phenylmethoxyphenoxy)-8-methylpurin-6-yl]oxy-N,N-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)N=2)=C1 WEBYALKYIHKVNM-UHFFFAOYSA-N 0.000 description 1
- SQXBGLGNPSCKHX-UHFFFAOYSA-N 3-[9-benzyl-2-[3-(2-chloroethyl)-5-methylphenoxy]-8-methylpurin-6-yl]oxy-4-chlorobenzenecarboximidamide Chemical compound N1=C(OC=2C=C(CCCl)C=C(C)C=2)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC(C(N)=N)=CC=C1Cl SQXBGLGNPSCKHX-UHFFFAOYSA-N 0.000 description 1
- PPQPMQUSWXTSSZ-UHFFFAOYSA-N 3-[9-benzyl-2-[3-(2-chloroethyl)-5-methylphenoxy]-8-methylpurin-6-yl]oxy-4-chlorobenzonitrile Chemical compound N1=C(OC=2C=C(CCCl)C=C(C)C=2)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC(C#N)=CC=C1Cl PPQPMQUSWXTSSZ-UHFFFAOYSA-N 0.000 description 1
- YFNXGMVOPRPRDY-UHFFFAOYSA-N 3-[9-benzyl-2-[3-(diaminomethylideneamino)-5-methylphenoxy]-8-methylpurin-6-yl]oxy-4-phenoxybenzenecarboximidamide Chemical compound N1=C(OC=2C=C(C=C(C)C=2)N=C(N)N)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC(C(N)=N)=CC=C1OC1=CC=CC=C1 YFNXGMVOPRPRDY-UHFFFAOYSA-N 0.000 description 1
- GQLSJXJSARJLIE-UHFFFAOYSA-N 3-[9-benzyl-6-(3-bromo-5-carbamimidoylphenoxy)-8-methylpurin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C=C(Br)C=3)C(N)=N)N=2)=C1 GQLSJXJSARJLIE-UHFFFAOYSA-N 0.000 description 1
- XYWNTBRIPRYJMV-UHFFFAOYSA-N 3-[9-benzyl-6-(3-bromo-5-cyanophenoxy)-8-methylpurin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C=C(Br)C=3)C#N)N=2)=C1 XYWNTBRIPRYJMV-UHFFFAOYSA-N 0.000 description 1
- QQKVONLOJGCKDQ-UHFFFAOYSA-N 3-[9-benzyl-6-(3-ethoxyphenoxy)-8-methylpurin-2-yl]oxy-4-tert-butylbenzenecarboximidamide Chemical compound CCOC1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(C)(C)C)N=2)=C1 QQKVONLOJGCKDQ-UHFFFAOYSA-N 0.000 description 1
- NZEOSALYTTZJDJ-UHFFFAOYSA-N 3-[9-benzyl-6-(3-ethoxyphenoxy)-8-methylpurin-2-yl]oxy-4-tert-butylbenzonitrile Chemical compound C(C)(C)(C)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)OCC)C=C(C=C1)C#N NZEOSALYTTZJDJ-UHFFFAOYSA-N 0.000 description 1
- JOVKUOPEKJPQAK-UHFFFAOYSA-N 3-[9-benzyl-6-(3-hydroxyphenoxy)-8-methylpurin-2-yl]oxy-4-methylbenzenecarboximidamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC=CC(O)=C1 JOVKUOPEKJPQAK-UHFFFAOYSA-N 0.000 description 1
- DQWJFPFEWYUNAS-UHFFFAOYSA-N 3-[9-benzyl-6-(5-cyano-2-phenylmethoxyphenoxy)-8-methylpurin-2-yl]oxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)N=2)=C1 DQWJFPFEWYUNAS-UHFFFAOYSA-N 0.000 description 1
- VNOCABZBMQXQGY-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-2-(3-methylphenoxy)purin-6-yl]oxy-4-methoxybenzenecarboximidamide Chemical compound COC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C)C=CC=2)=NC2=C1N=C(C)N2CC1=CC=CC=C1 VNOCABZBMQXQGY-UHFFFAOYSA-N 0.000 description 1
- NLTZLVZJKVKEGB-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-2-(3-methylphenoxy)purin-6-yl]oxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C)C=CC=2)=NC2=C1N=C(C)N2CC1=CC=CC=C1 NLTZLVZJKVKEGB-UHFFFAOYSA-N 0.000 description 1
- JYDIEAWWGQOTGP-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-(dimethylamino)benzenecarboximidamide Chemical compound CN(C)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC2=C1N=C(C)N2CC1=CC=CC=C1 JYDIEAWWGQOTGP-UHFFFAOYSA-N 0.000 description 1
- JGZYHYSXVWTVNC-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-(dimethylamino)benzonitrile Chemical compound CN(C)C1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC2=C1N=C(C)N2CC1=CC=CC=C1 JGZYHYSXVWTVNC-UHFFFAOYSA-N 0.000 description 1
- JAMFKZFYRIYKER-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-2-[3-(1-methylimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-methylbenzenecarboximidamide Chemical compound N1=C(OC=2C=C(C=CC=2)C=2N(C=CN=2)C)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC(C(N)=N)=CC=C1C JAMFKZFYRIYKER-UHFFFAOYSA-N 0.000 description 1
- HBWUGKWMFIUFHK-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-2-[3-(1-methylimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-methylbenzonitrile Chemical compound N1=C(OC=2C=C(C=CC=2)C=2N(C=CN=2)C)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC(C#N)=CC=C1C HBWUGKWMFIUFHK-UHFFFAOYSA-N 0.000 description 1
- VFCZAFGFFAQRFY-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-2-[4-(trifluoromethyl)phenoxy]purin-6-yl]oxy-5-methoxybenzenecarboximidamide Chemical compound NC(=N)C1=CC(OC)=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C=CC(=CC=3)C(F)(F)F)N=2)=C1 VFCZAFGFFAQRFY-UHFFFAOYSA-N 0.000 description 1
- PWTDRFCBWXBDOL-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-2-[4-(trifluoromethyl)phenoxy]purin-6-yl]oxy-5-methoxybenzonitrile Chemical compound N#CC1=CC(OC)=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C=CC(=CC=3)C(F)(F)F)N=2)=C1 PWTDRFCBWXBDOL-UHFFFAOYSA-N 0.000 description 1
- MAYCYFHYBYEBSB-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-6-(3-phenylmethoxyphenoxy)purin-2-yl]oxy-4-methylbenzonitrile Chemical compound CC1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)OCC2=CC=CC=C2)C=C(C=C1)C#N MAYCYFHYBYEBSB-UHFFFAOYSA-N 0.000 description 1
- NCIOLNCTKWLALV-UHFFFAOYSA-N 3-[9-benzyl-8-methyl-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-2-yl]oxy-4-hydroxybenzenecarboximidamide Chemical compound CN1CCN=C1c1cccc(Oc2nc(Oc3cc(ccc3O)C(N)=N)nc3n(Cc4ccccc4)c(C)nc23)c1 NCIOLNCTKWLALV-UHFFFAOYSA-N 0.000 description 1
- FPDCALJKJFQRIE-UHFFFAOYSA-N 3-[[1,5-diamino-4-benzyl-6-(3-bromo-5-cyanophenoxy)-2H-pyrimidin-2-yl]oxy]-N,N-dimethylbenzamide Chemical compound CN(C(=O)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC(=C2)C#N)Br)N)C=CC=1)C FPDCALJKJFQRIE-UHFFFAOYSA-N 0.000 description 1
- AVVNNGFICVYBLB-UHFFFAOYSA-N 3-[[1,5-diamino-4-benzyl-6-(3-phenylmethoxyphenoxy)-2H-pyrimidin-2-yl]oxy]-4-methylbenzonitrile Chemical compound CC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)OCC2=CC=CC=C2)N)C=C(C=C1)C#N AVVNNGFICVYBLB-UHFFFAOYSA-N 0.000 description 1
- NOZYSMBVLFCFTD-UHFFFAOYSA-N 3-[[1,5-diamino-4-benzyl-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-2H-pyrimidin-2-yl]oxy]-4-phenylmethoxybenzonitrile Chemical compound C(C1=CC=CC=C1)OC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C=2N(CCN=2)C)N)C=C(C=C1)C#N NOZYSMBVLFCFTD-UHFFFAOYSA-N 0.000 description 1
- AROUMKPKLCDKIF-UHFFFAOYSA-N 3-[[1-amino-4-benzyl-6-(3-bromo-5-cyanophenoxy)-5-nitro-2H-pyrimidin-2-yl]oxy]-N,N-dimethylbenzamide Chemical compound CN(C(=O)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=CC(=C2)C#N)Br)N)C=CC=1)C AROUMKPKLCDKIF-UHFFFAOYSA-N 0.000 description 1
- NCURFNUSUNLPMH-UHFFFAOYSA-N 3-[[2-(2-amino-5-carbamimidoylphenoxy)-8-ethyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound N=1C(OC=2C=C(C=CC=2)C(=O)N(C)C)=C2NC(CC)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1N NCURFNUSUNLPMH-UHFFFAOYSA-N 0.000 description 1
- LHSACVQKJNCCFR-UHFFFAOYSA-N 3-[[2-(2-amino-5-cyanophenoxy)-8-ethyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound NC1=C(OC2=NC(=C3NC(=NC3=N2)CC)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N LHSACVQKJNCCFR-UHFFFAOYSA-N 0.000 description 1
- KQQQILDPHSFXRO-UHFFFAOYSA-N 3-[[2-(2-chloro-5-cyanophenoxy)-8-methyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound ClC1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N KQQQILDPHSFXRO-UHFFFAOYSA-N 0.000 description 1
- XWPDQYOIVBMXJK-UHFFFAOYSA-N 3-[[2-(2-tert-butyl-5-carbamimidoylphenoxy)-8-ethyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound N=1C(OC=2C=C(C=CC=2)C(=O)N(C)C)=C2NC(CC)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1C(C)(C)C XWPDQYOIVBMXJK-UHFFFAOYSA-N 0.000 description 1
- XEFYYVCLDQBELS-UHFFFAOYSA-N 3-[[2-(2-tert-butyl-5-carbamimidoylphenoxy)-8-methyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(C)(C)C)N=2)=C1 XEFYYVCLDQBELS-UHFFFAOYSA-N 0.000 description 1
- TYRIMEWLXXVFRN-UHFFFAOYSA-N 3-[[2-(2-tert-butyl-5-cyanophenoxy)-8-ethyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound C(C)(C)(C)C1=C(OC2=NC(=C3NC(=NC3=N2)CC)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N TYRIMEWLXXVFRN-UHFFFAOYSA-N 0.000 description 1
- UTRRWLHEYKLULD-UHFFFAOYSA-N 3-[[2-(2-tert-butyl-5-cyanophenoxy)-8-methyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound C(C)(C)(C)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N UTRRWLHEYKLULD-UHFFFAOYSA-N 0.000 description 1
- WLQNQDJQULEGIT-UHFFFAOYSA-N 3-[[2-(5-carbamimidoyl-2-chlorophenoxy)-8-methyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C(=CC=C(C=3)C(N)=N)Cl)N=2)=C1 WLQNQDJQULEGIT-UHFFFAOYSA-N 0.000 description 1
- HNVBQPRASMJJMR-UHFFFAOYSA-N 3-[[2-(5-carbamimidoyl-2-ethoxyphenoxy)-8-methyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(NC(C)=N2)C2=N1 HNVBQPRASMJJMR-UHFFFAOYSA-N 0.000 description 1
- ISSJWPZWWZVUPM-UHFFFAOYSA-N 3-[[2-(5-carbamimidoyl-2-hydroxyphenoxy)-8-methyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound CN(C)C(=O)c1cccc(Oc2nc(Oc3cc(ccc3O)C(N)=N)nc3nc(C)[nH]c23)c1 ISSJWPZWWZVUPM-UHFFFAOYSA-N 0.000 description 1
- CTXBJSGJAHGKEP-UHFFFAOYSA-N 3-[[2-(5-carbamimidoyl-2-methoxyphenoxy)-8-methyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound COC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(NC(C)=N2)C2=N1 CTXBJSGJAHGKEP-UHFFFAOYSA-N 0.000 description 1
- NLBLQRSUSXAFHU-UHFFFAOYSA-N 3-[[2-(5-carbamimidoyl-2-methylphenoxy)-8-ethyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound N=1C(OC=2C=C(C=CC=2)C(=O)N(C)C)=C2NC(CC)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1C NLBLQRSUSXAFHU-UHFFFAOYSA-N 0.000 description 1
- APPPCOSNZVJBNJ-UHFFFAOYSA-N 3-[[2-(5-carbamimidoyl-2-methylphenoxy)-8-methyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C)N=2)=C1 APPPCOSNZVJBNJ-UHFFFAOYSA-N 0.000 description 1
- JWMFKEJCOYZQKK-UHFFFAOYSA-N 3-[[2-(5-carbamimidoyl-2-phenoxyphenoxy)-8-methyl-7h-purin-6-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C(=CC=C(C=3)C(N)=N)OC=3C=CC=CC=3)N=2)=C1 JWMFKEJCOYZQKK-UHFFFAOYSA-N 0.000 description 1
- WFBOFJHETUZZSR-UHFFFAOYSA-N 3-[[2-(5-carbamimidoyl-2-phenoxyphenoxy)-8-methyl-7h-purin-6-yl]oxy]benzoic acid Chemical compound N=1C(OC=2C=C(C=CC=2)C(O)=O)=C2NC(C)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1OC1=CC=CC=C1 WFBOFJHETUZZSR-UHFFFAOYSA-N 0.000 description 1
- CQCNTPMUVCLYRI-UHFFFAOYSA-N 3-[[2-(5-cyano-2-ethoxyphenoxy)-8-methyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound C(C)OC1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N CQCNTPMUVCLYRI-UHFFFAOYSA-N 0.000 description 1
- IFMZLJQCEJWCPX-UHFFFAOYSA-N 3-[[2-(5-cyano-2-methoxyphenoxy)-8-methyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound COC1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N IFMZLJQCEJWCPX-UHFFFAOYSA-N 0.000 description 1
- BROIEBAZRYJCJF-UHFFFAOYSA-N 3-[[2-(5-cyano-2-methylphenoxy)-8-ethyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound CC1=C(OC2=NC(=C3NC(=NC3=N2)CC)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N BROIEBAZRYJCJF-UHFFFAOYSA-N 0.000 description 1
- GOPYYLWFFKJUIG-UHFFFAOYSA-N 3-[[2-(5-cyano-2-phenoxyphenoxy)-8-methyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound O(C1=CC=CC=C1)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N GOPYYLWFFKJUIG-UHFFFAOYSA-N 0.000 description 1
- MTVBNDLUXUGIHU-UHFFFAOYSA-N 3-[[2-(5-cyano-2-phenoxyphenoxy)-8-methyl-7H-purin-6-yl]oxy]benzoic acid Chemical compound O(C1=CC=CC=C1)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)O)C=C(C=C1)C#N MTVBNDLUXUGIHU-UHFFFAOYSA-N 0.000 description 1
- WOYSBSVFBDWVCY-UHFFFAOYSA-N 3-[[2-(5-cyano-2-phenylmethoxyphenoxy)-8-methyl-7H-purin-6-yl]oxy]-N,N-dimethylbenzamide Chemical compound C(C1=CC=CC=C1)OC1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N WOYSBSVFBDWVCY-UHFFFAOYSA-N 0.000 description 1
- DAVRLBAJTXZANP-UHFFFAOYSA-N 3-[[2-[3-(diaminomethylideneamino)phenoxy]-8-ethyl-7h-purin-6-yl]oxy]-4-(dimethylamino)benzenecarboximidamide Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)N(C)C)=C2NC(CC)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 DAVRLBAJTXZANP-UHFFFAOYSA-N 0.000 description 1
- PCNGXZWEICPPCD-UHFFFAOYSA-N 3-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]-4-(dimethylamino)benzenecarboximidamide Chemical compound CN(C)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(NC(N)=N)C=CC=2)=NC2=C1NC(C)=N2 PCNGXZWEICPPCD-UHFFFAOYSA-N 0.000 description 1
- KGFJPKHUQVTUDP-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(2-chloro-5-cyanophenoxy)-2H-pyrimidin-4-yl]oxy]-N,N-dimethylbenzamide Chemical compound ClC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N KGFJPKHUQVTUDP-UHFFFAOYSA-N 0.000 description 1
- LRVIFCAKCZPJFE-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(2-tert-butyl-5-cyanophenoxy)-2H-pyrimidin-4-yl]oxy]-N,N-dimethylbenzamide Chemical compound C(C)(C)(C)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N LRVIFCAKCZPJFE-UHFFFAOYSA-N 0.000 description 1
- LXCUHJZJRKRNHY-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(3,5-diaminophenoxy)-2H-pyrimidin-4-yl]oxy]-5-ethoxybenzonitrile Chemical compound NC=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC(=C2)C#N)OCC)N)C=C(C=1)N LXCUHJZJRKRNHY-UHFFFAOYSA-N 0.000 description 1
- COTYLXXQPHBSHZ-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(3-chloro-5-methoxyphenoxy)-2H-pyrimidin-4-yl]oxy]-4-ethoxybenzonitrile Chemical compound ClC=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)OCC)N)C=C(C=1)OC COTYLXXQPHBSHZ-UHFFFAOYSA-N 0.000 description 1
- ABYBYQODOHXWHY-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(3-methylphenoxy)-2H-pyrimidin-4-yl]oxy]-4-methoxybenzonitrile Chemical compound CC=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)OC)N)C=CC=1 ABYBYQODOHXWHY-UHFFFAOYSA-N 0.000 description 1
- FEYQOSYIUKVUHC-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(5-cyano-2-ethoxyphenoxy)-2H-pyrimidin-4-yl]oxy]-N,N-dimethylbenzamide Chemical compound C(C)OC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N FEYQOSYIUKVUHC-UHFFFAOYSA-N 0.000 description 1
- JPYWOGUNENWWOW-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(5-cyano-2-methoxyphenoxy)-2H-pyrimidin-4-yl]oxy]-N,N-dimethylbenzamide Chemical compound COC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N JPYWOGUNENWWOW-UHFFFAOYSA-N 0.000 description 1
- DWCCEZGGXKQJSW-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(5-cyano-2-methylphenoxy)-2H-pyrimidin-4-yl]oxy]-N,N-dimethylbenzamide Chemical compound CC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N DWCCEZGGXKQJSW-UHFFFAOYSA-N 0.000 description 1
- RIMLOTFFFWXOLR-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(5-cyano-2-phenoxyphenoxy)-2H-pyrimidin-4-yl]oxy]-N,N-dimethylbenzamide Chemical compound O(C1=CC=CC=C1)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N RIMLOTFFFWXOLR-UHFFFAOYSA-N 0.000 description 1
- SIRFCGSXSQZYEQ-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(5-cyano-2-phenoxyphenoxy)-2H-pyrimidin-4-yl]oxy]benzoic acid Chemical compound O(C1=CC=CC=C1)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)O)N)C=C(C=C1)C#N SIRFCGSXSQZYEQ-UHFFFAOYSA-N 0.000 description 1
- FEBFJHDEDNJNOZ-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-(5-cyano-2-phenylmethoxyphenoxy)-2H-pyrimidin-4-yl]oxy]-N,N-dimethylbenzamide Chemical compound C(C1=CC=CC=C1)OC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N FEBFJHDEDNJNOZ-UHFFFAOYSA-N 0.000 description 1
- HLDOKWFSSPQODN-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-2H-pyrimidin-4-yl]oxy]-4-(dimethylamino)benzonitrile Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)N(C)C)N)C=CC=1 HLDOKWFSSPQODN-UHFFFAOYSA-N 0.000 description 1
- JAHYNAXBISSQQJ-UHFFFAOYSA-N 3-[[3,5-diamino-6-benzyl-2-[4-(trifluoromethyl)phenoxy]-2H-pyrimidin-4-yl]oxy]-5-methoxybenzonitrile Chemical compound FC(C1=CC=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC(=C2)C#N)OC)N)C=C1)(F)F JAHYNAXBISSQQJ-UHFFFAOYSA-N 0.000 description 1
- LAFCLTVLWBKSRC-UHFFFAOYSA-N 3-[[3-amino-6-benzyl-2-(3,5-dinitrophenoxy)-5-nitro-2H-pyrimidin-4-yl]oxy]-5-ethoxybenzonitrile Chemical compound [N+](=O)([O-])C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=CC(=C2)C#N)OCC)N)C=C(C=1)[N+](=O)[O-] LAFCLTVLWBKSRC-UHFFFAOYSA-N 0.000 description 1
- QZADIMNAHWKQJA-UHFFFAOYSA-N 3-[[3-amino-6-benzyl-2-(3-chloro-5-methoxyphenoxy)-5-nitro-2H-pyrimidin-4-yl]oxy]-4-ethoxybenzonitrile Chemical compound ClC=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)OCC)N)C=C(C=1)OC QZADIMNAHWKQJA-UHFFFAOYSA-N 0.000 description 1
- FMNRNKJANPCRAQ-UHFFFAOYSA-N 3-[[3-amino-6-benzyl-2-(3-methylphenoxy)-5-nitro-2H-pyrimidin-4-yl]oxy]-4-methoxybenzonitrile Chemical compound CC=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)OC)N)C=CC=1 FMNRNKJANPCRAQ-UHFFFAOYSA-N 0.000 description 1
- GWGWPTHXAVVYBD-UHFFFAOYSA-N 3-[[3-amino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-4-(dimethylamino)benzonitrile Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)N(C)C)N)C=CC=1 GWGWPTHXAVVYBD-UHFFFAOYSA-N 0.000 description 1
- VTECKOZQLYGYOE-UHFFFAOYSA-N 3-[[3-amino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-4-nitrobenzonitrile Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)[N+](=O)[O-])N)C=CC=1 VTECKOZQLYGYOE-UHFFFAOYSA-N 0.000 description 1
- DDVJXTVYSJRGRF-UHFFFAOYSA-N 3-[[3-amino-6-benzyl-2-[3-(1-methylimidazol-2-yl)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-4-methylbenzonitrile Chemical compound CN1C(=NC=C1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)C)N)C=CC=1 DDVJXTVYSJRGRF-UHFFFAOYSA-N 0.000 description 1
- LAVVTXJMGWYCDR-UHFFFAOYSA-N 3-[[3-amino-6-benzyl-2-[3-(2-chloroethyl)-5-methylphenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-4-chlorobenzonitrile Chemical compound ClCCC=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)Cl)N)C=C(C=1)C LAVVTXJMGWYCDR-UHFFFAOYSA-N 0.000 description 1
- MPYVXFQLFWMFKS-UHFFFAOYSA-N 3-[[3-amino-6-benzyl-5-nitro-2-[4-(trifluoromethyl)phenoxy]-2H-pyrimidin-4-yl]oxy]-5-methoxybenzonitrile Chemical compound FC(C1=CC=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=CC(=C2)C#N)OC)N)C=C1)(F)F MPYVXFQLFWMFKS-UHFFFAOYSA-N 0.000 description 1
- VZHBMGAXBKCOJM-UHFFFAOYSA-N 3-[[6-(2-amino-5-carbamimidoylphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C(=CC=C(C=3)C(N)=N)N)N=2)=C1 VZHBMGAXBKCOJM-UHFFFAOYSA-N 0.000 description 1
- LDCKSBJMGRKKGL-UHFFFAOYSA-N 3-[[6-(2-amino-5-carbamimidoylphenoxy)-8-phenyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(NC3=C(OC=3C(=CC=C(C=3)C(N)=N)N)N=2)C=2C=CC=CC=2)=C1 LDCKSBJMGRKKGL-UHFFFAOYSA-N 0.000 description 1
- DPIBRFSNLFGKDP-UHFFFAOYSA-N 3-[[6-(2-amino-5-cyanophenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C(=CC=C(C=3)C#N)N)N=2)=C1 DPIBRFSNLFGKDP-UHFFFAOYSA-N 0.000 description 1
- AHKJPNATZPLEKC-UHFFFAOYSA-N 3-[[6-(2-amino-5-cyanophenoxy)-8-phenyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(NC3=C(OC=3C(=CC=C(C=3)C#N)N)N=2)C=2C=CC=CC=2)=C1 AHKJPNATZPLEKC-UHFFFAOYSA-N 0.000 description 1
- KDKJRRDOFZUZKU-UHFFFAOYSA-N 3-[[6-(2-chloro-5-cyanophenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C(=CC=C(C=3)C#N)Cl)N=2)=C1 KDKJRRDOFZUZKU-UHFFFAOYSA-N 0.000 description 1
- SGNWGINIVQQVLT-UHFFFAOYSA-N 3-[[6-(3-amino-4-carbamimidoylphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C=C(N)C(C(N)=N)=CC=3)N=2)=C1 SGNWGINIVQQVLT-UHFFFAOYSA-N 0.000 description 1
- IMTZPAHQLGGURX-UHFFFAOYSA-N 3-[[6-(3-amino-4-cyanophenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C=C(N)C(C#N)=CC=3)N=2)=C1 IMTZPAHQLGGURX-UHFFFAOYSA-N 0.000 description 1
- RLADSALWDMTWDJ-UHFFFAOYSA-N 3-[[6-(3-amino-4-cyanophenoxy)-8-phenyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(NC3=C(OC=3C=C(N)C(C#N)=CC=3)N=2)C=2C=CC=CC=2)=C1 RLADSALWDMTWDJ-UHFFFAOYSA-N 0.000 description 1
- IBXNFQBXCIIPFR-UHFFFAOYSA-N 3-[[6-(3-bromo-5-carbamimidoylphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C=C(C=C(Br)C=3)C(N)=N)N=2)=C1 IBXNFQBXCIIPFR-UHFFFAOYSA-N 0.000 description 1
- ZBZUSAGLKLSYEH-UHFFFAOYSA-N 3-[[6-(3-bromo-5-cyanophenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C=C(C=C(Br)C=3)C#N)N=2)=C1 ZBZUSAGLKLSYEH-UHFFFAOYSA-N 0.000 description 1
- PSFJAOAZHUSQEF-UHFFFAOYSA-N 3-[[6-(3-carbamimidoyl-5-phenoxyphenoxy)-8-ethyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound N=1C(OC=2C=C(C=C(OC=3C=CC=CC=3)C=2)C(N)=N)=C2NC(CC)=NC2=NC=1OC1=CC=CC(C(=O)N(C)C)=C1 PSFJAOAZHUSQEF-UHFFFAOYSA-N 0.000 description 1
- SIHBKRKAJKMDIR-UHFFFAOYSA-N 3-[[6-(3-carbamimidoyl-5-phenoxyphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C=C(C=C(OC=4C=CC=CC=4)C=3)C(N)=N)N=2)=C1 SIHBKRKAJKMDIR-UHFFFAOYSA-N 0.000 description 1
- FXNPUUQIIOKWEU-UHFFFAOYSA-N 3-[[6-(3-cyano-5-phenoxyphenoxy)-8-ethyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound N=1C(OC=2C=C(C=C(OC=3C=CC=CC=3)C=2)C#N)=C2NC(CC)=NC2=NC=1OC1=CC=CC(C(=O)N(C)C)=C1 FXNPUUQIIOKWEU-UHFFFAOYSA-N 0.000 description 1
- IOASTXVJLXGYKW-UHFFFAOYSA-N 3-[[6-(3-cyano-5-phenoxyphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C=C(C=C(OC=4C=CC=CC=4)C=3)C#N)N=2)=C1 IOASTXVJLXGYKW-UHFFFAOYSA-N 0.000 description 1
- OVOGRAIJWDHLRY-UHFFFAOYSA-N 3-[[6-(3-hydroxyphenoxy)-8-methyl-7h-purin-2-yl]oxy]-4-methylbenzenecarboximidamide Chemical compound N=1C(OC=2C=C(O)C=CC=2)=C2NC(C)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1C OVOGRAIJWDHLRY-UHFFFAOYSA-N 0.000 description 1
- XNBYWRDYDLLTTB-UHFFFAOYSA-N 3-[[6-(4-carbamimidoyl-3-methylphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C=C(C)C(C(N)=N)=CC=3)N=2)=C1 XNBYWRDYDLLTTB-UHFFFAOYSA-N 0.000 description 1
- LIHYYGJORXOOBR-UHFFFAOYSA-N 3-[[6-(4-carbamimidoyl-3-methylphenoxy)-8-phenyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(NC3=C(OC=3C=C(C)C(C(N)=N)=CC=3)N=2)C=2C=CC=CC=2)=C1 LIHYYGJORXOOBR-UHFFFAOYSA-N 0.000 description 1
- KUHXMNGDXGRYHU-UHFFFAOYSA-N 3-[[6-(4-cyano-3-methylphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C=C(C)C(C#N)=CC=3)N=2)=C1 KUHXMNGDXGRYHU-UHFFFAOYSA-N 0.000 description 1
- BIIKZVOYRWICPL-UHFFFAOYSA-N 3-[[6-(5-carbamimidoyl-2-chlorophenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C(=CC=C(C=3)C(N)=N)Cl)N=2)=C1 BIIKZVOYRWICPL-UHFFFAOYSA-N 0.000 description 1
- PVNMHNPHDCNYSI-UHFFFAOYSA-N 3-[[6-(5-carbamimidoyl-2-methylphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C(=CC=C(C=3)C(N)=N)C)N=2)=C1 PVNMHNPHDCNYSI-UHFFFAOYSA-N 0.000 description 1
- AGFVLDOUTXGLJM-UHFFFAOYSA-N 3-[[6-(5-carbamimidoyl-2-methylphenoxy)-8-phenyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(NC3=C(OC=3C(=CC=C(C=3)C(N)=N)C)N=2)C=2C=CC=CC=2)=C1 AGFVLDOUTXGLJM-UHFFFAOYSA-N 0.000 description 1
- FBGQRDJNLPAGDO-UHFFFAOYSA-N 3-[[6-(5-cyano-2-methylphenoxy)-8-methyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C(=CC=C(C=3)C#N)C)N=2)=C1 FBGQRDJNLPAGDO-UHFFFAOYSA-N 0.000 description 1
- LRJVZRPXKPVDFN-UHFFFAOYSA-N 3-[[6-(5-cyano-2-methylphenoxy)-8-phenyl-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(NC3=C(OC=3C(=CC=C(C=3)C#N)C)N=2)C=2C=CC=CC=2)=C1 LRJVZRPXKPVDFN-UHFFFAOYSA-N 0.000 description 1
- QHFZZZTZDCSELO-UHFFFAOYSA-N 3-[[8-benzyl-6-(2-chloro-5-cyanophenoxy)-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(CC=4C=CC=CC=4)NC3=C(OC=3C(=CC=C(C=3)C#N)Cl)N=2)=C1 QHFZZZTZDCSELO-UHFFFAOYSA-N 0.000 description 1
- CALPMZBORQEQHQ-UHFFFAOYSA-N 3-[[8-benzyl-6-(3-bromo-5-carbamimidoylphenoxy)-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(CC=4C=CC=CC=4)NC3=C(OC=3C=C(C=C(Br)C=3)C(N)=N)N=2)=C1 CALPMZBORQEQHQ-UHFFFAOYSA-N 0.000 description 1
- WHUQAHSETIVVBV-UHFFFAOYSA-N 3-[[8-benzyl-6-(3-bromo-5-cyanophenoxy)-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(CC=4C=CC=CC=4)NC3=C(OC=3C=C(C=C(Br)C=3)C#N)N=2)=C1 WHUQAHSETIVVBV-UHFFFAOYSA-N 0.000 description 1
- GPZILDVRUKOOBC-UHFFFAOYSA-N 3-[[8-benzyl-6-(5-carbamimidoyl-2-chlorophenoxy)-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(CC=4C=CC=CC=4)NC3=C(OC=3C(=CC=C(C=3)C(N)=N)Cl)N=2)=C1 GPZILDVRUKOOBC-UHFFFAOYSA-N 0.000 description 1
- IRGCYAIHXRREQI-UHFFFAOYSA-N 3-[[8-benzyl-6-(5-carbamimidoyl-2-methylphenoxy)-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(CC=4C=CC=CC=4)NC3=C(OC=3C(=CC=C(C=3)C(N)=N)C)N=2)=C1 IRGCYAIHXRREQI-UHFFFAOYSA-N 0.000 description 1
- UGKBZGZQNZFOAO-UHFFFAOYSA-N 3-[[8-benzyl-6-(5-cyano-2-methylphenoxy)-7h-purin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N=C(CC=4C=CC=CC=4)NC3=C(OC=3C(=CC=C(C=3)C#N)C)N=2)=C1 UGKBZGZQNZFOAO-UHFFFAOYSA-N 0.000 description 1
- IFRYPWONXNSYSC-UHFFFAOYSA-N 3-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]-4-methoxybenzenecarboximidamide Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)OC)=C2NC(CC)=NC2=NC=1OC(C=1)=CC=CC=1C1=NCCN1C IFRYPWONXNSYSC-UHFFFAOYSA-N 0.000 description 1
- HQZJNOHSLDQTFB-UHFFFAOYSA-N 3-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]-4-methoxybenzonitrile Chemical compound N=1C(OC=2C(=CC=C(C=2)C#N)OC)=C2NC(CC)=NC2=NC=1OC(C=1)=CC=CC=1C1=NCCN1C HQZJNOHSLDQTFB-UHFFFAOYSA-N 0.000 description 1
- WGQZFEGTXQVVPG-UHFFFAOYSA-N 3-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]-4-phenoxybenzenecarboximidamide Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)=C2NC(CC)=NC2=NC=1OC(C=1)=CC=CC=1C1=NCCN1C WGQZFEGTXQVVPG-UHFFFAOYSA-N 0.000 description 1
- WKIQPQPHVJDZLV-UHFFFAOYSA-N 3-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]-4-phenoxybenzonitrile Chemical compound N=1C(OC=2C(=CC=C(C=2)C#N)OC=2C=CC=CC=2)=C2NC(CC)=NC2=NC=1OC(C=1)=CC=CC=1C1=NCCN1C WKIQPQPHVJDZLV-UHFFFAOYSA-N 0.000 description 1
- XJWAODWXMQAQGP-UHFFFAOYSA-N 3-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]-5-methoxybenzenecarboximidamide Chemical compound N=1C(OC=2C=C(C=C(OC)C=2)C(N)=N)=C2NC(CC)=NC2=NC=1OC(C=1)=CC=CC=1C1=NCCN1C XJWAODWXMQAQGP-UHFFFAOYSA-N 0.000 description 1
- KTJZEWRFWUASFW-UHFFFAOYSA-N 3-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]-5-methoxybenzonitrile Chemical compound N=1C(OC=2C=C(C=C(OC)C=2)C#N)=C2NC(CC)=NC2=NC=1OC(C=1)=CC=CC=1C1=NCCN1C KTJZEWRFWUASFW-UHFFFAOYSA-N 0.000 description 1
- TXDBSEGEQVOYEU-UHFFFAOYSA-N 3-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]-4-phenoxybenzenecarboximidamide Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C(=CC=C(C=3)C(N)=N)OC=3C=CC=CC=3)N=2)=C1 TXDBSEGEQVOYEU-UHFFFAOYSA-N 0.000 description 1
- FEIVJGPFOCFURO-UHFFFAOYSA-N 3-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]-4-phenoxybenzonitrile Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N=C(C)NC3=C(OC=3C(=CC=C(C=3)C#N)OC=3C=CC=CC=3)N=2)=C1 FEIVJGPFOCFURO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- AUUPXZULSRIYTQ-UHFFFAOYSA-N 3-bromo-5-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxybenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C=C(Br)C=2)C#N)=N1 AUUPXZULSRIYTQ-UHFFFAOYSA-N 0.000 description 1
- VEAFOLQISNOGHT-UHFFFAOYSA-N 3-ethoxy-5-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzenecarboximidamide Chemical compound NC(=N)C1=CC(OCC)=CC(OC=2C=3NC(CC)=NC=3N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)=C1 VEAFOLQISNOGHT-UHFFFAOYSA-N 0.000 description 1
- AYUKTSCVNXUFAT-UHFFFAOYSA-N 3-ethoxy-5-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzonitrile Chemical compound N#CC1=CC(OCC)=CC(OC=2C=3NC(CC)=NC=3N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)=C1 AYUKTSCVNXUFAT-UHFFFAOYSA-N 0.000 description 1
- IAYGYZZIIDYUPU-UHFFFAOYSA-N 3-ethoxy-5-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzenecarboximidamide Chemical compound NC(=N)C1=CC(OCC)=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)=C1 IAYGYZZIIDYUPU-UHFFFAOYSA-N 0.000 description 1
- DBVBMIOYRZUDMD-UHFFFAOYSA-N 3-ethoxy-5-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzonitrile Chemical compound N#CC1=CC(OCC)=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)=C1 DBVBMIOYRZUDMD-UHFFFAOYSA-N 0.000 description 1
- QLXRTAIZTUBEON-UHFFFAOYSA-N 3-methoxy-5-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzenecarboximidamide Chemical compound NC(=N)C1=CC(OC)=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)=C1 QLXRTAIZTUBEON-UHFFFAOYSA-N 0.000 description 1
- UOUCIYJVOFMLQR-UHFFFAOYSA-N 3-methoxy-5-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzonitrile Chemical compound N#CC1=CC(OC)=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)=C1 UOUCIYJVOFMLQR-UHFFFAOYSA-N 0.000 description 1
- PZCZFUNYNTUJCM-UHFFFAOYSA-N 4-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-(dimethylamino)benzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)N(C)C)=N1 PZCZFUNYNTUJCM-UHFFFAOYSA-N 0.000 description 1
- QVAVEMJWEWTKEO-UHFFFAOYSA-N 4-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-methylbenzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C)C(C#N)=CC=2)=N1 QVAVEMJWEWTKEO-UHFFFAOYSA-N 0.000 description 1
- BSDNAGMITUCJSO-UHFFFAOYSA-N 4-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-nitrobenzonitrile Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)[N+]([O-])=O)=N1 BSDNAGMITUCJSO-UHFFFAOYSA-N 0.000 description 1
- WDLXIZVVERJZCV-UHFFFAOYSA-N 4-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-2-(dimethylamino)benzonitrile Chemical compound C1=C(C#N)C(N(C)C)=CC(OC=2C(=C(N)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 WDLXIZVVERJZCV-UHFFFAOYSA-N 0.000 description 1
- LHSGFOMJVTVCBU-UHFFFAOYSA-N 4-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-2-methylbenzonitrile Chemical compound C1=C(C#N)C(C)=CC(OC=2C(=C(N)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 LHSGFOMJVTVCBU-UHFFFAOYSA-N 0.000 description 1
- WYKZKROGJMODCG-UHFFFAOYSA-N 4-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-2-nitrobenzonitrile Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)[N+]([O-])=O)=N1 WYKZKROGJMODCG-UHFFFAOYSA-N 0.000 description 1
- BASLDSFJVSQUSB-UHFFFAOYSA-N 4-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-(dimethylamino)benzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)N(C)C)=N1 BASLDSFJVSQUSB-UHFFFAOYSA-N 0.000 description 1
- NXPXZZNLZONVGE-UHFFFAOYSA-N 4-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-methylbenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C)C(C#N)=CC=2)=N1 NXPXZZNLZONVGE-UHFFFAOYSA-N 0.000 description 1
- SGTNDCQHZUDILH-UHFFFAOYSA-N 4-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-nitrobenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)[N+]([O-])=O)=N1 SGTNDCQHZUDILH-UHFFFAOYSA-N 0.000 description 1
- CSRBQBWWVUVECZ-UHFFFAOYSA-N 4-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-(dimethylamino)benzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)N(C)C)N CSRBQBWWVUVECZ-UHFFFAOYSA-N 0.000 description 1
- YKZUWXSTYNLVIE-UHFFFAOYSA-N 4-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-methylbenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)C)N YKZUWXSTYNLVIE-UHFFFAOYSA-N 0.000 description 1
- SPBDCHPUWYYTNG-UHFFFAOYSA-N 4-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-nitrobenzonitrile Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)[N+](=O)[O-])N SPBDCHPUWYYTNG-UHFFFAOYSA-N 0.000 description 1
- BDJKMQKKDLNRHQ-UHFFFAOYSA-N 4-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-(dimethylamino)benzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)N(C)C)N BDJKMQKKDLNRHQ-UHFFFAOYSA-N 0.000 description 1
- BZMJCQVMZZJPOA-UHFFFAOYSA-N 4-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-methylbenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)C)N BZMJCQVMZZJPOA-UHFFFAOYSA-N 0.000 description 1
- CNFIFDIMAAFRQY-UHFFFAOYSA-N 4-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-nitrobenzonitrile Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)[N+](=O)[O-])N CNFIFDIMAAFRQY-UHFFFAOYSA-N 0.000 description 1
- KJLOQWRVFQBMCH-UHFFFAOYSA-N 4-[9-benzyl-2-[3-(dimethylamino)phenoxy]-8-methylpurin-6-yl]oxy-2-methylbenzenecarboximidamide Chemical compound CN(C)C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C)C(C(N)=N)=CC=3)N=2)=C1 KJLOQWRVFQBMCH-UHFFFAOYSA-N 0.000 description 1
- UMWXGKSIXRMPHC-UHFFFAOYSA-N 4-[9-benzyl-2-[3-(dimethylamino)phenoxy]-8-methylpurin-6-yl]oxy-2-methylbenzonitrile Chemical compound CN(C)C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C)C(C#N)=CC=3)N=2)=C1 UMWXGKSIXRMPHC-UHFFFAOYSA-N 0.000 description 1
- VFQLYLOJDHUESX-UHFFFAOYSA-N 4-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-2-(dimethylamino)benzenecarboximidamide Chemical compound C1=C(C(N)=N)C(N(C)C)=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)=C1 VFQLYLOJDHUESX-UHFFFAOYSA-N 0.000 description 1
- FFDJBTWQGYXOHG-UHFFFAOYSA-N 4-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-2-(dimethylamino)benzonitrile Chemical compound C1=C(C#N)C(N(C)C)=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C=C(C=CC=3)C=3N(CCN=3)C)N=2)=C1 FFDJBTWQGYXOHG-UHFFFAOYSA-N 0.000 description 1
- WFGKLTDGPJMEKY-UHFFFAOYSA-N 4-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]-2-(dimethylamino)benzenecarboximidamide Chemical compound C1=C(C(N)=N)C(N(C)C)=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C=C(NC(N)=N)C=CC=3)N=2)=C1 WFGKLTDGPJMEKY-UHFFFAOYSA-N 0.000 description 1
- FVYJGBFDSZFRIL-UHFFFAOYSA-N 4-[[3,5-diamino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-2H-pyrimidin-4-yl]oxy]-2-(dimethylamino)benzonitrile Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=C(C=C2)C#N)N(C)C)N)C=CC=1 FVYJGBFDSZFRIL-UHFFFAOYSA-N 0.000 description 1
- REBMYYCYKXBILB-UHFFFAOYSA-N 4-[[3,5-diamino-6-benzyl-2-[3-(dimethylamino)phenoxy]-2H-pyrimidin-4-yl]oxy]-2-methylbenzonitrile Chemical compound CN(C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=C(C=C2)C#N)C)N)C=CC=1)C REBMYYCYKXBILB-UHFFFAOYSA-N 0.000 description 1
- DUZWRNZHKXTXIH-UHFFFAOYSA-N 4-[[3-amino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-2-(dimethylamino)benzonitrile Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=C(C=C2)C#N)N(C)C)N)C=CC=1 DUZWRNZHKXTXIH-UHFFFAOYSA-N 0.000 description 1
- OLADPWDKTZFSQU-UHFFFAOYSA-N 4-[[3-amino-6-benzyl-2-[3-(dimethylamino)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-2-methylbenzonitrile Chemical compound CN(C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=C(C=C2)C#N)C)N)C=CC=1)C OLADPWDKTZFSQU-UHFFFAOYSA-N 0.000 description 1
- DASNFAJFFPUQJN-UHFFFAOYSA-N 4-amino-2-[2-[5-carbamimidoyl-2-(diethylcarbamoyl)phenoxy]-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-4-oxobutanoic acid Chemical compound CCN(CC)C(=O)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(N=C(C)N2C(CC(N)=O)C(O)=O)C2=N1 DASNFAJFFPUQJN-UHFFFAOYSA-N 0.000 description 1
- MGGFJGODKXTYGL-UHFFFAOYSA-N 4-amino-3-[4-(benzylamino)-5-nitro-6-[3-(trifluoromethoxy)phenoxy]pyrimidin-2-yl]oxybenzonitrile Chemical compound NC1=CC=C(C#N)C=C1OC1=NC(NCC=2C=CC=CC=2)=C([N+]([O-])=O)C(OC=2C=C(OC(F)(F)F)C=CC=2)=N1 MGGFJGODKXTYGL-UHFFFAOYSA-N 0.000 description 1
- DRDGONOFXJBFFD-UHFFFAOYSA-N 4-amino-3-[6-[3-(diaminomethylideneamino)phenoxy]-8,9-diethylpurin-2-yl]oxybenzenecarboximidamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)N)N=C2N(CC)C(CC)=NC2=C1OC1=CC=CC(NC(N)=N)=C1 DRDGONOFXJBFFD-UHFFFAOYSA-N 0.000 description 1
- JBPNHWCQWNYSOY-UHFFFAOYSA-N 4-amino-3-[8,9-diethyl-6-[3-(trifluoromethoxy)phenoxy]purin-2-yl]oxybenzenecarboximidamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)N)N=C2N(CC)C(CC)=NC2=C1OC1=CC=CC(OC(F)(F)F)=C1 JBPNHWCQWNYSOY-UHFFFAOYSA-N 0.000 description 1
- CTOLELKREDBCLN-UHFFFAOYSA-N 4-amino-3-[8,9-diethyl-6-[3-(trifluoromethoxy)phenoxy]purin-2-yl]oxybenzonitrile Chemical compound NC1=C(OC2=NC(=C3N=C(N(C3=N2)CC)CC)OC2=CC(=CC=C2)OC(F)(F)F)C=C(C=C1)C#N CTOLELKREDBCLN-UHFFFAOYSA-N 0.000 description 1
- BAXBTMRMQMZVCT-UHFFFAOYSA-N 4-amino-3-[9-benzyl-6-[3-(diaminomethylideneamino)phenoxy]-8-methylpurin-2-yl]oxybenzenecarboximidamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)N)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC=CC(NC(N)=N)=C1 BAXBTMRMQMZVCT-UHFFFAOYSA-N 0.000 description 1
- QNGNFCJHXIZGTP-UHFFFAOYSA-N 4-amino-3-[9-benzyl-8-methyl-6-[3-(trifluoromethoxy)phenoxy]purin-2-yl]oxybenzenecarboximidamide Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)N)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC=CC(OC(F)(F)F)=C1 QNGNFCJHXIZGTP-UHFFFAOYSA-N 0.000 description 1
- HDWISQQZOOSSDU-UHFFFAOYSA-N 4-amino-3-[9-benzyl-8-methyl-6-[3-(trifluoromethoxy)phenoxy]purin-2-yl]oxybenzonitrile Chemical compound NC1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)OC(F)(F)F)C=C(C=C1)C#N HDWISQQZOOSSDU-UHFFFAOYSA-N 0.000 description 1
- PSACPODGLPOFCN-UHFFFAOYSA-N 4-amino-3-[[1,5-diamino-4-benzyl-6-[3-(trifluoromethoxy)phenoxy]-2H-pyrimidin-2-yl]oxy]benzonitrile Chemical compound NC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)OC(F)(F)F)N)C=C(C=C1)C#N PSACPODGLPOFCN-UHFFFAOYSA-N 0.000 description 1
- AJLPUVRVTRQNRL-UHFFFAOYSA-N 4-amino-3-[[6-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-2-yl]oxy]benzenecarboximidamide Chemical compound N=1C(OC=2C=C(NC(N)=N)C=CC=2)=C2NC(C)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1N AJLPUVRVTRQNRL-UHFFFAOYSA-N 0.000 description 1
- BHJCDAHDMPEWNO-UHFFFAOYSA-N 4-amino-3-[[8-ethyl-6-[3-(trifluoromethoxy)phenoxy]-7H-purin-2-yl]oxy]benzonitrile Chemical compound NC1=C(OC2=NC(=C3NC(=NC3=N2)CC)OC2=CC(=CC=C2)OC(F)(F)F)C=C(C=C1)C#N BHJCDAHDMPEWNO-UHFFFAOYSA-N 0.000 description 1
- LCXOHFGIDAKZJP-UHFFFAOYSA-N 4-amino-3-[[8-ethyl-6-[3-(trifluoromethoxy)phenoxy]-7h-purin-2-yl]oxy]benzenecarboximidamide Chemical compound N=1C(OC=2C=C(OC(F)(F)F)C=CC=2)=C2NC(CC)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1N LCXOHFGIDAKZJP-UHFFFAOYSA-N 0.000 description 1
- UVEKCSKBYHRKLF-UHFFFAOYSA-N 4-carbamimidoyl-2-[6-[3-(carbamoylamino)phenoxy]-8,9-diethylpurin-2-yl]oxybenzoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C(O)=O)N=C2N(CC)C(CC)=NC2=C1OC1=CC=CC(NC(N)=O)=C1 UVEKCSKBYHRKLF-UHFFFAOYSA-N 0.000 description 1
- AHEYHLDDQYYHFQ-UHFFFAOYSA-N 4-carbamimidoyl-2-[6-[3-(dimethylcarbamoyl)phenoxy]-9-(1-ethoxy-3-hydroxy-1-oxopropan-2-yl)-8-methylpurin-2-yl]oxybenzoic acid Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C(O)=O)N=C2N(C(CO)C(=O)OCC)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 AHEYHLDDQYYHFQ-UHFFFAOYSA-N 0.000 description 1
- AORPTVGAHAHVAE-UHFFFAOYSA-N 4-carbamimidoyl-2-[9-(1-carboxy-2-hydroxyethyl)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-2-yl]oxybenzoic acid Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(C(CO)C(O)=O)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(O)=O)N=2)=C1 AORPTVGAHAHVAE-UHFFFAOYSA-N 0.000 description 1
- RPRDNQIROOQWIF-UHFFFAOYSA-N 4-carbamimidoyl-2-[[2-[3-(diaminomethylideneamino)phenoxy]-8-(trifluoromethyl)-7h-purin-6-yl]oxy]benzamide Chemical compound NC(N)=NC1=CC=CC(OC=2N=C3N=C(NC3=C(OC=3C(=CC=C(C=3)C(N)=N)C(N)=O)N=2)C(F)(F)F)=C1 RPRDNQIROOQWIF-UHFFFAOYSA-N 0.000 description 1
- WJNSAXZQPYRLNU-UHFFFAOYSA-N 4-carbamimidoyl-2-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzamide Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)C(N)=O)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 WJNSAXZQPYRLNU-UHFFFAOYSA-N 0.000 description 1
- VSCLHVGNXITYIS-UHFFFAOYSA-N 4-carbamimidoyl-2-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzoic acid Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)C(O)=O)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 VSCLHVGNXITYIS-UHFFFAOYSA-N 0.000 description 1
- VUWLMYKLMWQSEA-UHFFFAOYSA-N 4-carbamimidoyl-2-[[6-[3-(carbamoylamino)phenoxy]-8-methyl-7h-purin-2-yl]oxy]benzoic acid Chemical compound N=1C(OC=2C=C(NC(N)=O)C=CC=2)=C2NC(C)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1C(O)=O VUWLMYKLMWQSEA-UHFFFAOYSA-N 0.000 description 1
- JANGTXOLXSVGJZ-UHFFFAOYSA-N 4-carbamimidoyl-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-ethyl-7h-purin-2-yl]oxy]-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(NC(CC)=N2)C2=N1 JANGTXOLXSVGJZ-UHFFFAOYSA-N 0.000 description 1
- KRAVRLBFXJBTJK-UHFFFAOYSA-N 4-carbamimidoyl-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-ethyl-7h-purin-2-yl]oxy]benzoic acid Chemical compound N=1C(OC=2C=C(C=CC=2)C(=O)N(C)C)=C2NC(CC)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1C(O)=O KRAVRLBFXJBTJK-UHFFFAOYSA-N 0.000 description 1
- IVUXMBNAJKTDRO-UHFFFAOYSA-N 4-carbamimidoyl-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-methyl-7h-purin-2-yl]oxy]-n,n-diethylbenzamide Chemical compound CCN(CC)C(=O)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)N(C)C)=C(NC(C)=N2)C2=N1 IVUXMBNAJKTDRO-UHFFFAOYSA-N 0.000 description 1
- CCFCMICWRNFIPH-UHFFFAOYSA-N 4-carbamimidoyl-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-methyl-7h-purin-2-yl]oxy]benzoic acid Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(O)=O)N=2)=C1 CCFCMICWRNFIPH-UHFFFAOYSA-N 0.000 description 1
- WEOYXMGHEDCFRL-UHFFFAOYSA-N 4-chloro-2-methylsulfanyl-5-nitro-6-(3-nitrophenoxy)pyrimidine Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C=CC=2)[N+]([O-])=O)=N1 WEOYXMGHEDCFRL-UHFFFAOYSA-N 0.000 description 1
- MXVVHRJHPUREKC-UHFFFAOYSA-N 4-chloro-3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxybenzonitrile Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)Cl)=N1 MXVVHRJHPUREKC-UHFFFAOYSA-N 0.000 description 1
- XDYYAZDMQHQJGZ-UHFFFAOYSA-N 4-chloro-3-[[3,5-diamino-6-benzyl-2-[3-(2-chloroethyl)-5-methylphenoxy]-2H-pyrimidin-4-yl]oxy]benzonitrile Chemical compound ClCCC=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)Cl)N)C=C(C=1)C XDYYAZDMQHQJGZ-UHFFFAOYSA-N 0.000 description 1
- YHXVUMVJGMVTRP-UHFFFAOYSA-N 4-chloro-6-(3-chloro-5-methoxyphenoxy)-2-methylsulfanyl-5-nitropyrimidine Chemical compound COC1=CC(Cl)=CC(OC=2C(=C(Cl)N=C(SC)N=2)[N+]([O-])=O)=C1 YHXVUMVJGMVTRP-UHFFFAOYSA-N 0.000 description 1
- BHPNSXWYQNEXSO-UHFFFAOYSA-N 4-cyano-2-[5,6-diamino-2-[3-(diaminomethylideneamino)phenoxy]pyrimidin-4-yl]oxybenzamide Chemical compound NC(=N)NC1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)C(N)=O)C(N)=C(N)N=2)=C1 BHPNSXWYQNEXSO-UHFFFAOYSA-N 0.000 description 1
- SBUOABDBOSMVPQ-UHFFFAOYSA-N 4-cyano-2-[5,6-diamino-2-[3-(diaminomethylideneamino)phenoxy]pyrimidin-4-yl]oxybenzoic acid Chemical compound NC(=N)NC1=CC=CC(OC=2N=C(OC=3C(=CC=C(C=3)C#N)C(O)=O)C(N)=C(N)N=2)=C1 SBUOABDBOSMVPQ-UHFFFAOYSA-N 0.000 description 1
- DDJIKUILCIGPKG-UHFFFAOYSA-N 4-cyano-2-[[1,5-diamino-4-benzyl-6-[3-(carbamoylamino)phenoxy]-2H-pyrimidin-2-yl]oxy]benzoic acid Chemical compound C(=O)(O)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)NC(=O)N)N)C=C(C=C1)C#N DDJIKUILCIGPKG-UHFFFAOYSA-N 0.000 description 1
- QYPMHJKINLEOLS-UHFFFAOYSA-N 4-cyano-2-[[1,5-diamino-4-benzyl-6-[3-(dimethylcarbamoyl)phenoxy]-2H-pyrimidin-2-yl]oxy]-N,N-diethylbenzamide Chemical compound C(C)N(C(=O)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N)CC QYPMHJKINLEOLS-UHFFFAOYSA-N 0.000 description 1
- BWSTVOHLVPXRQO-UHFFFAOYSA-N 4-cyano-2-[[1,5-diamino-4-benzyl-6-[3-(dimethylcarbamoyl)phenoxy]-2H-pyrimidin-2-yl]oxy]benzoic acid Chemical compound C(=O)(O)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N BWSTVOHLVPXRQO-UHFFFAOYSA-N 0.000 description 1
- XTQZXCNSDCCBCA-UHFFFAOYSA-N 4-cyano-2-[[1,5-diamino-6-(3-aminophenoxy)-4-benzyl-2H-pyrimidin-2-yl]oxy]-N,N-diethylbenzamide Chemical compound C(C)N(C(=O)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)N)N)C=C(C=C1)C#N)CC XTQZXCNSDCCBCA-UHFFFAOYSA-N 0.000 description 1
- XBHVAVLUPCENQL-UHFFFAOYSA-N 4-cyano-2-[[2-[3-(diaminomethylideneamino)phenoxy]-8-(trifluoromethyl)-7h-purin-6-yl]oxy]benzamide Chemical compound NC(=N)NC1=CC=CC(OC=2N=C3N=C(NC3=C(OC=3C(=CC=C(C=3)C#N)C(N)=O)N=2)C(F)(F)F)=C1 XBHVAVLUPCENQL-UHFFFAOYSA-N 0.000 description 1
- UVJMTXDSERFXLC-UHFFFAOYSA-N 4-cyano-2-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzamide Chemical compound N=1C(OC=2C(=CC=C(C=2)C#N)C(N)=O)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 UVJMTXDSERFXLC-UHFFFAOYSA-N 0.000 description 1
- HJSYHZLECRIWAL-UHFFFAOYSA-N 4-cyano-2-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzoic acid Chemical compound N=1C(OC=2C(=CC=C(C=2)C#N)C(O)=O)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 HJSYHZLECRIWAL-UHFFFAOYSA-N 0.000 description 1
- FEIYHPLNYWQIAR-UHFFFAOYSA-N 4-cyano-2-[[3,5-diamino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-2H-pyrimidin-4-yl]oxy]benzamide Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)C(=O)N)N)C=CC=1 FEIYHPLNYWQIAR-UHFFFAOYSA-N 0.000 description 1
- QJIPSQUEZBHMOJ-UHFFFAOYSA-N 4-cyano-2-[[3,5-diamino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-2H-pyrimidin-4-yl]oxy]benzoic acid Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)C(=O)O)N)C=CC=1 QJIPSQUEZBHMOJ-UHFFFAOYSA-N 0.000 description 1
- WUKTXZOPIPHXET-UHFFFAOYSA-N 4-cyano-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-ethyl-7H-purin-2-yl]oxy]benzoic acid Chemical compound C(=O)(O)C1=C(OC2=NC(=C3NC(=NC3=N2)CC)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N WUKTXZOPIPHXET-UHFFFAOYSA-N 0.000 description 1
- YAOLXZBITQFHAC-UHFFFAOYSA-N 4-cyano-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-methyl-7H-purin-2-yl]oxy]benzoic acid Chemical compound C(=O)(O)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N YAOLXZBITQFHAC-UHFFFAOYSA-N 0.000 description 1
- CUURGLICIQNPSC-UHFFFAOYSA-N 4-ethoxy-3-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzenecarboximidamide Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC2=C1NC(CC)=N2 CUURGLICIQNPSC-UHFFFAOYSA-N 0.000 description 1
- HKMHFHBMQPZGAV-UHFFFAOYSA-N 4-ethoxy-3-[[8-ethyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzonitrile Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC2=C1NC(CC)=N2 HKMHFHBMQPZGAV-UHFFFAOYSA-N 0.000 description 1
- WRONFIWCTGBROH-UHFFFAOYSA-N 4-ethoxy-3-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzenecarboximidamide Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC2=C1NC(C)=N2 WRONFIWCTGBROH-UHFFFAOYSA-N 0.000 description 1
- ONQBWLLJVIMVHR-UHFFFAOYSA-N 4-ethoxy-3-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzonitrile Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC2=C1NC(C)=N2 ONQBWLLJVIMVHR-UHFFFAOYSA-N 0.000 description 1
- WCKKHAIRQAQMIJ-UHFFFAOYSA-N 4-hydroxy-3-[[8-methyl-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7H-purin-2-yl]oxy]benzenecarboximidamide Chemical compound CN1CCN=C1c1cccc(Oc2nc(Oc3cc(ccc3O)C(N)=N)nc3nc(C)[nH]c23)c1 WCKKHAIRQAQMIJ-UHFFFAOYSA-N 0.000 description 1
- RCFLGCXWLQNEJK-UHFFFAOYSA-N 4-methoxy-3-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzenecarboximidamide Chemical compound COC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC2=C1NC(C)=N2 RCFLGCXWLQNEJK-UHFFFAOYSA-N 0.000 description 1
- PDDKEMIKCOSYME-UHFFFAOYSA-N 4-methoxy-3-[[8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-7h-purin-6-yl]oxy]benzonitrile Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)C=2N(CCN=2)C)=NC2=C1NC(C)=N2 PDDKEMIKCOSYME-UHFFFAOYSA-N 0.000 description 1
- DQMXCZMNIRBNND-UHFFFAOYSA-N 4-methyl-3-[[8-methyl-6-(3-phenylmethoxyphenoxy)-7H-purin-2-yl]oxy]benzonitrile Chemical compound CC1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)OCC2=CC=CC=C2)C=C(C=C1)C#N DQMXCZMNIRBNND-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- CFHYZZRTZBFLOV-UHFFFAOYSA-N 4-tert-butyl-3-[6-(3-ethoxyphenoxy)-8,9-diethylpurin-2-yl]oxybenzenecarboximidamide Chemical compound CCOC1=CC=CC(OC=2C=3N=C(CC)N(CC)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(C)(C)C)N=2)=C1 CFHYZZRTZBFLOV-UHFFFAOYSA-N 0.000 description 1
- UWLWXOMUGRVGMK-UHFFFAOYSA-N 4-tert-butyl-3-[6-(3-ethoxyphenoxy)-8,9-diethylpurin-2-yl]oxybenzonitrile Chemical compound C(C)(C)(C)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC)CC)OC2=CC(=CC=C2)OCC)C=C(C=C1)C#N UWLWXOMUGRVGMK-UHFFFAOYSA-N 0.000 description 1
- QWAGIPCDOVYLLF-UHFFFAOYSA-N 4-tert-butyl-3-[[1,5-diamino-4-benzyl-6-(3-ethoxyphenoxy)-2H-pyrimidin-2-yl]oxy]benzonitrile Chemical compound C(C)(C)(C)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)OCC)N)C=C(C=C1)C#N QWAGIPCDOVYLLF-UHFFFAOYSA-N 0.000 description 1
- WCNPKAKNCXSKCZ-UHFFFAOYSA-N 4-tert-butyl-3-[[6-(3-ethoxyphenoxy)-8-methyl-7H-purin-2-yl]oxy]benzonitrile Chemical compound C(C)(C)(C)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)OCC)C=C(C=C1)C#N WCNPKAKNCXSKCZ-UHFFFAOYSA-N 0.000 description 1
- DMVGJHKNWHGDKY-UHFFFAOYSA-N 4-tert-butyl-3-[[6-(3-ethoxyphenoxy)-8-methyl-7h-purin-2-yl]oxy]benzenecarboximidamide Chemical compound CCOC1=CC=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(C)(C)C)N=2)=C1 DMVGJHKNWHGDKY-UHFFFAOYSA-N 0.000 description 1
- MVYBOIQGQPMQLR-UHFFFAOYSA-N 5-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzamide Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)C(N)=O)=N1 MVYBOIQGQPMQLR-UHFFFAOYSA-N 0.000 description 1
- ZISGJDSFFSZNQL-UHFFFAOYSA-N 5-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzoic acid Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)C(O)=O)=N1 ZISGJDSFFSZNQL-UHFFFAOYSA-N 0.000 description 1
- LWZPBMWJATZHIL-UHFFFAOYSA-N 5-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzamide Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)C(N)=O)=N1 LWZPBMWJATZHIL-UHFFFAOYSA-N 0.000 description 1
- IPXDYGLSSUIXHJ-UHFFFAOYSA-N 5-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzoic acid Chemical compound CS(=O)(=O)C1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)C(O)=O)=N1 IPXDYGLSSUIXHJ-UHFFFAOYSA-N 0.000 description 1
- QCDVEMAUYIEVIP-UHFFFAOYSA-N 5-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzamide Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)C(N)=O)=N1 QCDVEMAUYIEVIP-UHFFFAOYSA-N 0.000 description 1
- JJANLPZQPOQJRN-UHFFFAOYSA-N 5-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzoic acid Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)C(O)=O)=N1 JJANLPZQPOQJRN-UHFFFAOYSA-N 0.000 description 1
- PBASPXPEBATQFT-UHFFFAOYSA-N 5-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-cyanobenzamide Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)C(=O)N)N PBASPXPEBATQFT-UHFFFAOYSA-N 0.000 description 1
- ARFJILIDGNZMFI-UHFFFAOYSA-N 5-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-cyanobenzoic acid Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)C(=O)O)N ARFJILIDGNZMFI-UHFFFAOYSA-N 0.000 description 1
- OQZNMTXCOLSYBO-UHFFFAOYSA-N 5-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-cyanobenzamide Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)C(=O)N)N OQZNMTXCOLSYBO-UHFFFAOYSA-N 0.000 description 1
- YPZJVDBQMAXUTL-UHFFFAOYSA-N 5-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-cyanobenzoic acid Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)C(=O)O)N YPZJVDBQMAXUTL-UHFFFAOYSA-N 0.000 description 1
- ZZIDATADDHAILR-UHFFFAOYSA-N 5-[6-amino-2-[3-(diaminomethylideneamino)phenoxy]-5-nitropyrimidin-4-yl]oxy-2-cyanobenzamide Chemical compound NC(N)=NC1=CC=CC(OC=2N=C(OC=3C=C(C(C#N)=CC=3)C(N)=O)C(=C(N)N=2)[N+]([O-])=O)=C1 ZZIDATADDHAILR-UHFFFAOYSA-N 0.000 description 1
- UZZKESQIXQYSOY-UHFFFAOYSA-N 5-[6-amino-2-[3-(diaminomethylideneamino)phenoxy]-5-nitropyrimidin-4-yl]oxy-2-cyanobenzoic acid Chemical compound NC(=N)NC1=CC=CC(OC=2N=C(OC=3C=C(C(C#N)=CC=3)C(O)=O)C(=C(N)N=2)[N+]([O-])=O)=C1 UZZKESQIXQYSOY-UHFFFAOYSA-N 0.000 description 1
- NLFZJAOJZWDYCA-UHFFFAOYSA-N 5-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-2-carbamimidoylbenzamide Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C(C(N)=N)=CC=3)C(N)=O)N=2)=C1 NLFZJAOJZWDYCA-UHFFFAOYSA-N 0.000 description 1
- AEUSJRWNXVWUFR-UHFFFAOYSA-N 5-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-2-carbamimidoylbenzoic acid Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C(C(N)=N)=CC=3)C(O)=O)N=2)=C1 AEUSJRWNXVWUFR-UHFFFAOYSA-N 0.000 description 1
- IVCAVVUFAUYNCS-UHFFFAOYSA-N 5-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-2-cyanobenzamide Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C(C#N)=CC=3)C(N)=O)N=2)=C1 IVCAVVUFAUYNCS-UHFFFAOYSA-N 0.000 description 1
- SXRGWIFECANTQF-UHFFFAOYSA-N 5-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-2-cyanobenzoic acid Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C(C#N)=CC=3)C(O)=O)N=2)=C1 SXRGWIFECANTQF-UHFFFAOYSA-N 0.000 description 1
- CUVPKILNKVUKRA-UHFFFAOYSA-N 5-[[3-amino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-2-cyanobenzamide Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=C(C=C2)C#N)C(=O)N)N)C=CC=1 CUVPKILNKVUKRA-UHFFFAOYSA-N 0.000 description 1
- VJHRQXUISKYVDT-UHFFFAOYSA-N 5-[[3-amino-6-benzyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]-5-nitro-2H-pyrimidin-4-yl]oxy]-2-cyanobenzoic acid Chemical compound CN1C(=NCC1)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=C(C=C2)C#N)C(=O)O)N)C=CC=1 VJHRQXUISKYVDT-UHFFFAOYSA-N 0.000 description 1
- YECWFTVBHXJCGI-UHFFFAOYSA-N 5-[[8-tert-butyl-2-[3-(diaminomethylideneamino)phenoxy]-7h-purin-6-yl]oxy]-2-carbamimidoylbenzoic acid Chemical compound N=1C(OC=2C=C(C(C(N)=N)=CC=2)C(O)=O)=C2NC(C(C)(C)C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 YECWFTVBHXJCGI-UHFFFAOYSA-N 0.000 description 1
- BGGPNGGDJWPIKD-UHFFFAOYSA-N 5-[[8-tert-butyl-2-[3-(diaminomethylideneamino)phenoxy]-7h-purin-6-yl]oxy]-2-cyanobenzoic acid Chemical compound N=1C(OC=2C=C(C(C#N)=CC=2)C(O)=O)=C2NC(C(C)(C)C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 BGGPNGGDJWPIKD-UHFFFAOYSA-N 0.000 description 1
- FMVXDFKPTLUZMU-UHFFFAOYSA-N 6-(3-amino-5-nitrophenoxy)-n-benzyl-2-methylsulfanyl-5-nitropyrimidin-4-amine Chemical compound [O-][N+](=O)C=1C(OC=2C=C(C=C(N)C=2)[N+]([O-])=O)=NC(SC)=NC=1NCC1=CC=CC=C1 FMVXDFKPTLUZMU-UHFFFAOYSA-N 0.000 description 1
- MVQUGOAWKHDBHC-UHFFFAOYSA-N 6-(3-amino-5-nitrophenoxy)-n-benzyl-2-methylsulfonyl-5-nitropyrimidin-4-amine Chemical compound [O-][N+](=O)C=1C(OC=2C=C(C=C(N)C=2)[N+]([O-])=O)=NC(S(=O)(=O)C)=NC=1NCC1=CC=CC=C1 MVQUGOAWKHDBHC-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- DQFYEBJUYRNMTE-UHFFFAOYSA-N CN(C(=O)C=1C=C(OC2=NC=C3NC(=NC3=N2)C)C=CC=1)C Chemical compound CN(C(=O)C=1C=C(OC2=NC=C3NC(=NC3=N2)C)C=CC=1)C DQFYEBJUYRNMTE-UHFFFAOYSA-N 0.000 description 1
- BVCWINBMDORNEU-UHFFFAOYSA-N CN(C(=O)C=1C=C(OC2=NC=C3NC(=NC3=N2)CC)C=CC=1)C Chemical compound CN(C(=O)C=1C=C(OC2=NC=C3NC(=NC3=N2)CC)C=CC=1)C BVCWINBMDORNEU-UHFFFAOYSA-N 0.000 description 1
- YJCFREMWOKOJHO-UHFFFAOYSA-N CN(C)C(=O)C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=CN=2)=C1 Chemical compound CN(C)C(=O)C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=CN=2)=C1 YJCFREMWOKOJHO-UHFFFAOYSA-N 0.000 description 1
- AYNLOOOZPYYTOT-UHFFFAOYSA-N CN1C(=NCC1)C=1C=C(ONC2=NC(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)N)C=CC1 Chemical compound CN1C(=NCC1)C=1C=C(ONC2=NC(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)N)C=CC1 AYNLOOOZPYYTOT-UHFFFAOYSA-N 0.000 description 1
- NZFHMUHBORALAG-UHFFFAOYSA-N CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C#N)N)N=2)=C1 Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C#N)N)N=2)=C1 NZFHMUHBORALAG-UHFFFAOYSA-N 0.000 description 1
- FZIBKKGONRIIMI-UHFFFAOYSA-N CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C(N)=N)N)N=2)=C1 Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C(N)=N)N)N=2)=C1 FZIBKKGONRIIMI-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 102100033299 Glia-derived nexin Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000003790 Thrombin receptors Human genes 0.000 description 1
- 108090000166 Thrombin receptors Proteins 0.000 description 1
- 102000012607 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- MCGLMFQDVZDHIH-UHFFFAOYSA-N [3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-5-methylphenyl]urea Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(NC(N)=O)C=C(C)C=2)=N1 MCGLMFQDVZDHIH-UHFFFAOYSA-N 0.000 description 1
- ZDNUTAOPLBVOJZ-UHFFFAOYSA-N [3-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxyphenyl]urea Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(NC(N)=O)C=CC=2)=N1 ZDNUTAOPLBVOJZ-UHFFFAOYSA-N 0.000 description 1
- HINVLLJLZMYFCH-UHFFFAOYSA-N [3-[6-(benzylamino)-2-methylsulfanyl-5-nitropyrimidin-4-yl]oxy-5-methylphenyl]urea Chemical compound [O-][N+](=O)C=1C(OC=2C=C(NC(N)=O)C=C(C)C=2)=NC(SC)=NC=1NCC1=CC=CC=C1 HINVLLJLZMYFCH-UHFFFAOYSA-N 0.000 description 1
- NUWZTVCRJOWGQA-UHFFFAOYSA-N [3-[6-(benzylamino)-2-methylsulfanyl-5-nitropyrimidin-4-yl]oxyphenyl]urea Chemical compound [O-][N+](=O)C=1C(OC=2C=C(NC(N)=O)C=CC=2)=NC(SC)=NC=1NCC1=CC=CC=C1 NUWZTVCRJOWGQA-UHFFFAOYSA-N 0.000 description 1
- VOTYFJHWWBHNRG-UHFFFAOYSA-N [3-[6-(benzylamino)-2-methylsulfonyl-5-nitropyrimidin-4-yl]oxy-5-methylphenyl]urea Chemical compound CC1=CC(NC(N)=O)=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 VOTYFJHWWBHNRG-UHFFFAOYSA-N 0.000 description 1
- UWXVUASPAZARET-UHFFFAOYSA-N [3-[6-(benzylamino)-2-methylsulfonyl-5-nitropyrimidin-4-yl]oxyphenyl]urea Chemical compound [O-][N+](=O)C=1C(OC=2C=C(NC(N)=O)C=CC=2)=NC(S(=O)(=O)C)=NC=1NCC1=CC=CC=C1 UWXVUASPAZARET-UHFFFAOYSA-N 0.000 description 1
- UWHUQLYYBOPKRI-UHFFFAOYSA-N [3-[9-benzyl-6-(3-carbamimidoyl-5-phenoxyphenoxy)-8-methylpurin-2-yl]oxyphenyl]urea Chemical compound N1=C(OC=2C=C(NC(N)=O)C=CC=2)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC(C=C(C=1)C(N)=N)=CC=1OC1=CC=CC=C1 UWHUQLYYBOPKRI-UHFFFAOYSA-N 0.000 description 1
- SFJHECPJWPTNKB-UHFFFAOYSA-N [3-[9-benzyl-6-(3-cyano-5-phenoxyphenoxy)-8-methylpurin-2-yl]oxyphenyl]urea Chemical compound N1=C(OC=2C=C(NC(N)=O)C=CC=2)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC(C=C(C=1)C#N)=CC=1OC1=CC=CC=C1 SFJHECPJWPTNKB-UHFFFAOYSA-N 0.000 description 1
- GPGCBMGXSLATTJ-UHFFFAOYSA-N [3-[[1,5-diamino-4-benzyl-6-(3-cyano-5-phenoxyphenoxy)-2H-pyrimidin-2-yl]oxy]phenyl]urea Chemical compound N(C(=O)N)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC(=C2)C#N)OC2=CC=CC=C2)N)C=CC=1 GPGCBMGXSLATTJ-UHFFFAOYSA-N 0.000 description 1
- AHZKHGABUYDSRJ-UHFFFAOYSA-N [3-[[1-amino-4-benzyl-6-(3-cyano-5-phenoxyphenoxy)-5-nitro-2H-pyrimidin-2-yl]oxy]phenyl]urea Chemical compound N(C(=O)N)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=CC(=C2)C#N)OC2=CC=CC=C2)N)C=CC=1 AHZKHGABUYDSRJ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001455 anti-clotting effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- NEUYCJRBZNYGHX-UHFFFAOYSA-N benzyl 2-[4-(3-aminophenoxy)-6-(benzylamino)-5-nitropyrimidin-2-yl]oxy-4-cyanobenzoate Chemical compound NC1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)C(=O)OCC=3C=CC=CC=3)N=2)[N+]([O-])=O)=C1 NEUYCJRBZNYGHX-UHFFFAOYSA-N 0.000 description 1
- LCFKJRAAYMBDPY-UHFFFAOYSA-N benzyl 2-[4-(benzylamino)-6-[3-(dimethylcarbamoyl)phenoxy]-5-nitropyrimidin-2-yl]oxy-4-cyanobenzoate Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(OC=3C(=CC=C(C=3)C#N)C(=O)OCC=3C=CC=CC=3)N=2)[N+]([O-])=O)=C1 LCFKJRAAYMBDPY-UHFFFAOYSA-N 0.000 description 1
- NWSWWBVFJCEAEC-UHFFFAOYSA-N benzyl 2-[6-(3-aminophenoxy)-8,9-diethylpurin-2-yl]oxy-4-carbamimidoylbenzoate Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C(=O)OCC=2C=CC=CC=2)N=C2N(CC)C(CC)=NC2=C1OC1=CC=CC(N)=C1 NWSWWBVFJCEAEC-UHFFFAOYSA-N 0.000 description 1
- QSDLBXLKZHDFQM-UHFFFAOYSA-N benzyl 2-[6-(3-aminophenoxy)-9-benzyl-8-methylpurin-2-yl]oxy-4-carbamimidoylbenzoate Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C(=O)OCC=2C=CC=CC=2)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC=CC(N)=C1 QSDLBXLKZHDFQM-UHFFFAOYSA-N 0.000 description 1
- FSEMWQQDMMVDCD-UHFFFAOYSA-N benzyl 2-[6-(3-aminophenoxy)-9-benzyl-8-methylpurin-2-yl]oxy-4-cyanobenzoate Chemical compound C(C1=CC=CC=C1)OC(=O)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)N)C=C(C=C1)C#N FSEMWQQDMMVDCD-UHFFFAOYSA-N 0.000 description 1
- JYGCYDLBLSFZSS-UHFFFAOYSA-N benzyl 2-[9-benzyl-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-2-yl]oxy-4-carbamimidoylbenzoate Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3N=C(C)N(CC=4C=CC=CC=4)C=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(=O)OCC=3C=CC=CC=3)N=2)=C1 JYGCYDLBLSFZSS-UHFFFAOYSA-N 0.000 description 1
- CZBKCMBQNCDCOD-UHFFFAOYSA-N benzyl 2-[9-benzyl-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-2-yl]oxy-4-cyanobenzoate Chemical compound C(C1=CC=CC=C1)OC(=O)C1=C(OC2=NC(=C3N=C(N(C3=N2)CC2=CC=CC=C2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N CZBKCMBQNCDCOD-UHFFFAOYSA-N 0.000 description 1
- PPGKVGUAWJEVAC-UHFFFAOYSA-N benzyl 2-[[6-(3-aminophenoxy)-8-methyl-7H-purin-2-yl]oxy]-4-cyanobenzoate Chemical compound C(C1=CC=CC=C1)OC(=O)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)N)C=C(C=C1)C#N PPGKVGUAWJEVAC-UHFFFAOYSA-N 0.000 description 1
- GAEUQAVNHGFZKR-UHFFFAOYSA-N benzyl 2-[[6-(3-aminophenoxy)-8-methyl-7h-purin-2-yl]oxy]-4-carbamimidoylbenzoate Chemical compound N=1C(OC=2C=C(N)C=CC=2)=C2NC(C)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1C(=O)OCC1=CC=CC=C1 GAEUQAVNHGFZKR-UHFFFAOYSA-N 0.000 description 1
- WYYFODXZRXIWTE-UHFFFAOYSA-N benzyl 4-carbamimidoyl-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-ethyl-7h-purin-2-yl]oxy]benzoate Chemical compound N=1C(OC=2C=C(C=CC=2)C(=O)N(C)C)=C2NC(CC)=NC2=NC=1OC1=CC(C(N)=N)=CC=C1C(=O)OCC1=CC=CC=C1 WYYFODXZRXIWTE-UHFFFAOYSA-N 0.000 description 1
- WUOBQXPCOIRUNL-UHFFFAOYSA-N benzyl 4-carbamimidoyl-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-methyl-7h-purin-2-yl]oxy]benzoate Chemical compound CN(C)C(=O)C1=CC=CC(OC=2C=3NC(C)=NC=3N=C(OC=3C(=CC=C(C=3)C(N)=N)C(=O)OCC=3C=CC=CC=3)N=2)=C1 WUOBQXPCOIRUNL-UHFFFAOYSA-N 0.000 description 1
- HTDSQDLMHWOTOI-UHFFFAOYSA-N benzyl 4-cyano-2-[[1,5-diamino-4-benzyl-6-[3-(dimethylcarbamoyl)phenoxy]-2H-pyrimidin-2-yl]oxy]benzoate Chemical compound C(C1=CC=CC=C1)OC(=O)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)N(C)C)N)C=C(C=C1)C#N HTDSQDLMHWOTOI-UHFFFAOYSA-N 0.000 description 1
- YTEOWCSYYDIEDV-UHFFFAOYSA-N benzyl 4-cyano-2-[[1,5-diamino-6-(3-aminophenoxy)-4-benzyl-2H-pyrimidin-2-yl]oxy]benzoate Chemical compound C(C1=CC=CC=C1)OC(=O)C1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)N)N)C=C(C=C1)C#N YTEOWCSYYDIEDV-UHFFFAOYSA-N 0.000 description 1
- CSKRFVQNHRMHRG-UHFFFAOYSA-N benzyl 4-cyano-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-ethyl-7H-purin-2-yl]oxy]benzoate Chemical compound C(C1=CC=CC=C1)OC(=O)C1=C(OC2=NC(=C3NC(=NC3=N2)CC)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N CSKRFVQNHRMHRG-UHFFFAOYSA-N 0.000 description 1
- DFOKFNCVYZBIRF-UHFFFAOYSA-N benzyl 4-cyano-2-[[6-[3-(dimethylcarbamoyl)phenoxy]-8-methyl-7H-purin-2-yl]oxy]benzoate Chemical compound C(C1=CC=CC=C1)OC(=O)C1=C(OC2=NC(=C3NC(=NC3=N2)C)OC2=CC(=CC=C2)C(=O)N(C)C)C=C(C=C1)C#N DFOKFNCVYZBIRF-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000007820 coagulation assay Methods 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGEBACRLASPKJF-UHFFFAOYSA-N diethyl 2-[2-(5-carbamimidoyl-2-hydroxyphenoxy)-8-methyl-6-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-9-yl]butanedioate Chemical compound OC1=C(OC2=NC(=C3N=C(N(C3=N2)C(CC(=O)OCC)C(=O)OCC)C)OC2=CC(=CC=C2)C=2N(CCN=2)C)C=C(C=C1)C(N)=N UGEBACRLASPKJF-UHFFFAOYSA-N 0.000 description 1
- HFPWEOBNZZFEND-UHFFFAOYSA-N diethyl 2-[2-(5-carbamimidoyl-2-methoxyphenoxy)-8-methyl-6-[3-[3-[(2-methylpropan-2-yl)oxy]-3-oxopropyl]phenoxy]purin-9-yl]pentanedioate Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC)N=C2N(C(C(=O)OCC)CCC(=O)OCC)C(C)=NC2=C1OC1=CC=CC(CCC(=O)OC(C)(C)C)=C1 HFPWEOBNZZFEND-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HZZAQKGEFGPRLA-UHFFFAOYSA-N ethyl 2-[2-(2-amino-5-carbamimidoylphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-(1h-imidazol-5-yl)propanoate Chemical compound CC1=NC2=C(OC=3C=C(C=CC=3)C(=O)N(C)C)N=C(OC=3C(=CC=C(C=3)C(N)=N)N)N=C2N1C(C(=O)OCC)CC1=CNC=N1 HZZAQKGEFGPRLA-UHFFFAOYSA-N 0.000 description 1
- QPFHRPBYIQQJPR-UHFFFAOYSA-N ethyl 2-[2-(5-carbamimidoyl-2-chlorophenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-phenylpropanoate Chemical compound CC1=NC2=C(OC=3C=C(C=CC=3)C(=O)N(C)C)N=C(OC=3C(=CC=C(C=3)C(N)=N)Cl)N=C2N1C(C(=O)OCC)CC1=CC=CC=C1 QPFHRPBYIQQJPR-UHFFFAOYSA-N 0.000 description 1
- MXYWAWSMTSRJJV-UHFFFAOYSA-N ethyl 2-[2-(5-carbamimidoyl-2-ethoxyphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-4-methylpentanoate Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OCC)N=C2N(C(CC(C)C)C(=O)OCC)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 MXYWAWSMTSRJJV-UHFFFAOYSA-N 0.000 description 1
- ZAYIPJVASXGWCA-UHFFFAOYSA-N ethyl 2-[2-(5-carbamimidoyl-2-hydroxyphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]propanoate Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)O)N=C2N(C(C)C(=O)OCC)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 ZAYIPJVASXGWCA-UHFFFAOYSA-N 0.000 description 1
- JECALBZXAYBHIQ-UHFFFAOYSA-N ethyl 2-[2-(5-carbamimidoyl-2-methylphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-(4-sulfanylphenyl)propanoate Chemical compound CC1=NC2=C(OC=3C=C(C=CC=3)C(=O)N(C)C)N=C(OC=3C(=CC=C(C=3)C(N)=N)C)N=C2N1C(C(=O)OCC)CC1=CC=C(S)C=C1 JECALBZXAYBHIQ-UHFFFAOYSA-N 0.000 description 1
- ZXVOYHRDESHEHE-UHFFFAOYSA-N ethyl 2-[2-(5-carbamimidoyl-2-phenoxyphenoxy)-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-3-methylpentanoate Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC=2C=CC=CC=2)N=C2N(C(C(C)CC)C(=O)OCC)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 ZXVOYHRDESHEHE-UHFFFAOYSA-N 0.000 description 1
- QSUJNVYWZDENOH-UHFFFAOYSA-N ethyl 4-[9-benzyl-6-(5-carbamimidoyl-2-methylphenoxy)-8-methylpurin-2-yl]oxybenzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OC1=NC(OC=2C(=CC=C(C=2)C(N)=N)C)=C(N=C(C)N2CC=3C=CC=CC=3)C2=N1 QSUJNVYWZDENOH-UHFFFAOYSA-N 0.000 description 1
- ZYYWEMINNBYEAB-UHFFFAOYSA-N ethyl 4-[9-benzyl-6-(5-cyano-2-methylphenoxy)-8-methylpurin-2-yl]oxybenzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OC1=NC(OC=2C(=CC=C(C=2)C#N)C)=C(N=C(C)N2CC=3C=CC=CC=3)C2=N1 ZYYWEMINNBYEAB-UHFFFAOYSA-N 0.000 description 1
- BJCPUHWXACLUMW-UHFFFAOYSA-N ethyl 4-[[1,5-diamino-4-benzyl-6-(5-cyano-2-methylphenoxy)-2H-pyrimidin-2-yl]oxy]benzoate Chemical compound C(C)OC(=O)C1=CC=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=C(C=CC(=C2)C#N)C)N)C=C1 BJCPUHWXACLUMW-UHFFFAOYSA-N 0.000 description 1
- GWPBMZXBGZAORX-UHFFFAOYSA-N ethyl 4-[[1-amino-4-benzyl-6-(5-cyano-2-methylphenoxy)-5-nitro-2H-pyrimidin-2-yl]oxy]benzoate Chemical compound C(C)OC(=O)C1=CC=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=C(C=CC(=C2)C#N)C)N)C=C1 GWPBMZXBGZAORX-UHFFFAOYSA-N 0.000 description 1
- RVMSAWZYEOLCBK-UHFFFAOYSA-N ethyl 4-amino-2-[2-[5-carbamimidoyl-2-(diethylcarbamoyl)phenoxy]-6-[3-(dimethylcarbamoyl)phenoxy]-8-methylpurin-9-yl]-4-oxobutanoate Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)C(=O)N(CC)CC)N=C2N(C(CC(N)=O)C(=O)OCC)C(C)=NC2=C1OC1=CC=CC(C(=O)N(C)C)=C1 RVMSAWZYEOLCBK-UHFFFAOYSA-N 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical compound O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- FDVXEJBWICFKCC-UHFFFAOYSA-N methyl 2-[6-(4-carbamimidoyl-2-phenoxyphenoxy)-2-[3-(dimethylcarbamoyl)phenoxy]-8-ethylpurin-9-yl]butanoate Chemical compound N1=C(OC=2C=C(C=CC=2)C(=O)N(C)C)N=C2N(C(C(=O)OC)CC)C(CC)=NC2=C1OC1=CC=C(C(N)=N)C=C1OC1=CC=CC=C1 FDVXEJBWICFKCC-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- BMZGVJSXRCJWIG-UHFFFAOYSA-N n-benzyl-2-methylsulfanyl-5-nitro-6-(3-nitrophenoxy)pyrimidin-4-amine Chemical compound [O-][N+](=O)C=1C(OC=2C=C(C=CC=2)[N+]([O-])=O)=NC(SC)=NC=1NCC1=CC=CC=C1 BMZGVJSXRCJWIG-UHFFFAOYSA-N 0.000 description 1
- WYYYKYCGLAQHRF-UHFFFAOYSA-N n-benzyl-2-methylsulfonyl-5-nitro-6-(3-nitrophenoxy)pyrimidin-4-amine Chemical compound [O-][N+](=O)C=1C(OC=2C=C(C=CC=2)[N+]([O-])=O)=NC(S(=O)(=O)C)=NC=1NCC1=CC=CC=C1 WYYYKYCGLAQHRF-UHFFFAOYSA-N 0.000 description 1
- YOVYWTPAAXIBKO-UHFFFAOYSA-N n-benzyl-6-(3-chloro-5-methoxyphenoxy)-2-methylsulfanyl-5-nitropyrimidin-4-amine Chemical compound COC1=CC(Cl)=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(SC)N=2)[N+]([O-])=O)=C1 YOVYWTPAAXIBKO-UHFFFAOYSA-N 0.000 description 1
- ZQRQLNIAQXLOOK-UHFFFAOYSA-N n-benzyl-6-(3-chloro-5-methoxyphenoxy)-2-methylsulfonyl-5-nitropyrimidin-4-amine Chemical compound COC1=CC(Cl)=CC(OC=2C(=C(NCC=3C=CC=CC=3)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 ZQRQLNIAQXLOOK-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical class NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000015139 regulation of coagulation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OCYLEXQKQARPEX-UHFFFAOYSA-N tert-butyl 2-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzoate Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C(=O)OC(C)(C)C)=N1 OCYLEXQKQARPEX-UHFFFAOYSA-N 0.000 description 1
- CREYESKXNCWEBJ-UHFFFAOYSA-N tert-butyl 2-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(C#N)C=C1OC1=NC(S(C)(=O)=O)=NC(N)=C1[N+]([O-])=O CREYESKXNCWEBJ-UHFFFAOYSA-N 0.000 description 1
- PUNXECKNORJTGX-UHFFFAOYSA-N tert-butyl 2-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-4-cyanobenzoate Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C(=CC=C(C=2)C#N)C(=O)OC(C)(C)C)=N1 PUNXECKNORJTGX-UHFFFAOYSA-N 0.000 description 1
- XITLOJVNUBEZQT-UHFFFAOYSA-N tert-butyl 2-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-cyanobenzoate Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)C(=O)OC(C)(C)C)N XITLOJVNUBEZQT-UHFFFAOYSA-N 0.000 description 1
- OGGOGZRVEICBCJ-UHFFFAOYSA-N tert-butyl 2-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-4-cyanobenzoate Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=C(C=CC(=C1)C#N)C(=O)OC(C)(C)C)N OGGOGZRVEICBCJ-UHFFFAOYSA-N 0.000 description 1
- XCKLFXHQNOLJND-UHFFFAOYSA-N tert-butyl 2-[6-amino-2-[3-(diaminomethylideneamino)phenoxy]-5-nitropyrimidin-4-yl]oxy-4-cyanobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(NC(N)=N)C=CC=2)=NC(N)=C1[N+]([O-])=O XCKLFXHQNOLJND-UHFFFAOYSA-N 0.000 description 1
- AMDIBHCEIXCLIL-UHFFFAOYSA-N tert-butyl 2-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-carbamimidoylbenzoate Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C(N)=N)C(=O)OC(C)(C)C)N=2)=C1 AMDIBHCEIXCLIL-UHFFFAOYSA-N 0.000 description 1
- XXAOOUKDUKMWME-UHFFFAOYSA-N tert-butyl 2-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-4-cyanobenzoate Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C(=CC=C(C=3)C#N)C(=O)OC(C)(C)C)N=2)=C1 XXAOOUKDUKMWME-UHFFFAOYSA-N 0.000 description 1
- COKLFXWTDQPLBT-UHFFFAOYSA-N tert-butyl 2-[[8-tert-butyl-2-[3-(diaminomethylideneamino)phenoxy]-7h-purin-6-yl]oxy]-4-carbamimidoylbenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)N=C(N)N)=NC2=C1NC(C(C)(C)C)=N2 COKLFXWTDQPLBT-UHFFFAOYSA-N 0.000 description 1
- LSZBXPPUOJKXAW-UHFFFAOYSA-N tert-butyl 2-[[8-tert-butyl-2-[3-(diaminomethylideneamino)phenoxy]-7h-purin-6-yl]oxy]-4-cyanobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)N=C(N)N)=NC2=C1NC(C(C)(C)C)=N2 LSZBXPPUOJKXAW-UHFFFAOYSA-N 0.000 description 1
- NSKSTZCGCGNTKT-UHFFFAOYSA-N tert-butyl 2-carbamimidoyl-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-(trifluoromethyl)-7h-purin-6-yl]oxy]benzoate Chemical compound C1=C(C(N)=N)C(C(=O)OC(C)(C)C)=CC(OC=2C=3NC(=NC=3N=C(OC=3C=C(NC(N)=N)C=CC=3)N=2)C(F)(F)F)=C1 NSKSTZCGCGNTKT-UHFFFAOYSA-N 0.000 description 1
- PQHSDHJIHXQUMT-UHFFFAOYSA-N tert-butyl 2-carbamimidoyl-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzoate Chemical compound N=1C(OC=2C=C(C(C(N)=N)=CC=2)C(=O)OC(C)(C)C)=C2NC(C)=NC2=NC=1OC1=CC=CC(N=C(N)N)=C1 PQHSDHJIHXQUMT-UHFFFAOYSA-N 0.000 description 1
- UWPQXPXLMJLNES-UHFFFAOYSA-N tert-butyl 2-cyano-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-(trifluoromethyl)-7h-purin-6-yl]oxy]benzoate Chemical compound C1=C(C#N)C(C(=O)OC(C)(C)C)=CC(OC=2C=3NC(=NC=3N=C(OC=3C=C(C=CC=3)N=C(N)N)N=2)C(F)(F)F)=C1 UWPQXPXLMJLNES-UHFFFAOYSA-N 0.000 description 1
- HADTYDHYFKVWTC-UHFFFAOYSA-N tert-butyl 2-cyano-5-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzoate Chemical compound N=1C(OC=2C=C(C(C#N)=CC=2)C(=O)OC(C)(C)C)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 HADTYDHYFKVWTC-UHFFFAOYSA-N 0.000 description 1
- PHVYTTQJQSSTAG-UHFFFAOYSA-N tert-butyl 3-[2-(5-carbamimidoyl-2-ethoxyphenoxy)-8,9-diethylpurin-6-yl]oxybenzoate Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)OC(C)(C)C)=C(N=C(CC)N2CC)C2=N1 PHVYTTQJQSSTAG-UHFFFAOYSA-N 0.000 description 1
- RUBDCOGXHGBGLJ-UHFFFAOYSA-N tert-butyl 3-[3-[2-(5-carbamimidoyl-2-methoxyphenoxy)-8,9-diethylpurin-6-yl]oxyphenyl]propanoate Chemical compound N1=C(OC=2C(=CC=C(C=2)C(N)=N)OC)N=C2N(CC)C(CC)=NC2=C1OC1=CC=CC(CCC(=O)OC(C)(C)C)=C1 RUBDCOGXHGBGLJ-UHFFFAOYSA-N 0.000 description 1
- ZNMNJKXGHXFLEC-UHFFFAOYSA-N tert-butyl 3-[3-[6-(benzylamino)-2-(5-cyano-2-methoxyphenoxy)-5-nitropyrimidin-4-yl]oxyphenyl]propanoate Chemical compound COC1=CC=C(C#N)C=C1OC1=NC(NCC=2C=CC=CC=2)=C([N+]([O-])=O)C(OC=2C=C(CCC(=O)OC(C)(C)C)C=CC=2)=N1 ZNMNJKXGHXFLEC-UHFFFAOYSA-N 0.000 description 1
- CURDJBQWNPAZSL-UHFFFAOYSA-N tert-butyl 3-[3-[9-benzyl-2-(5-carbamimidoyl-2-methoxyphenoxy)-8-methylpurin-6-yl]oxyphenyl]propanoate Chemical compound COC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(CCC(=O)OC(C)(C)C)C=CC=2)=C(N=C(C)N2CC=3C=CC=CC=3)C2=N1 CURDJBQWNPAZSL-UHFFFAOYSA-N 0.000 description 1
- MLILAJKLBBQZGO-UHFFFAOYSA-N tert-butyl 3-[3-[[2-(5-carbamimidoyl-2-methoxyphenoxy)-8-methyl-7h-purin-6-yl]oxy]phenyl]propanoate Chemical compound COC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(CCC(=O)OC(C)(C)C)C=CC=2)=C(NC(C)=N2)C2=N1 MLILAJKLBBQZGO-UHFFFAOYSA-N 0.000 description 1
- IQXXLXJSPNBIEA-UHFFFAOYSA-N tert-butyl 3-[3-[[3,5-diamino-6-benzyl-2-(5-cyano-2-methoxyphenoxy)-2H-pyrimidin-4-yl]oxy]phenyl]propanoate Chemical compound COC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)CCC(=O)OC(C)(C)C)N)C=C(C=C1)C#N IQXXLXJSPNBIEA-UHFFFAOYSA-N 0.000 description 1
- BTOBONIUJAHINE-UHFFFAOYSA-N tert-butyl 3-[6-(3-amino-4-carbamimidoylphenoxy)-9-benzyl-8-methylpurin-2-yl]oxybenzoate Chemical compound N1=C(OC=2C=C(C=CC=2)C(=O)OC(C)(C)C)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC=C(C(N)=N)C(N)=C1 BTOBONIUJAHINE-UHFFFAOYSA-N 0.000 description 1
- AUEJDIPOQASLJD-UHFFFAOYSA-N tert-butyl 3-[6-(3-amino-4-cyanophenoxy)-9-benzyl-8-methylpurin-2-yl]oxybenzoate Chemical compound N1=C(OC=2C=C(C=CC=2)C(=O)OC(C)(C)C)N=C2N(CC=3C=CC=CC=3)C(C)=NC2=C1OC1=CC=C(C#N)C(N)=C1 AUEJDIPOQASLJD-UHFFFAOYSA-N 0.000 description 1
- YRNBJBZAQLALAH-UHFFFAOYSA-N tert-butyl 3-[6-(benzylamino)-2-(5-cyano-2-ethoxyphenoxy)-5-nitropyrimidin-4-yl]oxybenzoate Chemical compound CCOC1=CC=C(C#N)C=C1OC1=NC(NCC=2C=CC=CC=2)=C([N+]([O-])=O)C(OC=2C=C(C=CC=2)C(=O)OC(C)(C)C)=N1 YRNBJBZAQLALAH-UHFFFAOYSA-N 0.000 description 1
- WJLYVTOUXORVIW-UHFFFAOYSA-N tert-butyl 3-[9-benzyl-2-(5-carbamimidoyl-2-ethoxyphenoxy)-8-methylpurin-6-yl]oxybenzoate Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)OC(C)(C)C)=C(N=C(C)N2CC=3C=CC=CC=3)C2=N1 WJLYVTOUXORVIW-UHFFFAOYSA-N 0.000 description 1
- VUWVOTHFESVWIU-UHFFFAOYSA-N tert-butyl 3-[[1,5-diamino-6-(3-amino-4-cyanophenoxy)-4-benzyl-2H-pyrimidin-2-yl]oxy]benzoate Chemical compound C(C)(C)(C)OC(=O)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=C(C=C2)C#N)N)N)C=CC=1 VUWVOTHFESVWIU-UHFFFAOYSA-N 0.000 description 1
- ITZWPSJXFKUMGA-UHFFFAOYSA-N tert-butyl 3-[[1-amino-4-benzyl-6-(4-cyano-3-nitrophenoxy)-5-nitro-2H-pyrimidin-2-yl]oxy]benzoate Chemical compound C(C)(C)(C)OC(=O)C=1C=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)[N+](=O)[O-])OC2=CC(=C(C=C2)C#N)[N+](=O)[O-])N)C=CC=1 ITZWPSJXFKUMGA-UHFFFAOYSA-N 0.000 description 1
- UBBNJDXAVPFPGK-UHFFFAOYSA-N tert-butyl 3-[[2-(5-carbamimidoyl-2-ethoxyphenoxy)-8-methyl-7h-purin-6-yl]oxy]benzoate Chemical compound CCOC1=CC=C(C(N)=N)C=C1OC1=NC(OC=2C=C(C=CC=2)C(=O)OC(C)(C)C)=C(NC(C)=N2)C2=N1 UBBNJDXAVPFPGK-UHFFFAOYSA-N 0.000 description 1
- BAIMODGIUMWUKJ-UHFFFAOYSA-N tert-butyl 3-[[3,5-diamino-6-benzyl-2-(5-cyano-2-ethoxyphenoxy)-2H-pyrimidin-4-yl]oxy]benzoate Chemical compound C(C)OC1=C(OC2N(C(=C(C(=N2)CC2=CC=CC=C2)N)OC2=CC(=CC=C2)C(=O)OC(C)(C)C)N)C=C(C=C1)C#N BAIMODGIUMWUKJ-UHFFFAOYSA-N 0.000 description 1
- DMZGBKIOQVQNQN-UHFFFAOYSA-N tert-butyl 4-carbamimidoyl-2-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzoate Chemical compound N=1C(OC=2C(=CC=C(C=2)C(N)=N)C(=O)OC(C)(C)C)=C2NC(C)=NC2=NC=1OC1=CC=CC(N=C(N)N)=C1 DMZGBKIOQVQNQN-UHFFFAOYSA-N 0.000 description 1
- MSZTWLNWBOYXFP-UHFFFAOYSA-N tert-butyl 4-cyano-2-[5,6-diamino-2-[3-(diaminomethylideneamino)phenoxy]pyrimidin-4-yl]oxybenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(C#N)C=C1OC1=NC(OC=2C=C(C=CC=2)N=C(N)N)=NC(N)=C1N MSZTWLNWBOYXFP-UHFFFAOYSA-N 0.000 description 1
- IBBAUCZUDBVBQH-UHFFFAOYSA-N tert-butyl 4-cyano-2-[[2-[3-(diaminomethylideneamino)phenoxy]-8-methyl-7h-purin-6-yl]oxy]benzoate Chemical compound N=1C(OC=2C(=CC=C(C=2)C#N)C(=O)OC(C)(C)C)=C2NC(C)=NC2=NC=1OC1=CC=CC(NC(N)=N)=C1 IBBAUCZUDBVBQH-UHFFFAOYSA-N 0.000 description 1
- LCWQYNFIFBNXKX-UHFFFAOYSA-N tert-butyl 5-(6-amino-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzoate Chemical compound CSC1=NC(N)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)C(=O)OC(C)(C)C)=N1 LCWQYNFIFBNXKX-UHFFFAOYSA-N 0.000 description 1
- KHKANLVONGBQGS-UHFFFAOYSA-N tert-butyl 5-(6-amino-2-methylsulfonyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzoate Chemical compound C1=C(C#N)C(C(=O)OC(C)(C)C)=CC(OC=2C(=C(N)N=C(N=2)S(C)(=O)=O)[N+]([O-])=O)=C1 KHKANLVONGBQGS-UHFFFAOYSA-N 0.000 description 1
- FTWGMSHEDKWKTK-UHFFFAOYSA-N tert-butyl 5-(6-chloro-2-methylsulfanyl-5-nitropyrimidin-4-yl)oxy-2-cyanobenzoate Chemical compound CSC1=NC(Cl)=C([N+]([O-])=O)C(OC=2C=C(C(C#N)=CC=2)C(=O)OC(C)(C)C)=N1 FTWGMSHEDKWKTK-UHFFFAOYSA-N 0.000 description 1
- PRFXVNRQULBNNG-UHFFFAOYSA-N tert-butyl 5-[(3-amino-6-benzyl-2-methylsulfanyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-cyanobenzoate Chemical compound CSC1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)C(=O)OC(C)(C)C)N PRFXVNRQULBNNG-UHFFFAOYSA-N 0.000 description 1
- NSOSIBHKNSLMQI-UHFFFAOYSA-N tert-butyl 5-[(3-amino-6-benzyl-2-methylsulfonyl-5-nitro-2H-pyrimidin-4-yl)oxy]-2-cyanobenzoate Chemical compound CS(=O)(=O)C1N(C(=C(C(=N1)CC1=CC=CC=C1)[N+](=O)[O-])OC1=CC(=C(C=C1)C#N)C(=O)OC(C)(C)C)N NSOSIBHKNSLMQI-UHFFFAOYSA-N 0.000 description 1
- KPNCIVLNMWPCMM-UHFFFAOYSA-N tert-butyl 5-[6-amino-2-[3-(diaminomethylideneamino)phenoxy]-5-nitropyrimidin-4-yl]oxy-2-cyanobenzoate Chemical compound C1=C(C#N)C(C(=O)OC(C)(C)C)=CC(OC=2C(=C(N)N=C(OC=3C=C(NC(N)=N)C=CC=3)N=2)[N+]([O-])=O)=C1 KPNCIVLNMWPCMM-UHFFFAOYSA-N 0.000 description 1
- BSDWPTXGGHTQFJ-UHFFFAOYSA-N tert-butyl 5-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-2-carbamimidoylbenzoate Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C(C(N)=N)=CC=3)C(=O)OC(C)(C)C)N=2)=C1 BSDWPTXGGHTQFJ-UHFFFAOYSA-N 0.000 description 1
- YEPUKQXQPIZUKY-UHFFFAOYSA-N tert-butyl 5-[9-benzyl-8-methyl-2-[3-(1-methyl-4,5-dihydroimidazol-2-yl)phenoxy]purin-6-yl]oxy-2-cyanobenzoate Chemical compound CN1CCN=C1C1=CC=CC(OC=2N=C3N(CC=4C=CC=CC=4)C(C)=NC3=C(OC=3C=C(C(C#N)=CC=3)C(=O)OC(C)(C)C)N=2)=C1 YEPUKQXQPIZUKY-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 항응혈제로서 유용한 퓨린 유도체에 관한 것이다. 본 발명은 또한 본 발명의 화합물을 함유하는 제약 조성물, 및 상기 화합물을 사용한 혈전 활성의 특징을 갖는 질병 상태의 치료 방법에 관한 것이다.
Description
인자 Xa는 트립신계 세린 프로테아제 부류 효소의 일원이다. 인자 Xa 및 Va는 칼슘 이온 및 인지질과 1 대 1 결합하여 프로트롬빈을 트롬빈으로 전환시키는 프로트롬비나제 복합체를 형성한다. 이어서, 트롬빈은 피브리노겐을 피브린으로 전환시키고, 이는 중합되어 불용성 피브린을 형성한다.
응혈 캐스캐이드에서, 프로트롬비나제 복합체는 고유(표면 활성화된) 및 외부(혈관 상해 조직 인자에 의한) 경로의 수렴점이다 (Biochemistry, (1991), Vol. 30, p.10363; and Cell, (1988), Vol. 53, pp 505-518). 응혈 캐스캐이드 모델은 조직 인자 경로 억제제(TFPI)의 작용 모델을 발견하면서 더욱 다듬어졌다 (Seminars in Hematology, 1992, Vol. 29, pp 159-161). TFPI는 유리 인자 Xa에 대해 인자 Va와 경쟁하는, 3개의 쿠니츠계(Kunitz-like) 도메인을 지닌 순환하는 다중 도메인 세린 프로테아제 억제제이다. 일단 형성되면, 인자 Xa와 TFPI의 2원 복합체는 인자 VIIa와 조직 인자 복합체에 대한 강력한 억제제가 된다.
인자 Xa는 2개의 상이한 복합체, 즉 응혈 캐스캐이드에서 "Xa 버스트(burst)" 경로 상에서의 조직 인자-VIIa 복합체 및 "지속적 Xa" 경로의 인자 IXa-VIIIa 복합체(TENase)에 의해 활성화될 수 있다. 혈관 상해 후에, "Xa-버스트" 경로는 조직 인자(TF)를 통해 활성화된다. 응혈 캐스캐이드의 상승적 조절은 "지속적인 Xa" 경로를 통한 증가된 인자 Xa 생산에 의해 일어난다. 응혈 캐스캐이드의 감소적 조절은 인자 Xa-TFPI 복합체가 형성되어 인자 Xa가 제거될 뿐만 아니라, "Xa 버스트" 경로를 통한 인자 형성을 추가로 억제한다. 따라서, 응혈 캐스캐이드는 인자 Xa에 의해 자연적으로 조절된다.
응혈을 방지하기 위하여 트롬빈에 대한 인자 Xa의 억제가 갖는 1차적 잇점은 트롬빈의 다중 기능에 대한 인자 Xa의 병소적 기능이다. 트롬빈은 피브리노겐에서 피브린, 인자 VIII에서 VIIIa, 인자 V에서 Va, 및 인자 XI에서 XIa으로의 전환을 촉매화할뿐 아니라, 혈소판을 활성화시키고, 단구적 화학 주성 인자이고, 림프구 및 평활근 세포에 대한 미토겐이다. 트롬빈은 트롬보모듈린과 결합하여 인자 Va 및 VIIIa의 생체 내 항응혈 불활성자인, 단백질 C를 활성화시킨다. 순환 중인 트롬빈은, 헤파린 또는 다른 프로테오글리칸 관련 글리코사미노글리칸에 의한 촉매화 반응에서 항트롬빈 III(ATIII) 및 헤파린 조촉매 II(HCII)에 의해 신속하게 불활성화되는 반면, 조직 중의 트롬빈은 프로테아제인 넥신에 의해 불활성화된다. 트롬빈은 피브리노겐 결합 및 절단에 사용되는 동일한 음이온 결합 부위 및 활성화 부위를 요구하는, 독특한 "속박된(tethered) 리간드" 트롬빈 수용체(Cell(1991), Vol. 64, p.1057)를 통해, 그리고 트롬보모듈린 결합 및 단백질 C 활성화에 의해 그의 다중 세포 활성화 기능을 수행한다. 따라서, 생체내 표적 분자의 다양한 군은 트롬빈과의 결합에 경쟁적이고, 이후의 단백질 분해 과정은 세포 유형 및, 수용체, 조절자, 기질 또는 억제제가 트롬빈에 결합하는 것에 따라 매우 다양한 생리학적 중요성을 가질 것이다.
항 혈액정지 단백질 및 진드기 항응혈제 펩티드(TAP)에 대한 공개된 자료는 인자 Xa 억제제는 항응혈제로 효과적임을 입증하고 있다 (Thrombosis and Haemostasis(1992), Vol. 67, pp371-376; and Science(1990), Vol. 248, pp. 593-596).
인자 Xa의 활성화 부위는 메카니즘 기재 또는 강력 결합 억제제에 의해 차단될 수 있다 (강력 결합 억제제는 효소와 억제제간의 공유 결합의 부재에 의해 메카니즘 기재 억제제는 상이하다). 2가지 유형의 메카니즘 기재 억제제는 효소-억제제 결합의 가수분해의 용이성에 의해 가역적 및 비가역적으로 구별되어 공지되어 있다 (Thrombosis Res(1992), Vol. 67, pp. 221-231; and Trends Pharmacol. Sci.(1987), Vol. 8, pp. 303-307). 일련의 구아니딘 화합물은 강력 결합 억제제의 일례이다(Thrombosis Res.(1980), Vol. 19, pp. 339-349). 또한, 3-아미디노페릴아릴 유도체(Thrombosis Res.(1983), Vol. 29, pp. 635-642) 및 비스(아미디노)벤질 시클로케톤(Thrombosis Res.(1980), Vol. 17, pp. 545-548)을 비롯한 일련의 아릴아미드 함유 화합물 외에, 아릴술포닐-아르기닌-피페리딘-카르복실산 유도체는 강력 결합 억제제로 나타내진다(Biochem(1984), Vol. 23, pp. 85-90). 그러나, 이 화합물들은 인자 Xa에 대한 낮은 선별성을 나타낸다.
〈관련 개시물〉
유럽 특허 출원 제 0 540 051호(Nagahara 등)은 인자 Xa의 가역적 억제를 통해 강력한 항응혈제 효과를 나타낼 수 있는 방향족 아미딘 유도체를 기재하고 있다.
α,α'-비스(아미디노벤질리덴)시클로알카논 및 α,α'-비스(아미디노벤질)시클로알카논은 문헌[Pharmazie(1977), Vol. 32, No. 3, pp. 141-145]에 기재되어 있다. 상기 화합물은 세린 프로테아제 억제제로 개시되어 있다.
〈발명의 요약〉
본 발명은 사람의 인자 Xa를 억제함에 따라, 혈전 활성의 특징을 갖는 질병 상태를 치료하기 위한 약제로서 유용한, 화합물 또는 제약학적으로 허용 가능한 그의 염에 관한 것이다.
따라서, 본 발명은 하나의 측면에서, 단독 입체 이성질체로서 또는 그의 혼합물로서 화학식 I 내지 화학식 IV의 화합물로 구성된 군으로부터 선택된 화합물, 또는 제약학적으로 허용 가능한 그의 염을 제공한다.
상기 식 중,
Z1및 Z2는 독립적으로 -O-, -N(R10)- 또는 -OCH2-이고,
R1및 R4는 각각 독립적으로 수소, 할로, 알킬, -OR10, -C(O)OR10, -C-(O)N(R10)R11, -N(R10)R11, -N(R10)C(O)R10, 또는 -N(H)S(O)2R13이고,
R2는 -C(NH)NH2, -C(NH)N(H)OR10, -C(NH)N(H)C(O)OR13, -C(NH)N(H)C(O)R10, -C- (NH)N(H)S(O)2R13, 또는 -C(NH)N(H)C(O)N(H)R10이고,
R3은 할로, 알킬, 할로알킬, 할로알콕시, 우레이도, 시아노, 구아니디노, -OR10, -C(NH)NH2, -C(NH)N(H)OR10, -C(O)N(R10)R11, -R12-C(O)N(R10)R11, -CH(OH)C-(O)N(R10)R11, -N(R10)R11, -R12-N(R10)R11, -C(O)OR10, R12-C(O)OR10, -N(R10)C(O)R10, (1,2)-테트라히드로피리미디닐(임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고,
R5는 수소, 할로, 알킬, 시클로알킬, 할로알킬, 아릴, 아랄킬, 알킬티오, 히드록시, 메르캅토, 알콕시, 또는 -N(R10)R11이고,
R6은 -(C(R7)(R8))n-R9(여기서, n은 1 내지 4임), 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)인데,
여기서, 각 R7은 독립적으로 수소, 알킬, 알케닐, 알키닐, 할로알킬, 할로알케닐, 시클로알킬, 시클로알킬알킬, -C(O)OR10, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -C-(O)-R12-N(R10)R11, -R12-C(O)R10, -R12-C(O)N(R10)N(R10)R11, -R12-C(R10)(OR10)-R12-N(R10)R11, -C(R10)(OR10)C(O)OR11, -R12-C(R10)(C(O)OR10)2, -C(R10)(N(R10)R11)C(O)OR10, -R12-C(R10)(N(R10)R11)C(O)OR10, -C(R10)(OR10)R11, -R12-N(R10)R11, -R12-N(R10)C(O)OR13, -R12-N(R10)C(O)OR11, -R12-N(R10)C(NR10)R13, -R12-N(R10)S(O)2R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12-N(R10)C(NR10)N(R10)N(R10)R11, -R12-N(R10)-R12-C(R10)(N(R10)R11)C(O)OR10, -R12-N(R10)S(O)R11, -R12OR10, -R12-ON(R10)C(NR10)N(R10) R11, -R12-OS(O)2OR10, -R12-P(O)(OR10)R11, -R12-OP(O)(OR10)2, -R12-P(O)(OR10)2, -R12-SR10, -R12-S-R12-C(O)OR10, -R12-S-R12-N(R10)R11, -R12-S-R12-C(R10)(N(R10)R11)C(O)OR10, -R12-S-R12-N(R10)C(O)OR10, -R12-S-R12-N(R10)C(O)R10, -R12-S-S-R12-C(R10)(N(R10)R11)C(0)OR10, -R12-SC(O)N(R10)R11, -R12-SC(S)N(R10)R11, -R12-S(O)R10, -R12-S(O)2R13, -R12-S(O)OR10, -R12-S(O)2OR10, -R12-S(O)2N(R10)R11, -R12-S(O)(NR10)R11이거나,
또는 각 R7은 아릴(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,
또는 각 R7은 아랄킬(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,
또는 각 R7은 헤테로시클릴(임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,
또는 각 R7은 헤테로시클릴알킬(여기서, 헤테로시클릴 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C-(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,
또는 각 R7은 아다만틸(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,
또는 각 R7은 아다만틸알킬(여기서, 아다만틸 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S-(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이고,
각 R8은 독립적으로 수소, 알킬, 시클로알킬, 또는 아릴이고,
R9는 -C(O)OR10또는 -C(O)N(R10)R11이고,
R10및 R11은 각각 독립적으로 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고,
R12는 직쇄 또는 분지쇄 알킬렌이고,
R13은 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이다.
다른 측면에서, 치료적 유효량의 상기 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 및 제약학적으로 허용 가능한 부형제를 포함하는, 혈전 활성의 특징을 갖는 질병 상태를 지닌 사람을 치료하는데 유용한 조성물을 제공한다.
다른 측면에서, 본 발명은 치료적 유효량의 상기 본 발명의 화합물을 필요로하는 사람에게 투여하는 것을 포함하는, 혈전 활성의 특징을 갖는 질병 상태를 지닌 사람의 치료 방법을 제공한다.
다른 측면에서, 본 발명은 치료적 유효량의 상기 본 발명의 화합물을 필요로하는 사람에게 투여하는 것을 포함하는, 인자 Xa의 억제에 의해 완화되는 질병 상태를 지닌 사람의 치료 방법을 제공한다.
다른 측면에서, 본 발명은 본 발명의 화합물을 투여함으로써 시험관 내 또는 생체 내에서 사람 인자 Xa의 억제 방법을 제공한다.
본 발명은 효소, 즉 인자 Xa를 억제하여 항응혈제로서 유용한 퓨린 유도체, 제약학적으로 허용 가능한 그의 염에 관한 것이다. 또한, 유도체 또는 제약학적으로 허용 가능한 그의 염을 함유하는 제약 조성물, 및 그의 사용 방법에 관한 것이다.
〈정의〉
본원의 명세서 및 청구의 범위에서 사용된 하기 용어들은 다른 언급이 없는 한 다음과 같은 의미를 갖는다.
"알킬"은 탄소 및 수소로만 구성되고, 불포화되지 않고, 탄소 원자수 1 내지 6의 직쇄 또는 분지쇄의 1가 또는 2가 라디칼로서, 예를 들어, 메틸, 에틸, n-프로필, 1-메틸에틸(이소-프로필), n-부틸, n-펜틸, 1,1,-디메틸에틸(t-부틸) 등이 있다.
"알케닐"은 탄소 및 수소로만 구성되고, 1개 이상의 이중 결합을 갖고, 탄소 원자수 1 내지 6의 직쇄 또는 분지쇄의 1가 또는 2가 라디칼로서, 예를 들어 에테닐, 프로프-1-에닐, 부트-1-에닐, 펜트-1-에닐, 펜타-1,4-디에닐 등이 있다.
"알키닐"은 탄소 및 수소로만 구성되고, 1개 이상의 3중 결합을 갖고, 탄소 원자수 1 내지 6의 직쇄 또는 분지쇄의 1가 또는 2가 라디칼로서, 예를 들어, 에티닐, 프로프-1-닐, 부트-1-닐, 펜트-1-이닐, 펜트-3-이닐 등이 있다.
"알콕시"는 화학식 -ORa(여기서, Ra는 상기 정의된 바와 같음)의 라디칼로서, 예를 들어, 메톡시, 에톡시, n-프로폭시, 1-메틸에톡시 (이소프로폭시), n-부톡시, n-펜톡시, 1,1,-디메틸에톡시(t-부톡시) 등이 있다.
"알콕시카르보닐"은 화학식 -C(O)ORa(여기서, Ra는 상기 정의된 바와 같음)의 라디칼로서, 예를 들어, 메톡시카르보닐, 에톡시카르보닐, n-프로폭시카르보닐, 이소프로폭시카르보닐, t-부톡시카르보닐 등이 있다.
"알킬렌"은 카르보닐 및 수소로만 구성되고, 불포화되지 않고, 탄소 원자수 1 내지 6의 직쇄 또는 분지쇄의 2가 라디칼로서, 예를 들어, 메틸렌, 에틸렌, 프로필렌, n-부틸렌 등이 있다.
"알킬티오"는 화학식 -SRa(여기서, Ra는 상기 정의된 바와 같음)의 라디칼로서, 예를 들어, 메틸티오, 에틸티오, n-프로필티오, t-부틸티오 등이 있다.
"아미디노"는 라디칼 -C(NH)-NH2이다.
"아미노카르보닐"은 라디칼 -C(O)NH2이다.
"아릴"은 페닐 또는 나프틸 라디칼이다.
"아랄킬"은 화학식 -RaRb(여기서, Ra는 상기 정의된 바와 같은 알킬이고, Rb는 상기 정의된 바와 같은 아릴임)의 라디칼로서, 예를 들어 벤질이다.
"아랄콕시"는 화학식 -ORc(여기서, Rc는 상기 정의된 바와 같은 아랄킬임)의 라디칼로서, 예를 들어 벤질옥시이다.
"시클로알킬"은 포화되고, 탄소 및 수소 원자로만 구성된, 안정한 3원 내지 7원 모노시클릭 라디칼로서, 예를 들어, 시클로프로필, 시클로부틸, 시클로펜틸, 시클로헥실 등이 있다.
"시클로알킬알킬"은 상기 정의된 시클로알킬 라디칼에 의해 치환된, 상기 정의된 바와 같은 알킬 라디칼로서, 예를 들어 (시클로부틸)메틸, 2-(시클로펜틸)에틸, 3-(시클로헥실)프로필 등이 있다.
"디알킬아미노"는 화학식 -NRaRa(여기서, Ra는 독립적으로 상기 정의된 바와 같은 알킬임)의 라디칼로서, 예를 들어 디메틸아미노, 메틸에틸아미노, 디에틸아미노, 디프로필아미노, 에틸프로필아미노 등이 있다.
"디알킬아미노카르보닐"은 -C(O)NRaRa(여기서, Ra는 독립적으로 상기 정의된 바와 같은 알킬 라디칼임)의 라디칼로서, 예를 들어 디메틸아미노카르보닐, 메틸에틸아미노카르보닐, 디에틸아미노카르보닐, 디프로필아미노카르보닐, 에틸프로필아미노카르보닐 등이 있다.
"할로"는 브로모, 요오도, 클로로 또는 플루오로이다.
"할로알킬"은 상기 정의된 1종 이상의 할로 라디칼에 의해 치환된 상기 정의된 바와 같은 알킬 라디칼로서, 예를 들어, 트리플루오로메틸, 디플루오로매틸, 트리클로로베틸, 2-트리플루오로에틸, 3-브로모-2-플루오로프로필, 1-브로모메틸-2-브로모에틸 등이 있다.
"할로알케닐"은 상기 정의된 1종 이상의 할로 라디칼에 의해 치환된 상기 정의된 바와 같은 알케닐 라디칼로서, 예를 들어, 2-디플루오로에테닐, 3-브로모-2-플루오로프로피-1-에닐 등이 있다.
"할로알콕시"는 화학식 -ORf(여기서, Rf는 상기 정의된 바와 같은 할로알콕시임)의 라디칼로서, 예를 들어, 트리플루오로메톡시, 디플루오로메톡시, 트리클로로메톡시, 2-트리플루오로에톡시, 1-플루오로메틸-2-플루오로에톡시, 3-브로모-2-플루오로프로폭시, 1-브로모메틸-2-브로모에톡시 등이 있다.
"헤테로시클릴"은 포화 또는 불포화된, 탄소 원자, 및 질소, 산소 및 황으로 구성된 군으로부터 선택된 1 내지 3개의 헤테로 원자로 구성된, 3원 내지 10원 모노시클릭 또는 비시클릭 라디칼로서, 여기서, 질소, 탄소 또는 황 원자는 임의로 산화될 수 있고, 질소 원자는 임의로 4급화될 수 있다. 헤테로시클릴 라디칼은 임의의 헤테로 원자 또는 탄소 원자가 주요 골격에 결합되어 안정한 구조를 형성할 수 있다. 이러한 헤테로시클릭 라디칼의 예로는 피페리디닐, 피페라지닐, 2-옥소피페라지닐, 2-옥소피페리디닐, 2-옥소피롤리디닐, 2-옥소아제피닐, 아제피닐, 피롤릴, 4-피페리도닐, 피롤리디닐, 피라졸릴, 피라졸리디닐, 이미다졸릴, 이미다졸리닐, 이미다졸리디닐, 피리디닐, 피라지닐, 피리미디닐, 피리다지닐, 옥사졸릴, 옥사졸리디닐, 트리아졸릴, 인다닐, 이속사졸릴, 이속사졸리디닐, 모르폴리닐, 티아졸릴, 이소티아졸릴, 퀴누클리디닐, 이소티아졸리디닐, 인돌릴, 이소인돌릴, 인돌리닐, 이소인돌리닐, 옥타히드로인돌릴, 옥타히드로이소인돌릴, 퀴놀릴, 이소퀴놀릴, 데카히드로이소퀴놀릴, 벤지미다졸릴, 티아디아졸릴, 벤조피라닐, 벤조티아졸릴, 벤족사졸릴, 푸릴, 테트라히드로푸릴, 테트라히드로피라닐, 티에닐, 벤조티에닐, 티아모르폴리닐, 티아모르폴리닐 술폭시드, 티아모르폴리닐 술폰, 및 옥사디아졸릴이 포함되나, 이에 한정되지는 않는다. 본 발명에서 바람직한 헤테로시클릭 라디칼로는 인돌릴, 이미다졸릴, 티아졸릴, 이속사졸릴, 트리아졸릴, 피리디닐, 티에닐, 벤조티에닐, 푸릴, 및 3,4-디히드로-2,3-디옥소-1(2H)-피리미디닐이 있다.
"헤테로시클릴알킬"은 화학식 -RaRg(여기서, Ra는 상기 정의된 바와 같은 알킬 라디칼이고, Rg는 상기 정의된 바와 같은 헤테로시클릴 라디칼임)의 라디칼로서, 예를 들어, 인돌리닐메틸 또는 이미다졸릴메틸 등이 있다.
"(1,2)-이미다졸릴"은 1- 또는 2-위치에 결합된 이미다졸릴 라디칼이다.
"(1,2)-이미다졸리닐"은 1- 또는 2-위치에 결합된 4,5-디히드로이미다졸릴 라디칼이다.
"모노알킬아미노"는 화학식 -NHRa(여기서, Ra는 상기 정의된 바와 같은 알킬라디칼임)의 라디칼로서, 예를 들어 메틸아미노, 에틸아미노, 프로필아미노 등이 있다.
"모노알킬아미노카르보닐"은 화학식 -C(O)NHRa(여기서, Ra는 상기 정의된 바와 같은 알킬 라디칼임)의 라디칼로서, 예를 들어 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐 등이 있다.
"(1,2)-테트라히드로피리미디닐"은 1- 또는 2-위치에 결합된 테트라히드로피리미디닐이다.
"아다만틸알킬"은 화학식 -RaRh(여기서, Ra는 상기 정의된 바와 같은 알킬 라디칼이고, Rh는 아다만틸 라디칼임)의 라디칼로서, 예를 들어, 아다만틸메틸, 2-아다만틸에틸 등이 있다.
"임의의" 또는 "임의로"는 후속 기재된 상황이 일어날 수도 일어나지 않을 수도 있음을 의미하고, 이는 상기 상황이 일어나는 경우와 일어나지 않는 경우가 포함된다. 예를 들어, "임의로 치환된 아릴"이란 아릴 라디칼이 치환될 수도 치환되지 않을 수도 있고, 여기에는 치환된 아릴 라디칼 및 치환기가 없는 아릴 라디칼이 모두 포함된다.
"제약학적으로 허용 가능한 염"에는 산 부가염 및 염기 부가염이 모두 포함된다.
"제약학적으로 허용 가능한 산 부가염"은 유리 염기의 생물학적 효율성 및 특성을 보유하는 염으로서, 생물학적으로 또는 그 외의 성질이 부적절하지 않고, 염산, 브롬화수소산, 황산, 질산, 인산 등과 같은 무기산, 및 아세트산, 트리플루오로아세트산, 프로피온산, 글리콜산, 피루브산, 옥살산, 말레산, 말론산, 숙신산, 푸마르산, 타르타르산, 시트르산, 벤조산, 신남산, 만델산, 메탄술폰산, 에탄술폰산, P-톨루엔술폰산, 살리실산 등의 유기산을 사용하여 형성된다.
"제약학적으로 허용 가능한 염기 부가염"은 생물학적으로 또는 그 외의 특성이 부적절하지 않으면서, 유리 염기의 생물학적 효율성 및 특성을 보유하는 염이다. 이 염들은 유리 산에 대해 무기 염기 또는 유기 염기를 가하여서 제조된다. 무기 염기로부터 유래된 염에는 나트륨, 칼륨, 리튬, 암모늄, 칼슘, 마그네슘, 철, 아연, 구리, 망간, 알루미늄 염 등이 포함되나, 이에 한정되지는 않는다. 바람직한 무기염에는 암모늄, 나트륨, 칼륨, 칼슘 및 마그네슘 염이 있다. 유기 염기로부터 유래된 염에는 1차, 2차 및 3차 아민, 자연적으로 치환된 아민을 비롯한 치환된 아민, 시클릭 아민 및 염기 이온 교환 수지, 예를 들어, 이소프로필아민, 트리메틸아민, 디에틸아민, 트리에틸아민, 트리프로필아민, 에탄올아민, 2-디메틸아미노에탄올, 2-디에틸아미노에탄올, 트리메타민, 디시클로헥실아민, 라이신, 아르기닌, 히스티딘, 카페인, 프로케인, 히드라바민, 콜린, 베타인, 에틸렌디아민, 글루코사민, 메틸글루카민, 데오브로민, 퓨린, 피페라진, 피페리딘, N-에틸피페리딘, 폴리아민 수지 등이 포함되나, 이에 한정되지는 않는다. 특히 바람직한 유기 염기에는 이소프로필아민, 디에틸아민, 에탄올아민, 트리메탄아민, 디시클로헥실아민, 콜린 및 카페인이 있다.
"치료적 유효량"이란 필요로하는 사람에게 투여되는 본 발명의 화합물의 양이, 하기 정의된 바와 같이, 혈전 활성의 특징을 갖는 질병 상태를 치료하는데 충분히 효과적인 것을 의미한다. "치료적 유효량"으로 구성된 본 발명의 화합물의 양은 화합물, 질병 상태 및 심도, 및 치료될 사람의 연령에 따라 좌우되나, 통상의 지식을 갖춘 당업계의 숙련가에 의해 통상적으로 투여될 수 있다.
본원에서 사용된 "치료"란
(i) 사람에서 일어나는 질병 상태, 특히 사람이 질병 상태에 대해 소인성이나, 아직 병을 지닌다고 진단되지 않는 상태를 예방하는 것,
(ii) 질병 상태를 억제하는 것, 즉 그의 발병을 억제하는 것, 또는
(iii) 질병 상태를 완화시키는 것, 즉 질병 상태를 퇴화시키는 것을 포함하는, 사람에서 혈전 활성의 특징을 갖는 질병 상태를 치료하는 것을 포함한다.
본원에 기재된 각 반응의 수율은 이론적 수율에 대한 백분율로 표시된다.
본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염은 그의 구조에 있어서 비대칭성 탄소 원자를 가질 수 있다. 따라서, 본 발명의 화합물 및 제약학적으로 허용 가능한 그의 염은 단일 입체 이성질체, 라세미체, 및 에난티오머 및 디아스테레오머의 혼합물로서 존재할 수 있다. 이러한 단일 입체 이성질체, 라세미체 및 그들의 혼합물은 본 발명의 영역 내에 속한다.
R1이 R3과 동일한 치환체이고, R2가 R4와 동일한 치환체이고, Z1및 Z2가 동일한 경우, 화학식 I의 화합물은 화학식 II의 화합물과 동일하고, 화학식 III의 화합물은 화학식 IV의 화합물과 동일하다.
본원에서 사용된 화합물 명칭은 I.U.P.A.C. 시스템의 변형된 형태이고, 여기서 본 발명의 화합물은 퓨린의 유도체로 명명된다. 예를 들어, Z1및 Z2가 모두 -O-이고, R1은 -OR10(여기서, R10은 페닐임)이고, R2는 -C(NH)NH2이고, R3은 -C(O)N(R10)R11(여기서, R10및 R11은 모두 메틸임)이고, R4는 수소이고, R5는 에틸이고, R6은 -(C(R7)(R8))n-R9[여기서, n은 1이고, R7은 수소이고, R8은 에틸이고, R9는 -C(O)OR10(여기서, R10은 메틸임)임]인 화학식 II로부터 선택된 본 발명의 화합물은 2-(3-디메틸아미노카르보닐페녹시)-6-(2-페녹시-4-아미디노페녹시)-9-(1-메톡시카르보닐프로필)-8-에틸퓨린으로 명명되는 하기 화학식의 화합물이다.
〈용도 및 투여〉
A. 용도
본 발명의 화합물은 인자 Xa의 억제제이어서 응혈 캐스캐이드에서 인자 Xa의 기능을 기재로한 혈전 활성의 특징을 갖는 질병 상태에 유용하다 (상기 배경 기술 참조). 화합물의 1차 적용 대상은 심근경색 이후의 장시간의 위험을 예방하는 것이다. 다른 적용 대상은 정형외과 수술 후에 심정맥 혈전증(DVT)의 예방 또는 일시적 국소빈혈이 일어나는 환자의 예방이다. 또한, 본 발명의 화합물은 DVT와 같은 쿠마린이 현재 사용되거나, 또는 관상 동맥 우회 이식 및 경피 경관 혈관 성형술과 같은 다른 유형의 수술에 적용할 수 있다. 또한, 본 화합물은 급성 전골수구성 백혈병, 당뇨병, 다발성 골수종, 패혈증에 따른 파종성 혈관내 응고, 감염에 따른 전격성 자반병, 성인성 호흡 곤란 증후군, 불안정한 앙기나, 및 인공 대동맥판 또는 대동맥관 관련 혈전성 합병증에 유용하다. 또한, 본 화합물은 혈전성 질병, 특히 이 질병이 발병할 위험성이 매우 높은 환자에서 예방하는데 유용하다.
또한, 본 발명의 화합물은 응혈 캐스캐이드의 다른 성분을 억제시키지 않으면서, 인자 Xa를 선택적으로 억제시키기 위한 시험관 내 진단 시약으로 유용하다.
B. 시험
본 발명의 화합물의 인자 Xa에 대한 억제 효과를 입증하기 위하여 사용된 1차 생물학적 검정은 세린 프로테아제, 즉 시험될 본 발명의 화합물만이 관여하는 간단한 염색체 분석이었다(예를 들어, Thrombosis Res. (1979), Vol. 16, pp. 245-254). 예를 들어, 4개의 조직 중 사람 세린 프로테아제, 유리 인자 Xa, 프로트롬비나제, 트롬빈(IIa) 및 조직 플라즈미노겐 활성자(tPA)가 1차 생물학적 검정에 사용될 수 있다. TPA에 대한 분석은 이전에 피브린 분해 과정 억제에 있어서 부적절한 부작용을 입증하는데 성공적으로 사용되어 왔다 (J. Med. Chem. (1963), Vol. 36, pp.314-319 참조). 인자 Xa를 억제하는데 있어서 본 발명의 화합물의 유용성을 입증하기 위한 유용한 다른 생물학적 검증은 시트레이트화 플라즈마에서 유리 인자 Xa에 대한 화합물의 효능을 입증하고 있다. 예를 들어, 본 발명의 화합물의 항응혈제 효능은 프로트롬빈 시간(PT) 또는 활성화된 부분적 트롬보플라스틴 시간(aPTT) 중 하나를 사용하여 시험되는 반면에, 화합물의 선별성은 트롬빈 응고 시간(TCT) 분석에 의해 확인한다. 1차 효소 분석에서 Ki와 시트레이트화 플라즈마에서 유리 인자 Xa에 대한 Ki와의 관계는 다른 플라즈마 성분과 반응하거나 또는 그에 의해 불활성화되는 화합물을 선별할 것이다, Ki와 연장된 PT와의 관계는 유리 인자 Xa 억제 분석에서의 효능이 임상적 응고 분석에서의 효능으로 해석됨을 입증하고 있다. 또한, 시트레이트화 플라즈마에서의 PT의 연장은 후속되는 약물동력학적 연구에서의 작용 지속 시간을 측정하는데 사용될 수 있다.
본 발명의 화합물의 활성을 입증하기 위한 분석에 대한 추가의 정보는 하기의 문헌을 참조한다. R. Lottenberg, Methods in Enzymology(1981), Vol. 80, pp. 341-361, H. Ohno, Thrombosis Research(1980), Vol. 19, pp. 579-588.
C. 일반적인 투여
본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염은 순수한 형태로 또는 적절한 제약 조성물의 형태로, 허용 가능한 투여 방식 또는 유사한 용도로 작용하는 작용제를 통해 투여될 수 있다. 따라서, 투여는 예를 들어, 경구적, 비강내, 비경구적, 국부적, 경피적, 또는 직장으로, 고형제, 반고형제, 동결건조형 분말제, 또는 액상 제제, 예를 들어, 정제, 좌약제, 알약제, 연성 탄성 캡슐제 및 경성 젤라틴 캡슐제, 분말제, 용액제, 현탁제, 또는 에어로졸제 등으로, 바람직하게는 정확한 투여량을 간단히 투여할 수 있는 적절한 단위 투여 형태로 이루어질 수 있다. 조성물에는 통상의 제약학적 담체 또는 부형제, 및 활성제로서 본 발명의 화합물을 포함할 것이고, 이외에 다른 약제, 담체, 보조제 등이 포함될 수 있다.
일반적으로, 목적하는 투여 방식에 따라, 제약학적으로 허용 가능한 조성물은 약 1 내지 99 중량%의 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 및 1 내지 99 중량%의 적절한 제약학적 부형제를 포함할 것이다. 바람직하게는, 조성물은 약 5 내지 75 중량%의 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 그리고 나머지는 적절한 제약학적 부형제를 포함할 것이다.
바람직한 투여 경로는 치료될 질병 상태의 심도에 따라 조절될 수 있는, 편리한 1일 투여 양생법을 사용하는 경구적 방법이다. 이러한 경구 투여를 위해서, 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염을 포함하는 제약학적으로 허용 가능한 조성물은 통상적으로 사용되는 임의의 부형제, 예를 들어, 제약용 만니톨, 락토즈, 녹말, 예비 젤라틴화된 녹말, 마그네슘 스테아레이트, 소듐 사카린, 탈크, 셀룰로오즈 에테르 유도체, 글루코즈, 젤라틴, 수크로즈, 시트레이트, 프로필 갈레이트 등을 혼입함으로써 제조된다. 이러한 조성물은 용액제, 현탁액제, 정제, 알약제, 캡슐제, 분말제, 서방형 제제 등의 형태를 지닌다.
바람직하게는 이러한 조성물은 캡슐제, 캐플렛트(caplet) 또는 정제의 형태를 지닐 수 있고, 또한 락토즈, 수쿠로즈, 디칼슘포스페이트와 같은 희석제; 크로스카르멜로즈 소듐 또는 그의 유도체와 같은 붕해제; 마그네슘 스테아레이트와 같은 윤활제; 및, 녹말, 검 아카시아, 폴리비닐피롤리돈, 젤라틴, 셀룰로즈 에테르 유도체와 같은 결합제를 함유할 수 있다.
또한, 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염은 생체 내에서 서서히 용해시키는, 담체, 예를 들어, 폴리옥시에틸린 글리콜 및 폴리에틸렌 글리콜(PEG), 예를 들어 PEG 1000(96%) 및 PEG 4000(4%) 내에 약 0.5% 내지 약 50 %의 활성 성분을 함유하는 좌약으로 제제될 수 있다.
제약학적으로 투여 가능한 액상 조성물은 예를 들어, 담체 내에 (약 0.5% 내지 약 20%) 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 및 임의의 제약 보조물, 예를 들어, 물, 염수, 덱스트로즈 수용액, 글리세롤, 에탄올 등을 용해, 분산시킴으로써 제조되어 용액제 또는 현탁액제를 형성할 수 있다.
원한다면, 본 발명의 제약 조성물은 또한 부수량의 보조 물질, 예를 들어 습윤제 또는 유화제, pH 완충제, 산화 방지제, 예를 들어, 시트르산, 소르비탄 모노라우레이트, 트리에탄올아민 올레이트, 부틸화 히드록시톨루엔 등을 함유할 수 있다.
상기 제제를 제조하기 위한 실제적인 방법은 당업자에게 공지되어 있거나 명백할 것이다. 문헌[Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pensylvania, 1990)]을 참조한다. 투여될 조성물은 어떠한 경우에도 본 발명의 교시에 따라 인자 Xa의 억제에 의해 완화되는 질병 상태를 치료하기 위한, 치료적 유효량의 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염을 함유할 것이다.
본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염은 사용될 특정 화합물의 활성, 대사적 안정성 및 화합물의 작용 시간, 연령, 체중, 일반적 건강 상태, 성별, 식이요법, 투여 방식 및 시간, 방출 속도, 약제의 혼합 사용, 특정 질병 상태의 심도, 및 치료 중인 대상을 비롯한 다양한 인자에 따라 변화될 수 있는 치료적 유효량으로 투여된다. 일반적으로, 1일 치료적 유효량은 1일 당 체중 ㎏ 당 약 0.14 ㎎ 내지 약 14.3 ㎎의 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염이고, 바람직하게는 1일 당 체중 ㎏ 당 약 0.7 ㎎ 내지 약 10 ㎎, 가장 바람직하게는 1일 당 체중 ㎏ 당 약 1.4 ㎎ 내지 약 7.2 ㎎이다. 예를 들어, 70 ㎏의 개인에게 투여하는 경우, 투여량 범위는 1일 당 약 10 ㎎ 내지 약 1.0 g의 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 바람직하게는 1일 당 약 50 ㎎ 내지 약 700 ㎎, 가장 바람직하게는 1일 당 약 100 ㎎ 내지 약 500 ㎎이다.
〈바람직한 실시 태양〉
상기 발명의 요약에서 제시된 본 발명의 화합물 중, 바람직한 군은
Z1및 Z2는 독립적으로 -O- 또는 -OCH2-이고;
R1및 R4는 각각 독립적으로 수소, 할로 또는 -OR10이고;
R2는 -C(NH)NH2, -C(NH)N(H)S(O)2R13, 또는 -C(NH)N(H)C(O)N(H)R10이고;
R3은 우레이도, 구아니디노, -C(O)N(R10)R11, -N(R10)R11, -C(O)OR10, -N-(R10)C(O)R10, (1,2)-테트라히드로피리미디닐(임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고;
R5는 수소, 할로, 알킬, 할로알킬, 아릴, 또는 아랄킬이고;
R6은 알킬, 아릴, 아랄킬, 또는 -(C(R7)(R8))n-R9(여기서, n은 1임)이고;
R7은 알킬, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -R12-C(R10)(C(O)OR10)2, -R12-N(R10)R11, -R12-N(R10)C(NR10)R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12OR10, -R12-OP(O)(OR10)2, -R12-SR10, -R12-S(O)2R13이거나,
또는 R7은 아랄킬(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,
또는 R7은 헤테로시클릴알킬(여기서, 헤테로시클릴 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C-(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이고;
R8은 독립적으로 수소 또는 알킬이고;
R9는 -C(O)OR10또는 -C(O)N(R10)R11이고;
R10및 R11은 각각 독립적으로 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고;
R12는 직쇄 또는 분지쇄 알킬렌이고;
R13은 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)인 화합물이다.
상기 화합물의 군 중, 바람직한 하부군의 화합물로는
Z1및 Z2는 각각 -O-이고;
R1은 수소 또는 -OR10이고;
R2는 -C(NH)NH2이고;
R3은 -C(O)N(R10)R11, (1,2)-테트라히드로피리미디닐 (임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴 (임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐 (임의로 알킬에 의해 치환됨)이고;
R4는 수소이고;
R5는 알킬 또는 아랄킬이고;
R6는 알킬, 아랄킬, 또는 -C(R7)(R8)-R9이고;
R7은 알킬, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -R12-C(R10)(C(O)OR10)2, -R12-N(R10)R11, -R12-N(R10)C(NR10)R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12OR10, -R12-OP(O)(OR10)2, -R12-SR10, -R12-S(O)2R13이거나,
또는 R7은 아랄킬(임의로 할로, 할로알킬, 히드록시, 및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,
또는 R7은 이미다졸릴알킬 또는 인돌릴알킬이고;
R8은 수소 또는 알킬이고;
R9는 -C(O)OR10또는 -C(O)N(R10)R11이고;
R10및 R11은 각각 독립적으로 수소 또는 알킬이고;
R12는 직쇄 또는 분지쇄 알킬렌이고;
R13은 알킬 또는 아릴인 화합물이다.
상기 하부군의 화합물 중, 바람직한 분류의 화합물은
Z1및 Z2는 각각 -O-이고;
R1은 수소이고;
R2는 -C(NH)NH2이고;
R3은 -C(O)N(R10)R11, (1,2)-테트라히드로피리미디닐 (임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴 (임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐 (임의로 알킬에 의해 치환됨)이고;
R4는 수소이고;
R5는 알킬이고;
R6는 아랄킬 또는 -C(R7)(R8)-R9이고;
R7은 알킬, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -R12-C(R10)(C(O)OR10)2, -R12-N(R10)R11, -R12-N(R10)C(NR10)R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12OR10, -R12-OP(O)(OR10)2, -R12-SR10, -R12-S(O)2R13이거나,
또는 R7은 아랄킬(임의로 할로, 할로알킬, 히드록시, 및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,
또는 R7은 이미다졸릴알킬 또는 인돌릴알킬이고;
R8은 수소 또는 알킬이고;
R9는 -C(O)OR10또는 -C(O)N(R10)R11이고;
R10및 R11은 각각 독립적으로 수소 또는 알킬이고;
R12는 직쇄 또는 분지쇄의 알킬렌이고;
R13은 알킬 또는 아릴인 화합물이다.
상기 분류의 화합물 중, 바람직한 아류 화합물은
R3은 -C(O)N(R10)R11, (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨) 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고;
R4는 수소이고;
R5는 알킬이고;
R6는 아랄킬 또는 -C(R7)(R8)-R9이고;
R7은 알킬, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -R12-C(R10)(C(O)OR10)2, -R12-N(R10)R11, -R12-N(R10)C(NR10)R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12OR10, -R12-OP(O)(OR10)2, -R12-SR10, -R12-S(O)2R13이고;
R8은 수소이고;
R9는 -C(O)OR10이고;
R10및 R11은 각각 독립적으로 수소 또는 알킬이고;
R12는 직쇄 또는 분지쇄의 알킬렌이고;
R13은 알킬 또는 아릴인 화합물이다.
상기 아류 화합물 중 바람직한 화합물은 R3은 -C(O)N(R10)R11이고; R4는 수소이고; R5는 메틸 또는 에틸이고; R6은 벤질이고; R10및 R11은 독립적으로 수소 또는 메틸인 화합물이다.
상기 아류 화합물 중 더욱 바람직한 화합물은 R3은 -C(O)N(R10)R11(여기서, R10및 R11은 모두 메틸임)이고, R4는 수소이고, R5는 메틸이고, R6은 벤질인 화합물, 즉 2-(2-히드록시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐)페녹시-8-메틸-9-벤질퓨린 및 6-(2-히드록시-5-시아노페녹시)-2-(3-디메틸아미노카르보닐)페녹시-8-메틸 -9-벤질퓨린이다.
〈본 발명의 화합물의 제조〉
편리하게, 하기 본 발명의 화합물의 제조 방법은 화학식 I 및 화학식 II의 화합물의 제조에 관한 것이다. 그러나, 유사한 합성 방법이 화학식 III 및 화학식 IV의 화합물의 제조에도 사용될 수 있는 것으로 이해된다. 또한, 하기 기재에서 제시된 화합물 중 치환체 및(또는) 변형체(예: R7및 R8)의 조합은 상기 조합이 안정한 화합물을 생성한다는 가정하에만 허용될 수 있는 것으로 이해된다.
A. 화학식 IIa의 화합물의 제조
화학식 IIa의 화합물은 Z1및 Z2는 모두 -O-이고, R2는 -C(NH)NH2인 화합물이다. 이 화합물들은 하기 반응식 1에 도시된 바에 따라 제조될 수 있되, 여기서 R1및 R4는 각각 독립적으로 수소, 할로, 알킬,-OR10, -C(O)OR10, -C(O)N(R10)R11, -N(R10)R11, -N(R10)C(O)R10, 또는 -N(H)S(O)2R13이고; R3은 할로, 알킬, 할로알킬, 할로알콕시, 우레이도, 시아노, 구아니디노, -OR10, -C(NH)NH2, -C(NH)N(H)OR10, -C(O)N(R10)R11, -R12-C(O)N(R10)R11, -CH(OH)C(O)N(R10)R11, -N(R10)R11, -R12-N(R10)R11, -C(O)OR10, R12-C(O)OR10, -N(R10)C(O)R10, (1,2)-테트라히드로피리미디닐(임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고; R5는 수소, 알킬, 시클로알킬, 할로알킬, 아릴, 또는 아랄킬이고; R6은 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고; 각각 R10및 R11은 독립적으로 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고; R12는 직쇄 또는 분지쇄 알킬렌이고; R13은 알킬, 아릴(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고, R14는 알킬이다.
화학식 A, 화학식 B, 화학식 D, 화학식 G 및 화학식 K의 화합물은 상업적으로, 예를 들어, 알드리치 케미칼사 또는 시그마 케미칼사 또는 ICN 바이오메디칼로부터 구입할 수 있거나, 또는 당업자에게 공지된 방법에 따라 제조할 수 있다.
일반적으로, 화학식 IIa의 화합물은 먼저, 비양성자성 용매, 예를 들어 아세토니트릴 중에서 약 -10℃ 내지 약 10℃의 온도, 바람직하게는 0℃에서, 화학식 A의 화합물을 탄산세슘과 같은 염기의 존재 하에 동몰량의 화학식 B의 화합물로 처리함으로써 제조하였다. 반응 혼합물을 실온에서 12 내지 20 시간, 바람직하게는 약 16시간 동안 교반시켰다. 이어서, 화학식 C의 화합물을 표준 단리 기술, 예를 들어, 추출, 진공 하에 용매의 제거 및 플래쉬 크로마토그래피를 사용하여 반응 혼합물로부터 단리하였다.
비양성자성 용매, 바람직하게는 아세토니트릴 중에서 화학식 C의 화합물을 약 -10℃ 내지 약 10℃의 온도, 바람직하게는 0℃에서, 탄산세슘과 같은 염기의 존재 하에 동몰량의 화학식 D의 화합물로 처리하였다. 생성된 반응 혼합물을 약 50℃로 약 3 내지 6시간, 바람직하게는 약 4시간 동안 가열하였다. 화학식 E의 화합물을 표준 기술, 예를 들어, 여과, 진공 하의 용매 제거 및 플래쉬 크로마토그래피를 사용하여 반응 혼합물로부터 단리하였다.
메탄올과 같은 양성자성 용매 중에서 화학식 E의 화합물을 약 -10℃ 내지 약 10℃의 온도, 바람직하게는 0℃에서, 포타슘 메타비술피트(KHSO5) 수용액과 같은 강력한 산화제로 처리하였다. 생성된 반응 혼합물을 실온에서 약 12 내지 16시간, 바람직하게는 약 15시간 동안 교반하였다. 혼합물을 농축하고, 메틸렌클로라이드과 같은 비양성자성 용매로 추출하여서 상응하는 화학식 F의 술포닐 화합물을 얻었다. 화학식 F의 화합물을 비양성자성 용매, 바람직하게는 아세토니트릴 중에 약 -10℃ 내지 약 10℃의 온도, 바람직하게는 0℃에서, 탄산세슘과 같은 염기의 존재 하에 용해시켰다. 화학식 G의 화합물을 용액에 가하고, 생성된 반응 혼합물을 실온에서 약 12 시간 내지 약 16시간 동안, 바람직하게는 약 16시간 동안 교반하였다. 화학식 H의 화합물을 단리 기술, 예를 들어, 진공 하의 용매 제거 및 플래쉬 크로마토그래피를 사용하여 반응 혼합물로부터 단리하였다.
화학식 H의 화합물을 Zn/HCl과 같은 표준 환원 조건 하에서 환원시켰다. 화학식 J의 생성된 아미노 화합물을 NaHCO3와 같은 약염기를 사용하는 중화와 같은 표준 기술을 통해 반응 혼합물로 부터 단리한 후, 에틸아세테이트와 같은 유기 용매를 사용하여 추출하고, 진공 하에 용매를 제거하였다. 화학식 J의 화합물을 약 60℃ 내지 약 75℃의 온도, 바람직하게는 약 70℃에서, 약 2 내지 4시간 동안, 바람직하게는 약 3시간 동안 테트라히드로푸란(THF)와 에탄올의 혼합물과 같은 극성 용매 중에서 화학식 K의 이미데이트로 처리하였다. 이어서, 화합물을 진공 하에 약 150℃ 내지 약 200℃, 바람직하게는 약 170℃에서, 약 1 내지 3시간 동안, 바람직하게는 약 2시간 동안 진공 하에 가열하였다. 이어서, 반응 혼합물을 농축하여 오일을 얻고, 이를 표준 정제 기술(여과, 추출 및 진공 하의 용매 제거)에 의해 정제하여서 순수한 화학식 L을 얻었다.
화학식 L의 화합물을 0℃의 알칸올, 바람직하게는 에탄올 중에 용해시키고, 생성된 용액을 무기산 기체, 바람직하게는 염산으로 포화시켰다. 반응 혼합물을 밀봉하고, 실온에서 약 12시간 내지 약 16시간 동안 가온시켰다. 반응 혼합물을 농축하고, 극성 용매, 예를 들어 에테르를 농축 혼합물에 가하였다. 생성된 침전물을 알칸올, 바람직하게는 에탄올에 용해시키고, 생성된 용액을 약 0℃로 냉각시킨 후, 무수 암모니아(기체)로 약 5 내지 20분 동안 처리하였다. 반응 혼합물을 밀봉하고, 실온 내지 100℃의 온도, 바람직하게는 약 60℃에서, 약 2 내지 6시간 동안, 바람직하게는 약 2시간 동안 가열하였다. 반응 혼합물을 냉각시키고, 용매를 증발시켰다. 화학식 IIa의 화합물을 표준 단리 기술, 예를 들어, 여과, 용매의 증발 및 예비 HPLC에 의한 정제에 의해 반응 혼합물로부터 단리하였다.
별법으로, 상기 생성된 용액을 무수 암모니아로 처리하는 대신, 생성된 용액을 화학식 NH2OR10의 화합물로 처리하여 R2가 -C(NH)N(H)OR10인 화학식 II의 화합물을 얻을 수 있다.
R3이 -C(NH)NH2또는 -C(NH)N(H)OR10인 화학식 IIa의 화합물은 화학식 L의 화합물에서 기재된 바와 유사한 방법으로 상응하는 시아노 화합물로부터 생성된다.
또한, R1, R3, R4또는 R6이 -C(O)N(R10)R11기 또는 -C(O)OR10기(여기서, R10및 R11은 각각 독립적으로 알킬, 임의로 치환된 아릴 또는 임의로 치환된 아랄킬임)을 포함하는 화학식 IIa의 화합물은 산성 조건 하에서 가수분해되어 R1, R3, R4또는 R6이 카르복시기를 함유하는 본 발명의 화합물을 제조할 수 있다.
또한, R1, R3, R4또는 R6이 -C(O)OR10기(여기서, R10은 수소, 알킬, 임의로 치환된 아릴 또는 임의로 치환된 아랄킬임)을 포함하는 화학식 IIa의 화합물은 표준 아미드화 조건 하에서 아미드화되어 R1, R3, R4또는 R6이 -C(O)N(R10)R11기(여기서, R10및 R11은 독립적으로 알킬, 임의로 치환된 아릴 또는 임의로 치환된 아랄킬임)를 함유하는 상응하는 화학식 IIa의 화합물을 형성할 수 있다.
또한, R1, R3, R4또는 R6이 아미노기를 함유하는 화학식 IIa의 화합물을 적절한 알킬화제로 처리하여 R1, R3, R4또는 R6이 -N(R10)R11또는 -N(R10)C(O)R11기(여기서, R10및 R11은 독립적으로 수소, 알킬, 임의로 치환된 아릴 또는 임의로 치환된 아랄킬임)를 함유하는 상응하는 화학식 IIa의 화합물을 얻을 수 있다.
화학식 IIa의 화합물은 추가로 적절한 산 할라이드, 바람직하게는 산 클로라이드, 또는 적절한 산 무수물 또는 등가물로 처리되어 R2가 -C(NH)N(H)C(O)R10(여기서, R10은 수소, 알킬, 임의로 치환된 아릴 또는 임의로 치환된 아랄킬임)인 본 발명의 화합물을 생성할 수 있다. 별법으로, 화학식 IIa의 화합물을 추가로 카르바모일클로라이드 또는 그의 등가물로 처리하여 R2가 -C(NH)N(H)C(O)R13(여기서, R13은 상기 발명의 요약에 기재된 바와 같음)인 본 발명의 화합물을 생성할 수 있다.
별법으로, 화학식 IIa의 화합물을 추가로 메틸렌클로라이드와 같은 극성 용매 중에서, 실온에서 화학식 R13-S(O)2-이미다졸(여기서, R13은 상기 발명의 요약에 기재된 바와 같음)의 화합물로 처리하여 R2가 -C(NH)N(H)S(O)2R13인 본 발명의 화합물을 얻을 수 있다.
별법으로, 화학식 IIa의 화합물을 추가로 극성 용매, 바람직하게는 메틸렌클로라이드 중에서, 실온에서, 약 6 내지 24시간 동안, 바람직하게는 약 12시간 동안, 적절히 N-R10-치환된 페닐카르바메이트로 처리하여 R2가 -C(NH)N(H)C(O)N(H)R10인 본 발명의 화합물을 얻을 수 있다.
또한, R6이 수소인 화학식 IIa의 화합물을 문헌[Dusert, P. Eur. J. Med. Chem. (1980), Vol. 15, No.3, p.199]에 기재된 방법과 유사한 방법으로 처리하여 R6이 -(C(R7)(R8))n-R9인 화학식 IIa의 화합물을 생성할 수 있다. 예를 들어, R6이 수소인 화학식 IIa의 화합물은 먼저 DMF와 같은 비양성자성 용매 중에서 수소화나트륨과 같은 강염기로 처리한 후, 동몰량의 화학식 X(C(R7)(R8)n-R9(여기서, X는 브로모 또는 클로로이고, n, R7, R8및 R9는 발명의 요약에 기재된 바와 같음)의 화합물로 처리하였다. 이어서, 생성된 반응 혼합물을 2 내지 6시간 동안, 바람직하게는 약 4시간 동안 실온 내지 약 80℃에서 교반하였다. R6이 -(C(R7)(R8)n-R9인 화학식 IIa의 화합물을 표준 단리 기술에 의해 반응 혼합물로부터 단리하였다.
별법으로, R5가 수소인 화학식 IIa의 화합물을 문헌[Stevenson, T.M., J. Org. Chem. (1984), Vol. 49, No. 12, p. 2158]에 기재된 방법과 유사한 방법으로 처리하여 R5가 할로인 화학식 IIa의 화합물을 생성할 수 있다. 예를 들어, R5가 수소인 화학식 IIa의 화합물을 카본 테트라클로라이드 중에서 온화한 친전자성 할로겐화제, 예를 들어 N-브로모숙신이미드 또는 N-클로로숙신이미드로 처리하여 R5가 클로로 또는 브로모인 화학식 IIa의 화합물을 생성할 수 있다.
또한, 화학식 J의 화합물은 적절한 반응 조건 하에 N,N-카르보닐디이미다졸 또는 N,N-티오카르보닐이미다졸로 처리하여 R5가 히드록시(카르보닐 호변이성질체로서) 또는 메르캅토인 화학식 L의 화합물을 형성할 수 있다. 이렇게 형성된 화합물은 상기 기재된 방법과 동일한 방법으로 처리하여 R5가 히드록시 또는 메르캅토인 화학식 IIa의 화합물을 형성할 수 있다.
또한, 화학식 J의 화합물은 문헌[Omar, A. Synthesis(1977), p. 864; Ram, S., Org. Prep. Proced. Int.(1985), Vol. 17, No.3, p.215; Janssens, F., J. Med. Chem.(1985), Vol. 28, No. 12, p. 1925]에 기재된 방법에 의해 화학식 R10NCS(여기서, R10은 발명의 요약에 기재된 바와 같음)의 티오이소시아네이트로 처리하여 R5가 -N(H)R10인 화학식 L의 화합물을 생성할 수 있다. 이어서, 본 화합물을 화학식 R11X의 알킬 할라이드 또는 화학식 R11C(O)X(여기서, X는 할로이고, R11은 발명의 요약에 기재된 바와 같음)의 산 할라이드와 같은 표준 알킬화제로 처리하여 R5는 -NR10R11이고, 5-위치의 질소가 이와 같이 알킬화된 화학식 L의 화합물을 생성할 수 있다.
유사하게, R5가 메트캅토인 화학식 IIa의 화합물은 탄산칼륨과 같은 온화한 염기의 존재 하에 디메틸술폭시드와 같은 쌍극성 용매 중에서 메틸브로마이드와 같을 알킬 할라이드로 처리하여 R5가 알킬티오인 화학식 IIa의 화합물을 얻을 수 있다.
유사하게, R5가 히드록시인 화학식 IIa의 화합물은 수소화나트륨과 같은 강염기 및 DMF와 같은 비양성자성 용매의 존재 하에 추가로 메틸브로마이드와 같은 알킬 할라이드로 처리하여 R5가 알콕시인 화학식 IIa의 화합물을 얻을 수 있다.
B. 화학식 IIa의 화합물의 제조
화학식 Ia의 화합물은 Z1및 Z2가 -O-이고, R2가 -C(NH)NH2인 화학식 Ia의 화합물이다. 이 화합물은 하기 반응식 2에 도시된 바와 같이 제조될 수 있되, X는 할로이고; R1및 R4는 각각 독립적으로 수소, 할로, 알킬, -OR10, -C(O)OR10, -C(O)N(R10)R11, -N(R10)R11, -N(R10)C(O)R10, 또는 -N(H)S(O)2R13이고; R3은 할로, 알킬, 할로알킬, 할로알콕시, 우레이도, 구아니디노, -OR10, -C(NH)NH2, -C(NH)N(H)OR10, -C(O)N(R10)R11, -R12-C(O)N(R10)R11, -CH(OH)C(O)N(R10)R11, -N(R10)R11, -R12-C(O)OR10, -C(O)OR10, -R12-C(O)OR10, -N(R10)C(O)R10, (1,2)-테트라히드로피리미디닐(임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고; R5는 수소, 알킬, 시클로알킬, 할로알킬, 아릴, 또는 아랄킬이고; R6은 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 시아노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 시아노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고; R10및 R11은 각각 독립적으로 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 시아노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 시아노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고; R12는 직쇄 또는 분지쇄 알킬렌이고; R13은 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 시아노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 시아노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고; R14는 알킬이다.
일반적으로, 화학식 Ia의 화합물은 화학식 A의 화합물을 화학식 F 및 G로부터 화학식 H의 화합물을 제조하기 위해 기재된 방법과 유사한 방법으로 화학식 G의 화합물로 처리하여 화학식 M의 화합물을 얻을 수 있다. 이어서, 화학식 M의 화합물을 화학식 C의 화합물에 대해 상기 기재된 방법과 유사한 방법으로 화학식 D의 화합물로 처리하여 화학식 N의 화합물을 얻을 수 있다. 이어서, 화학식 N의 화합물을 화학식 E의 화합물에 대해 기재된 방법과 유사한 방법으로 상응하는 화학식 O의 화합물로 산화시킨다. 화학식 O의 화합물을 화학식 A의 화합물에 대해 기재된 방법과 유사한 방법으로 화학식 B의 화합물로 처리하여 화학식 P의 화합물을 얻고, 이를 화학식 H의 화합물에 대해 기재된 방법과 유사한 방법으로 상응하는 화학식 Q의 화합물로 환원시킨다. 이어서, 화학식 Q의 화합물을 화학식 J의 화합물에 대해 기재된 방법과 유사한 방법으로 화학식 K의 알킬 이미데이트로 처리하여 화학식 R의 화합물을 얻고, 이를 화학식 L의 화합물에 대해 기재된 방법과 유사한 방법으로 화학식 Ia의 상응하는 아미딘 유도체로 전환한다.
또한, 화학식 IIa의 화합물에 대해 기재된 모든 다양한 치환체 전환은 화학식 Ia의 화합물에 적용되어 상기 반응식에는 도시되지 않은 본 발명의 추가의 화합물을 얻는다.
또한, 유사한 반응을 유사한 출발 물질 및 중간체 상에서 수행하여 상응하는 화학식 III의 화합물 및 화학식 IV의 화합물을 형성할 수 있다.
또한, 유리 염기 형태 또는 유리 산 형태로 존재하는 모든 본 발명의 화합물은 적절한 무기산 또는 유기산으로의 처리, 또는 적절한 무기 염기 또는 유기 염기로의 처리에 의해 제약학적으로 허용 가능한 염으로 전환될 수 있다. 또한, 본 발명의 화합물의 염은 화학업계의 숙련가에게 공지된 방법에 의해 유리 염기 형태 또는 유리 산 형태 또는 다른 염으로 전환될 수 있다.
하기 구체적인 제조예 및 실시예는 본 발명을 수행하기 위한 지침으로 제공되며, 본 발명의 영역을 제한하려는 것은 아니다.
〈제조예 1〉
화학식 C 및 P의 화합물
A. 0℃에서 200 ㎖의 아세토니트릴 중 4,6-디클로로-5-니트로-2-메틸티오피리미딘 5.0 g(20.8 밀리몰)에 탄산세슘 8.82 g(27.1 밀리몰), 이어서 3-히드록시-4-벤질옥시벤조니트릴 4.69 g (20.8 밀리몰)을 가하고, 생성된 반응 혼합물을 16시간 동안 교반하였다. 휘발물질을 증발시키고, 잔사를 실리카겔 상에서 크로마토그래피(헥산/에틸아세테이트, 2:1)하여 2-메틸티오-4-클로로-5-니트로-6-(2-벤질옥시 -5-시아노페녹시)피리미딘, 즉 화학식 C의 화합물 5.0 g을 얻을 수 있었다.
B. 유사한 방법으로, 하기 화학식 C의 화합물을 제조하였다.
2-메틸티오-4-클로로-5-니트로-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-클로로-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-브로모-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-메틸-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-메틸-4-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-니트로-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-니트로-4-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(2-디메틸아미노-5-시아노페녹시)피리미딘, 및
2-메틸티오-4-클로로-5-니트로-6-(3-디메틸아미노-4-시아노페녹시)피리미딘,
C. 유사한 방법으로, 2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘을 탄산세슘의 존재 하에 3-히드록시-4-벤질옥시벤조니트릴로 처리하여 2-(2-벤질옥시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘, 즉 화학식 P의 화합물을 얻었다.
D. 유사한 방법으로 화학식 P의 화합물을 제조하였다.
2-(2-벤질옥시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-메톡시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-에톡시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-페녹시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-클로로-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-메틸-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-t-부틸-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-니트로-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-카르복시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-아미노-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-벤질옥시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-(1-메틸이미다졸린-2-일)-페녹시)피리미딘,
2-(2-메톡시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-(2-(t-부톡시카르보닐)에틸)-페녹시)피리미딘,
2-(2-에톡시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-t-부톡시카르보닐-페녹시)피리미딘,
2-(2-페녹시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-카르복시페녹시)피리미딘,
2-(2-클로로-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-(2-아미노에틸)페녹시)피리미딘,
2-(2-메틸-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-(벤질옥시)페녹시)피리미딘,
2-(2-t-부틸-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-에톡시페녹시)피리미딘,
2-(2-니트로-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-구아니디노페녹시)피리미딘,
2-(2-카르복시-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-우레이도페녹시)피리미딘,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-아미노페녹시)피리미딘,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-니트로페녹시)피리미딘, 및
2-(2-아미노-5-시아노페녹시)-4-벤질아미노-5-니트로-6-(3-트리플루오로메톡시페녹시)피리미딘.
〈제조예 2〉
화학식 E 및 화학식 N의 화합물
A. 0℃에서 50 ㎖의 아세토니트릴 중 6-(2-벤질옥시-5-시아노페녹시)-4-클로로-5-니트로-2-메틸티오피리미딘 2.5 g (5.83 밀리몰)에 탄산세슘 2.47 g(7.58 밀리몰), 이어서 벤질아민 0.64 ㎖을 가하고, 반응 혼합물을 50℃에서 4시간 동안 가열하였다. 반응물을 여과하고, 여액을 증발시키고, 잔사를 실리카겔 상에서 크로마토그래피(에틸아세테이트:헥산)하여 6-(2-벤질옥시-5-시아노페녹시)-4-(벤질)아미노-5-니트로-2-메틸티오피리미딘, 즉 화학식 E의 화합물 1.82 g(65%)을 얻었다.
B. 유사한 방법으로, 화학식 E의 화합물을 제조하였다.
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-클로로-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-브로모-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-메틸-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-메틸-4-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-니트로-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-니트로-4-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(2-디메틸아미노-5-시아노페녹시)피리미딘,
2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-디메틸아미노-4-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-클로로-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-브로모-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-메틸-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-메틸-4-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-니트로-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-니트로-4-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-메틸티오-4-아미노-5-니트로-6-(2-디메틸아미노-5-시아노페녹시)피리미딘, 및
2-메틸티오-4-아미노-5-니트로-6-(3-디메틸아미노-4-시아노페녹시)피리미딘.
C. 유사한 방법으로, 0℃에서 90 ㎖의 아세토니트릴 중 2-메틸티오-4-클로로-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘, 즉 화학식 M의 화합물 3.19 g (8.65 밀리몰)에 탄산세슘 3.66 g(11.2 밀리몰), 이어서 벤질아민 0.95 ㎖ (8.65 밀리몰)을 기하였다. 반응 혼합물을 75℃에서 4시간 동안 가열하였다. 반응물을 여과하고, 여액을 증발시키고, 잔사를 실리카겔 상에서 크로마토그래피(에틸아세테이트:메탄올, 10:1)하여 2-메틸티오-4-(벤질)아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘, 즉 화학식 N의 화합물 1.76 g(48%)을 얻었다.
D. 유사한 방법으로, 화학식 N의 화합물을 제조하였다.
2-메틸티오-4-벤질아미노-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)페녹시)피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)-5-메톡시페녹시)피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)-5-클로로페녹시)피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-클로로-5-메톡시페녹시)피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-트리플루오로메틸-5-(디메틸아미노카르보닐)페녹시피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-구아니디노페녹시)피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-우레이도페녹시)피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-니트로페녹시)피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-구아니디노-5-메틸페녹시)피리미딘,
2-메틸티오-4-벤질아미노-5-니트로-6-(3-우레이도-5-메틸페녹시)피리미딘, 및
2-메틸티오-4-벤질아미노-5-니트로-6-(3-니트로-5-아미노페녹시)피리미딘.
〈제조예 3〉
화학식 F 및 O의 화합물
A. 0℃의 MeOH 40 ㎖ 및 디옥산 40 ㎖ 중의 2-메틸티오-4-벤질아미노-5-니트로-6-(2-벤질옥시-5-시아노페녹시)피리미딘 1.82 g(3.76 밀리몰)에 물 40 ㎖ 중의 포타슘 메타비술피트(KHSO5) 3.59 g(11.3 밀리몰)을 가하였다. 현탁액을 실온에서 가온시키고, 15시간 동안 교반하였다. 반응물을 25 ㎖로 농축하고, 메틸렌클로라이드 200 ㎖로 추출하였다. 유기층을 황산나트륨 상에서 건조시키고, 증발시키고, 실리카겔 상에서 크로마토그래피(2:1 헥산/에틸아세테이트)하여 2-메틸술포닐-4-벤질아미노-5-니트로-6-(2-벤질옥시-5-시아노페녹시)피리미딘, 즉 화학식 F의 화합물 0.26 g을 백색 고체로 얻었다.
B. 유사한 방법으로, 하기 화학식 F의 화합물을 제조하였다.
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-클로로-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-브로모-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-메틸-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-메틸-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-니트로-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-니트로-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(2-디메틸아미노-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-(벤질)아미노-5-니트로-6-(3-디메틸아미노-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-클로로-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-브로모-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-메틸-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-메틸-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-니트로-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-니트로-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-메틸술포닐-4-아미노-5-니트로-6-(2-디메틸아미노-5-시아노페녹시)피리미딘, 및
2-메틸술포닐-4-아미노-5-니트로-6-(3-디메틸아미노-4-시아노페녹시)피리미딘.
C. 유사한 방법으로, 2-메틸티오-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘, 즉 화학식 N의 화합물을 산화시켜 2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-디메틸아미노카르보닐페녹시)피리미딘, 즉 화학식 O의 화합물을 얻었다.
D. 유사한 방법으로, 화학식 O의 화합물을 제조하였다.
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)페녹시)피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)-5-메톡시페녹시)피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)-5-클로로페녹시)피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-클로로-5-메톡시페녹시)피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-트리플루오로메틸-5-(디메틸아미노카르보닐)페녹시피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-구아니디노페녹시)피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-우레이도페녹시)피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-니트로페녹시)피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-구아니디노-5-메틸페녹시)피리미딘,
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-우레이도-5-메틸페녹시)피리미딘, 및
2-메틸술포닐-4-벤질아미노-5-니트로-6-(3-니트로-5-아미노페녹시)피리미딘.
〈제조예 4〉
화학식 H 및 M의 화합물
A. 0℃의 아세토니트릴 15 ㎖ 중의 2-메틸술포닐-4-벤질아미노-5-니트로-6-(2-벤질옥시-5-시아노페녹시)피리미딘, 즉 화학식 F의 화합물 0.69 g(1.38 밀리몰)에 탄산세슘, 이어서 3-(디메틸아미노카르보닐)페놀 0.20 g(1.24 밀리몰)을 가하고, 반응물을 16시간 동안 교반하였다. 휘발물질을 증발시키고, 실리카겔 상에서 잔사를 크로마토그래피(7:2 CH2Cl2/에틸아세테이트)하여 2-(3-디메틸-아미노카르보닐페녹시)-4-벤질아미노-5-니트로-6-(2-벤질옥시-5-시아노페녹시)피리미딘, 즉 화학식 H의 화합물 0.29 g을 얻었다.
B. 유사한 방법으로, 하기 화학식 H의 화합물을 제조하였다.
2-(3-메틸페녹시)-4-(벤질)아미노-5-니트로-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-(3-클로로-5-메톡시페녹시)-4-(벤질)아미노-5-니트로-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-(4-트리플루오로메틸페녹시)-4-(벤질)아미노-5-니트로-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-(3,5-디니트로페녹시)-4-(벤질)아미노-5-니트로-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-(3-구아니디노-5-메틸페녹시)-4-(벤질)아미노-5-니트로-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-(3-우레이도페녹시)-4-(벤질)아미노-5-니트로-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-(3-(2-클로로에틸)-5-메틸페녹시)-4-(벤질)아미노-5-니트로-6-(2-클로로-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-(벤질)아미노-5-니트로-6-(3-브로모-5-시아노페녹시)피리미딘,
2-(4-에톡시카르보닐페녹시)-4-(벤질)아미노-5-니트로-6-(2-메틸-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(2-메틸-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노페녹시)-4-(벤질)아미노-5-니트로-6-(3-메틸-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(2-니트로-5-시아노페녹시)피리미딘,
2-(3-t-부톡시카르보닐페녹시)-4-(벤질)아미노-5-니트로-6-(3-니트로-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(3-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(2-디메틸아미노-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-니트로-6-(3-디메틸아미노-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-아미노-5-니트로-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-아미노-5-니트로-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-아미노-5-니트로-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-아미노-5-니트로-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-아미노-5-니트로-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-아미노-5-니트로-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-아미노-5-니트로-6-(2-클로로-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-아미노-5-니트로-6-(3-브로모-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-아미노-5-니트로-6-(2-메틸-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-아미노-5-니트로-6-(3-메틸-4-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-아미노-5-니트로-6-(2-니트로-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-아미노-5-니트로-6-(3-니트로-4-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4-아미노-5-니트로-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4-아미노-5-니트로-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4-아미노-5-니트로-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4-아미노-5-니트로-6-(3-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4-아미노-5-니트로-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4-아미노-5-니트로-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4-아미노-5-니트로-6-(2-디메틸아미노-5-시아노페녹시)피리미딘, 및
2-(3-구아니디노페녹시)-4-아미노-5-니트로-6-(3-디메틸아미노-4-시아노페녹시)피리미딘.
C. 유사한 방법으로, 2-메틸티오-5-니트로-4,6-디클로로피리미딘을 탄산세슘의 존재 하에 3-(디메틸아미노카르보닐)페놀로 처리하여 2-메틸티오-5-니트로-4-클로로-6-(3-디메틸아미노카르보닐페녹시)피리미딘, 즉 화학식 M의 화합물을 얻었다.
D. 유사한 방법으로, 화학식 M의 화합물을 제조하였다.
2-메틸티오-4-클로로-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)-5-메톡시페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-(2-디메틸아미노카르보닐)에틸)-5-클로로페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-클로로-5-메톡시페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-트리플루오로메틸-5-(디메틸아미노카르보닐)페녹시피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-구아니디노페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-우레이도페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-니트로페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-구아니디노-5-메틸페녹시)피리미딘,
2-메틸티오-4-클로로-5-니트로-6-(3-우레이도-5-메틸페녹시)피리미딘, 및
2-메틸티오-4-클로로-5-니트로-6-(3-니트로-5-아미노페녹시)피리미딘.
〈제조예 5〉
화학식 J 및 Q의 화합물
A. 2-(3-디메틸아미노카르보닐페녹시)-4-벤질아미노-5-니트로-6-(2-벤질옥시 -5-시아노페녹시)피리미딘, 즉 화학식 H의 화합물 0.29 g(0.47 밀리몰) 및 과립 아연 0.1 g을 10㎖의 THF 및 1.0㎖의 10% HCl 수용액과 혼합하였다. 반응물을 80 ℃에서 90분 동안 가열하였다. 휘발물질을 증발시켰다. 포화 NaHCO3수용액을 가하고, 용액을 에틸아세테이트 300 ㎖로 추출하였다. 유기 층을 황산나트륨 상에서 건조시키고, 증발시켜 2-(3-디메틸아미노카르보닐페녹시)-4-벤질아미노-5-아미노-6-(2-벤질옥시-5-시아노페녹시)피리미딘, 즉 화학식 J의 화합물 0.27 g을 얻었다.
B. 유사한 방법으로, 하기 화학식 J의 화합물을 제조하였다.
2-(3-메틸페녹시)-4-(벤질)아미노-5-아미노-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-(3-클로로-5-메톡시페녹시)-4-(벤질)아미노-5-아미노-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-(4-트리플루오로메틸페녹시)-4-(벤질)아미노-5-아미노-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-(3,5-디아미노페녹시)-4-(벤질)아미노-5-아미노-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-(3-구아니디노-5-메틸페녹시)-4-(벤질)아미노-5-아미노-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-(3-우레이도페녹시)-4-(벤질)아미노-5-아미노-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-(3-(2-클로로에틸)-5-메틸페녹시)-4-(벤질)아미노-5-아미노-6-(2-클로로-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4-(벤질)아미노-5-아미노-6-(3-브로모-5-시아노페녹시)피리미딘,
2-(4-에톡시카르보닐페녹시)-4-(벤질)아미노-5-아미노-6-(2-메틸-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(2-메틸-4-시아노페녹시)피리미딘,
2-(3-디메틸아미노페녹시)-4-(벤질)아미노-5-아미노-6-(3-메틸-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시-4-(벤질)아미노-5-아미노-6-(2-아미노-5-시아노페녹시)피리미딘,
2-(3-t-부톡시카르보닐페녹시)-4-(벤질)아미노-5-아미노-6-(3-아미노-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(3-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(2-디메틸아미노-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노-4-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4,5-디아미노-6-(2-메톡시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4,5-디아미노-6-(2-에톡시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4,5-디아미노-6-(3-메톡시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4,5-디아미노-6-(3-에톡시-5-시아노페녹시)피리미딘,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-4,5-디아미노-6-(2-페녹시-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4,5-디아미노-6-(3-페녹시-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4,5-디아미노-6-(2-클로로-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4,5-디아미노-6-(3-브로모-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4,5-디아미노-6-(2-메틸-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4,5-디아미노-6-(3-메틸-4-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4,5-디아미노-6-(2-아미노-5-시아노페녹시)피리미딘,
2-(3-디메틸아미노카르보닐페녹시)-4,5-디아미노-6-(3-아미노-4-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4,5-디아미노-6-(2-카르복시-5-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4,5-디아미노-6-(3-카르복시-4-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4,5-디아미노-6-(2-t-부톡시카르보닐-5-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4,5-디아미노-6-(2-t-부톡시카르보닐-4-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4,5-디아미노-6-(2-아미노카르보닐-5-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4,5-디아미노-6-(3-아미노카르보닐-4-시아노페녹시)피리미딘,
2-(3-구아니디노페녹시)-4,5-디아미노-6-(2-디메틸아미노-5-시아노페녹시)피리미딘, 및
2-(3-구아니디노페녹시)-4,5-디아미노-6-(3-디메틸아미노-4-시아노페녹시)피리미딘.
C. 유사한 방법으로, 2-(2-벤질옥시-5-시아노페녹시)-4-벤질아미노-5-니트로 -6-(3-디메틸아미노카르보닐)페녹시피리미딘, 즉 화학식 P의 화합물 1.2 g (1.95 밀리몰)을 환원시켜 2-(2-벤질옥시-5-시아노페녹시)-4-벤질아미노-5-아미노-6-(3-디메틸아미노카르보닐)페녹시피리미딘, 즉 화학식 Q의 화합물을 얻었다.
D. 유사한 방법으로, 하기 화학식 Q의 화합물을 제조하였다.
2-(2-벤질옥시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-메톡시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-에톡시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-페녹시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-클로로-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-메틸-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-t-부틸-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-아미노-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-카르복시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-아미노-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐페녹시)피리미딘,
2-(2-벤질옥시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-(1-메틸이미다졸린-2-일)-페녹시)피리미딘,
2-(2-메톡시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)피리미딘,
2-(2-에톡시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-t-부톡시카르보닐페녹시)피리미딘,
2-(2-페녹시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-카르복시페녹시)피리미딘,
2-(2-클로로-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-(2-아미노에틸))-페녹시)피리미딘,
2-(2-메틸-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-(벤질옥시)-페녹시)피리미딘,
2-(2-t-부틸-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-에톡시페녹시)피리미딘,
2-(2-아미노-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-구아니디노페녹시)피리미딘,
2-(2-카르복시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-우레이도페녹시)피리미딘,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-아미노페녹시)피리미딘,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-아미노페녹시)피리미딘, 및
2-(2-아미노-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-트리플루오로메톡시페녹시)피리미딘.
〈제조예 6〉
화학식 L 및 R의 화합물
A. 2-(3-디메틸아미노카르보닐페녹시)-4-(벤질)아미노-5-아미노-6-(2-벤질옥시 -5-시아노페녹시)피리미딘, 즉 화학식 J의 화합물 0.26 g(0.44 밀리몰)을 80℃에서 THF/에탄올 중에서 에틸 이미데이트 히드로클로라이드 0.17 g (1.3 밀리몰)로 6시간 동안 처리한 후, 오일로 농축하였다. 잔사를 진공 하에 170℃에서 2.0 시간 동안 모래조에서 가열하고, 냉각하고, 실리카 패드를 통해 여과하고, 메틸렌클로라이드 중 5% 메탄올로 용출시켰다. 휘발물질을 증발시켜 2-(3-디메틸아미노카르보닐페녹시)-6-(2-벤질옥시-5-시아노페녹시)-8-메틸-9-벤질퓨린, 즉 화학식 L의 화합물 0.20 g을 얻었다.
B. 유사한 방법으로, 하기 화학식 L의 화합물을 제조하였다.
2-(3-메틸페녹시)-6-(2-메톡시-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-클로로-5-메톡시페녹시)-6-(2-에톡시-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(4-트리플루오로메틸페녹시)-6-(3-메톡시-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3,5-디아미노페녹시)-6-(3-에톡시-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-구아니디노-5-메틸페녹시)-6-(2-페녹시-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-우레이도페녹시)-6-(3-페녹시-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(2-클로로에틸)-5-메틸페녹시)-6-(2-클로로-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-브로모-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(4-에톡시카르보닐페녹시)-6-(2-메틸-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸-2-일)페녹시)-6-(2-메틸-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-디메틸아미노페녹시)-6-(3-메틸-4-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-아미노-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-t-부톡시카르보닐페녹시)-6-(3-아미노-4-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-카르복시-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-카르복시-4-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-t-부톡시카르보닐-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-t-부톡시카르보닐-4-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-아미노카르보닐-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-아미노카르보닐-4-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-디메틸아미노-5-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-디메틸아미노-4-시아노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-메톡시-5-시아노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-에톡시-5-시아노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-메톡시-5-시아노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-에톡시-5-시아노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-페녹시-5-시아노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-페녹시-5-시아노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-클로로-5-시아노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-브로모-5-시아노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-메틸-5-시아노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-메틸-4-시아노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-아미노-5-시아노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-아미노-4-시아노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-카르복시-5-시아노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(3-카르복시-4-시아노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-t-부톡시카르보닐-5-시아노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(3-t-부톡시카르보닐-4-시아노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-아미노카르보닐-5-시아노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(3-아미노카르보닐-4-시아노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-디메틸아미노-5-시아노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(3-디메틸아미노-4-시아노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-메톡시-5-시아노페녹시)-8-에틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-에톡시-5-시아노페녹시)-8-에틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-메톡시-5-시아노페녹시)-8-에틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-에톡시-5-시아노페녹시)-8-에틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-페녹시-5-시아노페녹시)-8-에틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-페녹시-5-시아노페녹시)-8-에틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-클로로-5-시아노페녹시)-8-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-브로모-5-시아노페녹시)-8-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-메틸-5-시아노페녹시)-8-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-메틸-5-시아노페녹시)-8-페닐퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-메틸-4-시아노페녹시)-8-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-아미노-5-시아노페녹시)-8-페닐퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-아미노-4-시아노페녹시)-8-페닐퓨린,
2-(3-구아니디노페녹시)-6-(2-카르복시-5-시아노페녹시)-8-t-부틸퓨린,
2-(3-구아니디노페녹시)-6-(3-카르복시-4-시아노페녹시)-8-t-부틸퓨린,
2-(3-구아니디노페녹시)-6-(2-t-부톡시카르보닐-5-시아노페녹시)-8-t-부틸퓨린,
2-(3-구아니디노페녹시)-6-(3-t-부톡시카르보닐-4-시아노페녹시)-8-트리플루오로메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-아미노카르보닐-5-시아노페녹시)-8-트리플루오로메틸퓨린, 및
2-(3-구아니디노페녹시)-6-(3-아미노카르보닐-4-시아노페녹시)-8-에틸퓨린. 및
2-(3-구아니디노페녹시)-6-(2-디메틸아미노-5-시아노페녹시)-8-에틸퓨린.
C. 유사한 방법으로, 2-(2-벤질옥시-5-시아노페녹시)-4-(벤질)아미노-5-아미노-6-(3-디메틸아미노카르보닐)페녹시피리미딘 1.14 g(1.94 밀리몰)을 에틸이미데이트 히드로클로라이드 0.31 g(2.53 밀리몰)로 처리하여 2-(2-벤질옥시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐)페녹시-8-메틸-9-벤질퓨린, 즉 화학식 R의 화합물 0.31 g(2.53 밀리몰)을 얻었다.
D. 유사한 방법으로, 하기 화학식 R의 화합물을 제조하였다.
2-(2-벤질옥시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-메톡시-5-시아노페녹시)-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-에톡시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-페녹시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-클로로-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-메틸-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-t-부틸-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-카르복시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시-8-메틸-9-벤질퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-벤질옥시-5-시아노페녹시)-6-(3-(1-메틸이미다졸린-2-일)-페녹시)-8-메틸-9-벤질퓨린,
2-(2-메톡시-5-시아노페녹시)-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)-8-메틸-9-벤질퓨린,
2-(2-에톡시-5-시아노페녹시)-6-(3-t-부톡시카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-페녹시-5-시아노페녹시)-6-(3-카르복시페녹시)-8-메틸-9-벤질퓨린,
2-(2-클로로-5-시아노페녹시)-6-(3-(2-아미노에틸))-페녹시)-8-메틸-9-벤질퓨린,
2-(2-메틸-5-시아노페녹시)-6-(3-(벤질옥시)-페녹시)-8-메틸-9-벤질퓨린,
2-(2-t-부틸-5-시아노페녹시)-6-(3-에톡시페녹시)-8-메틸-9-벤질퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-구아니디노페녹시)-8-메틸-9-벤질퓨린,
2-(2-카르복시-5-시아노페녹시)-6-(3-우레이도페녹시)-8-메틸-9-벤질퓨린,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-6-(3-아미노페녹시)-8-메틸-9-벤질퓨린,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-6-(3-아미노페녹시)-8-메틸-9-벤질퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-트리플루오로메톡시페녹시)-8-메틸-9-벤질퓨린.
2-(2-벤질옥시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-메톡시-5-시아노페녹시)-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-에톡시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-페녹시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-클로로-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-메틸-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-t-부틸-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-카르복시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시-8-메틸퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-벤질옥시-5-시아노페녹시)-6-(3-(1-메틸이미다졸린-2-일)-페녹시)-8-메틸퓨린,
2-(2-메톡시-5-시아노페녹시)-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)-8-메틸퓨린,
2-(2-에톡시-5-시아노페녹시)-6-(3-t-부톡시카르보닐페녹시)-8-메틸퓨린,
2-(2-페녹시-5-시아노페녹시)-6-(3-카르복시페녹시)-8-메틸퓨린,
2-(2-클로로-5-시아노페녹시)-6-(3-(2-아미노에틸))-페녹시)-8-메틸퓨린,
2-(2-메틸-5-시아노페녹시)-6-(3-(벤질옥시)-페녹시)-8-메틸퓨린,
2-(2-t-부틸-5-시아노페녹시)-6-(3-에톡시페녹시)-8-메틸퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-구아니디노페녹시)-8-메틸퓨린,
2-(2-카르복시-5-시아노페녹시)-6-(3-우레이도페녹시)-8-메틸퓨린,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-6-(3-아미노페녹시)-8-메틸퓨린,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-6-(3-아미노페녹시)-8-메틸퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-트리플루오로메톡시페녹시)-8-에틸퓨린.
2-(2-메틸-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-t-부틸-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-카르복시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시-8-에틸퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸-9-에틸퓨린,
2-(2-벤질옥시-5-시아노페녹시)-6-(3-(1-메틸이미다졸린-2-일)-페녹시)-8-에틸-9-에틸퓨린,
2-(2-메톡시-5-시아노페녹시)-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)-8-에틸-9-에틸퓨린,
2-(2-에톡시-5-시아노페녹시)-6-(3-t-부톡시카르보닐페녹시)-8-에틸-9-에틸퓨린,
2-(2-페녹시-5-시아노페녹시)-6-(3-카르복시페녹시)-8-에틸-9-에틸퓨린,
2-(2-클로로-5-시아노페녹시)-6-(3-(2-아미노에틸))-페녹시)-8-에틸-9-에틸퓨린,
2-(2-메틸-5-시아노페녹시)-6-(3-(벤질옥시)-페녹시)-8-에틸-9-에틸퓨린,
2-(2-t-부틸-5-시아노페녹시)-6-(3-에톡시페녹시)-8-에틸-9-에틸퓨린,
2-(2-아미노-5-시아노페녹시)-6-(3-구아니디노페녹시)-8-에틸-9-에틸퓨린,
2-(2-카르복시-5-시아노페녹시)-6-(3-우레이도페녹시)-8-에틸-9-에틸퓨린,
2-(2-벤질옥시카르보닐-5-시아노페녹시)-6-(3-아미노페녹시)-8-에틸-9-에틸퓨린,
2-(2-디에틸아미노카르보닐-5-시아노페녹시)-6-(3-아미노페녹시)-8-에틸-9-에틸퓨린, 및
2-(2-아미노-5-시아노페녹시)-6-(3-트리플루오로메톡시페녹시)-8-에틸-9-에틸퓨린.
〈실시예 1〉
화학식 I 및 II의 화합물
A. 6-(2-벤질옥시-5-시아노페녹시)-2-(3-디메틸아미노카르보닐)페녹시-8-메틸-9-벤질퓨린 0.2 g(0.33 밀리몰)을 0℃의 가압 용기에서 에탄올 5.0 ㎖에 용해시키고, HCl 기체로 포화시켰다. 반응물을 밀봉하고, 실온으로 16시간 동안 가온되도록 하였다. 이어서, 반응 혼합물을 20 ㎖로 농축시키고, 에테르를 가하였다. 생성된 침전물을 에탄올 30 ㎖에 용해시키고, 0℃로 냉각시키고, 암모니아 기체를 용액을 통해 10분 동안 버블링시켰다. 반응물을 밀봉하고, 60℃에서 2시간 동안 가열하였다. 반응 혼합물을 냉각시키고, 튜브를 조심스럽게 열고, 휘발물질을 증발시켜 조 생성물 0.152 g을 얻었다. 예비 HPLC에 의해 정제하여 6-(2-히드록시-5-아미디노페녹시)-2-(3-디메틸아미노카르보닐)페녹시-8-메틸-9-벤질퓨린, 즉 화학식 II의 화합물 0.015 g을 얻었다. NMR(DMSO·d6) 9.10(brs, 2), 8.80(brs, 2), 7.80(d, 1), 7.70(d, 1), 7.10-7.50(m, 10), 5.40(s, 2), 3.00(brs, 6), 2.70(s, 2).
B. 유사한 방법으로, 하기 화학식 II의 화합물을 제조하였다.
2-(3-메틸페녹시)-6-(2-메톡시-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-클로로-5-메톡시페녹시)-6-(2-에톡시-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(4-트리플루오로메틸페녹시)-6-(3-메톡시-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3,5-디아미노페녹시)-6-(3-에톡시-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-구아니디노-5-메틸페녹시)-6-(2-페녹시-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-우레이도페녹시)-6-(3-페녹시-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(2-클로로에틸)-5-메틸페녹시)-6-(2-클로로-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-브로모-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(4-에톡시카르보닐페녹시)-6-(2-메틸-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸-2-일)페녹시)-6-(2-메틸-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-디메틸아미노페녹시)-6-(3-메틸-4-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-아미노-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-t-부톡시카르보닐페녹시)-6-(3-아미노-4-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-카르복시-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-카르복시-4-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-t-부톡시카르보닐-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-t-부톡시카르보닐-4-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-아미노카르보닐-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-아미노카르보닐-4-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-디메틸아미노-5-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-디메틸아미노-4-아미디노페녹시)-8-메틸-9-벤질퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-메톡시-5-아미디노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-에톡시-5-아미디노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-메톡시-5-아미디노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-에톡시-5-아미디노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-페녹시-5-아미디노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-페녹시-5-아미디노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-클로로-5-아미디노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-브로모-5-아미디노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-메틸-5-아미디노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-메틸-4-아미디노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-아미노-5-아미디노페녹시)-8-메틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-아미노-4-아미디노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-카르복시-5-아미디노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(3-카르복시-4-아미디노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-t-부톡시카르보닐-5-아미디노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(3-t-부톡시카르보닐-4-아미디노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-아미노카르보닐-5-아미디노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(3-아미노카르보닐-4-아미디노페녹시)-8-메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-디메틸아미노-5-아미디노페녹시)-8-메틸퓨린, 및
2-(3-구아니디노페녹시)-6-(3-디메틸아미노-4-아미디노페녹시)-8-메틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-메톡시-5-아미디노페녹시)-8-에틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-에톡시-5-아미디노페녹시)-8-에틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-메톡시-5-아미디노페녹시)-8-에틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(3-에톡시-5-아미디노페녹시)-8-에틸퓨린,
2-(3-(1-메틸이미다졸린-2-일)페녹시)-6-(2-페녹시-5-아미디노페녹시)-8-에틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-페녹시-5-아미디노페녹시)-8-에틸퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-클로로-5-아미디노페녹시)-8-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-브로모-5-아미디노페녹시)-8-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-메틸-5-아미디노페녹시)-8-벤질퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-메틸-5-아미디노페녹시)-8-페닐퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-메틸-4-아미디노페녹시)-8-페닐퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(2-아미노-5-아미디노페녹시)-8-페닐퓨린,
2-(3-디메틸아미노카르보닐페녹시)-6-(3-아미노-5-아미디노페녹시)-8-페닐퓨린,
2-(3-구아니디노페녹시)-6-(2-카르복시-5-아미디노페녹시)-8-t-부틸퓨린,
2-(3-구아니디노페녹시)-6-(3-카르복시-4-아미디노페녹시)-8-t-부틸퓨린,
2-(3-구아니디노페녹시)-6-(2-t-부톡시카르보닐-5-아미디노페녹시)-8-t-부틸퓨린,
2-(3-구아니디노페녹시)-6-(3-t-부톡시카르보닐-4-아미디노페녹시)-8-트리플루오로메틸퓨린,
2-(3-구아니디노페녹시)-6-(2-아미노카르보닐-5-아미디노페녹시)-8-트리플루오로메틸퓨린,
2-(3-구아니디노페녹시)-6-(3-아미노카르보닐-4-아미디노페녹시)-8-에틸퓨린,
2-(3-구아니디노페녹시)-6-(2-디메틸아미노-5-아미디노페녹시)-8-에틸퓨린, 및
2-(3-구아니디노페녹시)-6-(3-디메틸아미노-4-아미디노페녹시)-8-에틸퓨린.
C. 유사한 방법으로, 2-(2-벤질옥시-5-시아노페녹시)-6-(3-디메틸아미노카르보닐)페녹시-8-메틸-9-벤질퓨린 0.65 g을 2-(2-히드록시-5-아미노페녹시)-6-(3-디메틸아미노카르보닐)-페녹시-8-메틸-9-벤질퓨린, 즉 화학식 I의 화합물 0.39 g으로 전환하였다. NMR(DMSO·d6) 9.10(brs, 2), 8.80(brs, 2), 7.70(d, 1), 7.65(d, 1), 7.50(dd, 1), 7.25-7.40(m, 8), 7.10(d, 1), 5.40(s, 2), 3.00(s, 3), 2.90(s, 3), 2.70(s, 3).
D. 유사한 방법으로, 하기 화학식 I의 화합물을 제조하였다.
2-(2-히드록시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-클로로-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-메틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-히드록시-5-아미디노페녹시)-6-(3-(1-메틸이미다졸린-2-일)-페녹시)-8-메틸-9-벤질퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)-8-메틸-9-벤질퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-t-부톡시카르보닐페녹시)-8-메틸-9-벤질퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-카르복시페녹시)-8-메틸-9-벤질퓨린,
2-(2-클로로-5-아미디노페녹시)-6-(3-(2-아미노에틸))-페녹시)-8-메틸-9-벤질퓨린,
2-(2-메틸-5-아미디노페녹시)-6-(3-히드록시페녹시)-8-메틸-9-벤질퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-에톡시페녹시)-8-메틸-9-벤질퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-구아니디노페녹시)-8-메틸-9-벤질퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-우레이도페녹시)-8-메틸-9-벤질퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-아미노페녹시)-8-메틸-9-벤질퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-아미노페녹시)-8-메틸-9-벤질퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-트리플루오로메톡시페녹시)-8-메틸-9-벤질퓨린,
2-(2-히드록시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-클로로-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-메틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸퓨린,
2-(2-히드록시-5-아미디노페녹시)-6-(3-(1-메틸이미다졸린-2-일)-페녹시)-8-메틸퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)-8-메틸퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-t-부톡시카르보닐페녹시)-8-메틸퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-카르복시페녹시)-8-메틸퓨린,
2-(2-클로로-5-아미디노페녹시)-6-(3-(2-아미노에틸))-페녹시)-8-메틸퓨린,
2-(2-메틸-5-아미디노페녹시)-6-(3-히드록시페녹시)-8-메틸퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-에톡시페녹시)-8-메틸퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-구아니디노페녹시)-8-메틸퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-우레이도페녹시)-8-메틸퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-아미노페녹시)-8-메틸퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-아미노페녹시)-8-메틸퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-트리플루오로메톡시페녹시)-8-에틸퓨린.
2-(2-메틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-에틸-9-에틸퓨린,
2-(2-히드록시-5-아미디노페녹시)-6-(3-(1-메틸이미다졸린-2-일)-페녹시)-8-에틸-9-에틸퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)-8-에틸-9-에틸퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-t-부톡시카르보닐페녹시)-8-에틸-9-에틸퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-카르복시페녹시)-8-에틸-9-에틸퓨린,
2-(2-클로로-5-아미디노페녹시)-6-(3-(2-아미노에틸))-페녹시)-8-에틸-9-에틸퓨린,
2-(2-메틸-5-아미디노페녹시)-6-(3-히드록시페녹시)-8-에틸-9-에틸퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-에톡시페녹시)-8-에틸-9-에틸퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-구아니디노페녹시)-8-에틸-9-에틸퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-우레이도페녹시)-8-에틸-9-에틸퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-아미노페녹시)-8-에틸-9-에틸퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-아미노페녹시)-8-에틸-9-에틸퓨린,및
2-(2-아미노-5-아미디노페녹시)-6-(3-트리플루오로메톡시페녹시)-8-에틸-9-에틸퓨린.
E. 상기에서 제조된 R5가 수소인 화학식 I 및 화학식 II의 화합물은 문헌[Dusert, P., Eur. J. Med. Chem.(1980), Vol. 3, p199]에 기재된 방법과 유사한 방법으로 추가로 처리되어 하기 화합물을 생성할 수 있다.
2-(2-히드록시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시에틸)퓨린,
2-(2-히드록시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-에톡시카르보닐에틸)퓨린,
2-(2-히드록시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-아미노카르보닐에틸)퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-메틸프로필)퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-에톡시카르보닐)-2-메틸프로필)퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-아미노카르보닐)-2-메틸프로필)퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-3-메틸부틸)퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-3-메틸부틸)퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-3-메틸부틸)퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-메틸부틸)퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-2-메틸부틸)퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-2-메틸부틸)퓨린,
2-(2-클로로-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-페닐에틸)퓨린,
2-(2-클로로-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-2-페닐에틸)퓨린,
2-(2-클로로-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-2-페닐에틸)퓨린,
2-(2-메틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-(4-메르캅토페닐)에틸)퓨린,
2-(2-메틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-2-(4-메르캅토페닐)에틸)퓨린,
2-(2-메틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-2-(4-메르캅토페닐)에틸)퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-(인돌린-3-일)에틸)퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-2-(인돌린-3-일)에틸)퓨린,
2-(2-t-부틸-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-2-(인돌린-3-일)에틸)퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-(이미다졸-4-일)에틸)퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-2-(이미다졸-4-일)에틸)퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-2-(이미다졸-4-일)에틸)퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-히드록시에틸)퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-2-히드록시에틸)퓨린,
2-(2-카르복시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-2-히드록시에틸)퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-히드록시프로필)퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-2-히드록시프로필)퓨린,
2-(2-벤질옥시카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-2-히드록시프로필)퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-카르복시-2-(아미노카르보닐)에틸)퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-2-(아미노카르보닐)에틸)퓨린,
2-(2-디에틸아미노카르보닐-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-(1,2-디(아미노카르보닐)에틸)퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐)페녹시)-8-메틸-9-(1-카르복시-3-(아미노카르보닐)프로필)퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐)페녹시)-8-메틸-9-(1-(에톡시카르보닐)-3-(아미노카르보닐)프로필)퓨린,
2-(2-아미노-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐)페녹시)-8-메틸-9-(1,3-디(아미노카르보닐)프로필)퓨린,
2-(2-히드록시-5-아미디노페녹시)-6-(3-(1-메틸이미다졸린-2-일)페녹시)-8-메틸-9-(1,2-디카르복시에틸)퓨린,
2-(2-히드록시-5-아미디노페녹시)-6-(3-(1-메틸이미다졸린-2-일)페녹시)-8-메틸-9-(1,2-디(에톡시카르보닐)에틸)퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)-8-메틸-9-(1,3-디카르복시프로필)퓨린,
2-(2-메톡시-5-아미디노페녹시)-6-(3-(2-(t-부톡시카르보닐)에틸)페녹시)-8-메틸-9-(1,3-디(에톡시카르보닐)프로필)퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-(t-부톡시카르보닐페녹시)-8-메틸-9-(1-카르복시-5-아미노펜틸)퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-t-부톡시카르보닐페녹시)-8-메틸-9-(1-(에톡시카르보닐)-5-아미노펜틸)퓨린,
2-(2-에톡시-5-아미디노페녹시)-6-(3-t-부톡시카르보닐페녹시)-8-메틸-9-(1-(아미노카르보닐)-5-아미노펜틸)퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-카르복시페녹시)-8-메틸-9-(1-카르복시-4-구아니디노부틸)퓨린,
2-(2-페녹시-5-아미디노페녹시)-6-(3-카르복시페녹시)-8-메틸-9-(1-(에톡시카르보닐)-4-구아니디노부틸)퓨린, 및
2-(2-페녹시-5-아미디노페녹시)-6-(3-카르복시페녹시)-8-메틸-9-(1-(아미노카르보닐)-4-구아니디노부틸)퓨린.
〈실시예 2〉
본 실시예는 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 즉 2-(3-디메틸아미노카르보닐페녹시)-6-(2-히드록시-4-아미디노페녹시)-9-(1-메톡시카르보닐-프로필)-8-메틸-9-벤질퓨린을 포함하는, 경구 투여를 위한 대표적인 제약 조성물의 제조 방법을 설명한다.
A. 성분중량/중량%
본 발명의 화합물20.0%
락토즈79.5%
마그네슘 스테아레이트0.5%
상기 성분들을 혼합하고, 각각 100 ㎎씩 경질 젤라틴 캡슐에 분배한다.
B. 성분중량/중량%
본 발명의 화합물20.0%
마그네슘 스테아레이트0.9%
녹말8.6%
락토즈79.6%
PVP(폴리비닐피롤리돈)0.9%
마그네슘 스테아레이트를 제외한 상기 성분들을 혼합하고, 과립화제로서 물을 사용하여 과립화한다. 이어서, 제제를 건조시키고, 마그네슘 스테아레이트와 혼합하여 적절한 정제 기계로 정제를 형성한다.
C. 성분
본 발명의 화합물0.1 g
프로필렌 글리콜20.0 g
폴리에틸렌 글리콜 40020.0 g
폴리소르베이트 801.0 g
물충분량 100 ㎖
본 발명을 화합물을 프로필렌 글리콜, 폴리에틸렌 글리콜 400 및 폴리소르베이트 80에 용해시킨다. 교반하면서 충분한 양의 물을 가하여, 여과되고 병에 담은 용액이 100 ㎖이 되게 한다.
D. 성분중량/중량%
본 발명의 화합물20.0%
땅콩 오일78.0%
스팬60 2.0%
본 발명을 화합물을 용융시키고, 혼합하여, 연질 탄성 캡슐에 충전한다.
E. 성분중량/중량%
본 발명의 화합물1.0%
메틸 또는 카르복시메틸 셀룰로오즈2.0%
0.9% 염수충분량 100 ㎖
본 발명의 화합물을 셀룰오로즈/염수 용액에 용해시키고, 사용을 위해 여과하여 병에 담았다.
〈실시예 3〉
본 실시예는 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 즉 2-(3-디메틸아미노카르보닐페녹시)-6-(2-페녹시-4-아미디노페녹시)-9-(1-메톡시카르보닐프로필)-8-메틸퓨린을 포함하는, 비경구적 투여를 위한 대표적인 제약 조성물의 제조 방법을 설명한다.
성분
본 발명의 화합물0.02 g
프로필렌 글리콜20.0 g
폴리에틸렌 글리콜 40020.0 g
폴리소르베이트 801.0 g
0.9% 염수충분량 100 ㎖
본 발명을 화합물을 프로필렌 글리콜, 폴리에틸렌 글리콜 400 및 폴리소르베이트 80에 용해시킨다. 교반하면서 충분한 양의 0.9% 염수를 가하여, 멸균 조건 하에 0.2 μ 막 필터를 통해 여과하고 충전된 용액이 100 ㎖이 되게 한다.
〈실시예 4〉
본 실시예는 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 즉 2-(3-디메틸아미노카르보닐페녹시)-6-(2-페녹시-4-아미디노페녹시)-9-(1-메톡시카르보닐프로필)-8-에틸-9-벤질퓨린을 포함하는, 좌약 형태의 대표적인 제약 조성물의 제조 방법을 설명한다.
성분중량/중량%
본 발명의 화합물1.0%
프로필렌 글리콜 100074.5%
폴리에틸렌 글리콜 40024.5%
성분들을 용융시키고, 증기조에서 혼합하여, 총 중량이 2.5 g인 주형에 넣었다.
〈실시예 5〉
본 실시예는 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 즉 2-(3-디메틸아미노카르보닐페녹시)-6-(2-페녹시-4-아미디노페녹시)-9-(1-메톡시카르보닐프로필)-8-에틸-9-벤질퓨린을 포함하는, 흡입을 위한 대표적인 제약 조성물의 제조 방법을 설명한다.
성분중량/중량%
미세화된 본 발명의 화합물1.0%
미세화된 락토즈99.0%
성분들을 용융시키고, 혼합하여, 투여 펌프가 구비된 흡입기에 충전한다.
〈실시예 6〉
본 실시예는 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 즉 2-(3-디메틸아미노카르보닐페녹시)-6-(2-페녹시-4-아미디노페녹시)-9-(1-메톡시카르보닐프로필)-8-에틸퓨린을 포함하는, 네불라이징된 형태의 대표적인 제약 조성물의 제조 방법을 설명한다.
성분중량/중량%
본 발명의 화합물0.005%
물89.995%
에탄올10.000%
본 발명의 화합물을 에탄올에 용해시키고, 물과 혼합한다. 이어서, 제제를 투여 펌프가 구비된 네불라이저에 충전한다.
〈실시예 7〉
본 실시예는 본 발명의 화합물 또는 제약학적으로 허용 가능한 그의 염, 즉 2-(3-디메틸아미노카르보닐페녹시)-6-(2-페녹시-4-아미디노페녹시)-9-(1-메톡시카르보닐프로필)-8-에틸퓨린을 포함하는, 에어로졸 형태의 대표적인 제약 조성물의 제조 방법을 설명한다.
성분중량/중량%
본 발명의 화합물0.10%
추진제 11/1298.90%
올레산1.00%
본 발명의 화합물을 올레산 및 추진제에 분산시킨다. 이어서, 생성된 혼합물을 측량계가 구비된 에어로졸 용기에 넣는다.
〈실시예 8〉
(인자 Xa, 트롬빈 및 조직 플라즈미노겐 활성자에 대한 시험관 내 분석)
본 분석은 인자 Xa, 트롬빈 및 조직 플라즈미노겐 활성자에 대한 본 발명의 화합물의 활성을 입증한다. 상기 활성은 효소에 의한 펩티드 p-니트로아닐리드 절단의 초기 속도로 측정하였다. 절단 생성물인 p-니트로아닐린은 405 nm에서 몰흡광 계수가 9920 M-1㎝-1였다.
시약 및 용액
디메틸 술폭시드(DMSO)(분석용)
분석 완충액: 50 mM 트리스HCl, 150 mM NaCl, 2.5 mM CaCl2및 0.1% 폴리에틸렌 글리콜 6000, pH 7.5
효소(엔자임 리써치 랩):
1. 사람 인자 Xa 원액: 분석 완충액 중 0.281 ㎎/㎖, -80℃에서 보관.
(워킹 용액(2배 희석액): 분석 완충액 중 106 ng/㎖ 또는 2nM, 사용전에 제조)
2. 사람 트롬빈 원액: -80℃에서 보관(워킹 용액(2배 희석액): 분석 완충액 중 1200 ng/㎖ 또는 40nM, 사용전에 제조)
3. 사람 조직 플라즈미노겐 활성자(tPA)(2개의 사슬, 시그마사) 원액: 1 ㎎/㎖, -80℃에서 보관(워킹 용액(2배 희석액): 분석 완충액 중 1361 ng/㎖, 사용전에 제조)
염색체 유전자 기질(파르마시아 헤퍼사):
1.S222(FXa 분석) 원액: dH2O 중 6 mM, 4℃에서 보관(워킹 용액 (4배 희석액): 분석 완충액 중 656 μM)
2. S2302(트롬빈 분석) 원액: dH2O 중 10 mM, 4℃에서 보관(워킹 용액 (4배 희석액): 분석 완충액 중 1200 μM)
3. S2288(tPA 분석) 원액: dH2O 중 10 mM, 4℃에서 보관(워킹 용액 (4배 희석액): 분석 완충액 중 1484 μM)
(모든 기질 워킹 용액은 분석한지 5일째 제조하였다)
표준 억제제 화합물 원액: DMSO 중 5 mM, -20℃에서 보관.
시험 화합물(본 발명의 화합물) 원액: DMSO 중 10 mM, -20℃에서 보관.
분석 방법
분석을 96-웰 마이크로타이터 플레이트에서 총 부피 200 ㎕로 수행하였다. 분석 성분들은 최종 농도에서 50 mM 트리스HCl, 150 mM NaCl, 2.5 mM CaCl2, 0.1% 폴리에틸렌 글리콜 6000, pH 7.5였고, 표준 억제제 또는 시험 화합물의 부재 또는 존재 하에 효소 및 기질의 농도는 다음과 같다.
(1) 1 nM 인자 Xa 및 164 μM S2222; (2) 20 nM 트롬빈 및 300 μM S2302; 및 (3) 10 nM tPA 및 371 μM S2288.
분석에서 표준 억제제 화합물의 농도는 1 내지 3배 희석액 중에서 5 μM 내지 0.021 μM였다. 분석 중에서 시험 화합물의 농도는 통상적으로 1배 내지 3배 희석액 중에서 10 μM 내지 0.041 μM였다. 효능성 시험 화합물에 있어서, 인자 Xa 분석에 사용된 농도는 추가로 100배(100 nM 내지 0.41 nM) 또는 1000배(10 nM 내지 0.041 nM)로 희석하였다. 사용된 모든 기질 농도는 현 분석 조건 하에서 그들의 Km값과 동일하였다. 분석을 실온에서 수행하였다.
분석에서 제1 단계는 DMSO 중 10 mM 시험 화합물 원액(효능성 시험 화합물에 있어서, 10 mM 원액을 인자 Xa 분석에 대해 추가로 0.1 또는 0.01로 희석함)을 제조한 후, 96 웰 플레이트에서 바이오멕 1000(또는 멀티프로브 204)로 10 mM 원액을 순차적으로 희석한 워킹 용액은 다음과 같다:
(a) 분석 완충액 중에서 10 mM 원액을 1 내지 250배 희석하여 40 μM 워킹 용액을 제조함: 1 대 100 및 1 대 2.5.
(b) 40 μM 용액을 추가로 5개 순차적 희석(1:3)함(각 농도는 600 ㎕임). 총 6개의 희석된 시험 화합물 용액을 분석에서 사용하였다.
표준 억제제 화합물(5 mM 원액) 또는 DMSO(대조구)는 상기 시험 화합물에 대해 기재된 바와 동일한 희석 단계를 사용하였다.
분석에서 다음 단계는 바이오멕 또는 MP204를 사용하여 마이크로타이터 플래이트에 2회에 걸쳐 시험 화합물 워킹 용액(4배 희석액)(40 μM 내지 0.164 μM) 50 ㎕를 분배하였다. 여기에, 바이오멕 또는 MP204를 사용하여 효소 워킹 용액(2배 희석액) 100 ㎕를 가하였다. 생성된 용액을 실온에서 10분 동안 인큐베이션하였다.
바이오멕 또는 MP204를 사용하여 용액에 기질 워킹 용액(4배 희석액) 50 ㎕을 가하였다.
효소 키네틱스는 실온에서 써모맥스(THERMOmax) 플레이트 판독기에서 405 nm에서 10초 간격으로 5분 동안 측정하였다.
시험 물질의 Ki의 계산
효소 속도를 처음 2분 판독을 기재로 mOD/분으로 계산하였다. 엑셀 스프레드 시트에서 로그-로짓 식(선형) 또는 모리슨 식(비선형)에 대해 데이타를 계산하여 IC50값을 결정하였다. 이어서, IC50값을 2로 나누어 Ki값을 얻었다. 통상적으로, 3 nM 미만의 Ki(인자 Xa)값을 모리슨식으로부터 계산하였다.
본 발명의 화합물을, 이 분석에서 시험하여, 사람 인자 Xa 및 사람 트롬빈을 선별적으로 억제하는 능력을 입증하였다.
〈실시예 9〉
(사람 프로트롬비나제에 대한 시험관 내 분석)
본 분석은 본 발명의 화합물이 프로트롬비나제를 억제할 수 있음을 입증한다. 프로트롬비나제(PTase)는 프로트롬빈 활성화를 촉매하여 단편 1.2 및 트롬빈을 중간체로서 메조트롬빈과 함께 형성한다. 본 분석은 종말점 분석이다. 프로트롬비나제의 활성은 트롬빈의 활성(반응 생성물 중 하나) 또는 트롬빈 표준 곡선을 기초로 시간에 대한 형성된 트롬빈의 양에 의해 측정된다. 본 발명의 화합물의 IC50(PTase)를 측정하기 위하여, PTase 활성을 트롬빈 활성(mOD/분)으로 나타내었다.
재료
효소:
1. 사람 인자 Va(헤마톨로직 테크놀로지사, Cat# HCVA-0110) 워킹 용액: 50% 글리세롤 중 1.0 ㎎/㎖, 2 mM CaCl2, -20℃에서 보관.
2. 사람 인자 Xa(엔자임 리써치 랩 Cat# HFXa 1011) 워킹 용액: 분석 완충액 중 0.281 ㎎/㎖(BSA 없음), -80℃에서 보관.
3. 사람 프로트롬빈(FII)(엔자임 리써치 랩 Cat# HFXa 1002) 워킹 용액: 분석 완충액 중 FII를 4.85 ㎎/㎖로 희석함(BSA 없음), -80℃에서 보관.
인지질(PCPS) 소포:
PCPS 소포 (80% CP, 20% PS)를 바렌놀쯔 등의 문헌[Biochemistry(1977), Vol. 16, pp 2806-2810]에 보고된 방법에 의해 변형하여 제조하였다. 포스파티딜 세린(아반티 폴라 리피즈사 Cat # 840032): 클로로포름 중 10 ㎎/㎖, 뇌에서 정제, 질소 또는 아르곤 하에 -20℃에서 보관.
포스파타딜콜린(아반티 폴라 리피즈사 Cat # 850457): 클로로포름 중 50 ㎎/㎖, 16:0-18:1의 팔미토일-올레일로 합성됨, 질소 또는 아르곤 하에 -20℃에서 보관.
스펙트로자임-TH(아메리칸 다이아그노스티카사 Cat # 238L): 50 마이크로몰, 실온에서 보관) 워킹 용액: 증류수 10 ㎖ 중 50 마이크로몰 용해시킴.
BSA(시그마 케미칼사 Cat # A-7888, Fraction V, RIA grade)
분석 완충액: 50 mM 트리스 HCl, pH 7.5, 150 mM NaCl, 2.5 mM CaCl2, 0.1% PEG 6000(BDH), 0.05% BSA(시그마, Fraction V, RIA grade)
단일 플레이트 분석을 위해, 하기 워킹 용액을 제조하였다.
1. 프로트롬비나제 복합체:
(a) 100 μM PCPS (PCPS 원액(4.36 mM) 27.5 ㎕를 분석 완충액으로 최종 1200 ㎕로 희석함.
(b) 25 nM 사람 인자 Va: Va 원액(1 ㎎/㎖) 5.08 ㎕를 분석 완충액으로 최종 1200 ㎕로 희석함.
(c) 5 pM 사람 인자 Xa: Xa 원액 (0.281 ㎎/㎖)을 분석 완충액으로 1:1,220,000 희석함. 1200 ㎕ 이상을 제조함.
PCPS, Va 및 Xa의 순서로 각 성분을 동일하게 각 1100 ㎕로 혼합한다. 실온에서 5 내지 10분 동안 방치시키고, 즉시 사용하거나 또는 얼음에 보관함다 (사용하기 전에는 실온에 둔다).
2. 6 μM 사람 프로트롬빈(FII): FII 원액(4.85 ㎎/㎖) 124 ㎕를 분석 완충액으로 최종 1400 ㎕로 희석하였다.
3. 20 mM EDTA/분석 완충액: 0.5 M EDTA(pH 8.5) 0.8 ㎖에 분석 완충액 19.2 ㎖을 더한다.
4. 0.2 mM 스펙트로자임-TH/EDTA 완충액: SPTH 원액 (5 mM) 0.44 ㎖에 20 mM EDTA/분석 완충액 10.56 ㎖을 더한다.
5. 시험 화합물(본 발명의 화합물): 10 mM 원액(DMSO)로부터 워킹 용액(5배 희석액)을 제조하고, 1:3 순차적 희석하였다. 화합물을 6개의 농도에서 2개씩 분석하였다.
분석 조건 및 방법:
프로트롬비나제 반응을 PTase (20 μM PCPS, 5nM hFVa, 및 1 pM hFXa), 1.2 μM 사람 인자 II 및 다양한 농도의 시험 화합물 (5 μM 내지 0.021 μM 또는 낮은 농도 범위)를 포함하는 혼합물의 최종 50 ㎕에서 수행하였다. PTase를 가하여 반응을 시작하고, 실온에서 6분 동안 인큐베이션하엿다. EDTA/완충액을 최종 10 mM로 가하여 반응을 중단시켰다. 트롬빈(생성물)의 활성을, 기질로서 0.1 mM 스펙트로자임-TH의 존재 하에 405 nm에서 5분 동안(10초 간격으로) 실온에서 써모맥스 마이크로타이터 판독기로 측정하였다. 반응을 96-웰 마이크로타이터 플레이트에서 수행하였다.
분석 제1 단계에서, 희석된 시험 화합물(5배) 또는 완충액 10 ㎖를 플레이트에 2회 가하였다. 프로트롬빈(hFII)(5배) 10 ㎕를 각 웰에 가하였다. PTase 30 ㎕를 각 웰에 가하고, 약 30초 동안 혼합하였다. 플레이트를 실온에서 6분 동안 인큐베이션하였다.
다음 단계에서, 20 mM EDTA (분석 완충액 중에서) 50 ㎕를 각 웰에 가하여 반응을 중단시켰다. 이어서, 생성된 용액을 약 10초간 혼합하였다. 0.2 mM 스펙트로자임 100 ㎕를 각 웰에 가하였다. 이어서, 트롬빈 반응 속도를 405 nm에서 5분 동안 10초 간격으로 분자 장치 마이크로플레이트 판독기에서 측정하였다.
계산
트롬빈 반응 속도를 5분 반응으로부터 OD 판독하여 mOD/분으로 나타내었다. IC50값을 로그-로짓 곡선을 사용하여 계산하였다.
본 발명의 화합물이, 이 분석에 시험되어 프로트롬비나제를 억제할 수 있음을 입증하였다.
〈실시예 10〉
(생체 내 분석)
하기 분석은 본 화합물이 항응혈제로서 작용할 수 있음을 입증하고 있다.
숫컷 쥐 250 내지 330 g을 소듐 펜토바르비탈 (90 ㎎/㎏, 정맥내 투여)로 마취시키고, 외과 수술을 위해 준비했다. 좌측 경동맥을 혈압 측정 및 응혈 변수(프로트롬빈 시간(PT) 및 활성화 부분 트롬보플라스틴 시간(aPTT)를 모니터하기 위해 혈액 시료를 채취하기 위해 캐뉼러를 삽입했다. 꼬리 정맥에 시험 화합물(즉, 본 발명의 화합물 및 표준물) 투여 및 트롬보플라스틴 주입을 위해 캐뉼러를 삽입했다. 중앙선 절개로 복부를 개방하고, 복부 정맥을 신장 정맥으로부터 2 내지 3 ㎝ 조각으로 결찰시켰다. 수술 후, 동물을 실험하기 전에 안정시켰다. 시험 화합물을 정맥 환약으로 투여하였다(t=0). 3분 후(t=3), 트롬보플라스틴 주입을 시작했다. 2분간 주입한 후(t=5), 복부 정맥을 말단과 반대편 말단을 결찰시켰다. 혈관을 60분간 방치한 후, 동물에서 잘라내고, 절개하여, 혈전(존재한다면)을 조심스럽게 제거하고, 칭량하였다. 결과에 대한 통계적 분석은 윌콕신-매치드-패어즈 사인드 랭크 테스트(Wilcoxin-matched-pairs signed rank test)를 사용하여 수행하였다.
본 발명의 화합물은, 이 분석에서 시험되어 응혈을 억제할 수 있음을 입증하였다.
본 발명이 특정 실시 태양에 의해 설명되었지만, 당업자에게는 다양한 변형이 가능하고, 동등물은 본 발명의 진정한 취지 및 영역에서 벗어나지 않고 대체될 수 있음을 이해해야 한다. 또한, 많은 변형이 가능하고, 동등물은 본 발명의 진정한 취지 및 영역에서 벗어나지 않고 대체될 수 있다. 또한, 많은 변형이 본 발명의 목적, 정신 및 영역 내에서 특정 상황, 재료, 조성물, 방법, 단계(들)에 적용될 수 있다. 모든 상기 변형은 첨부된 청구의 범위 내에서 가능하다.
Claims (10)
- 단독 입체 이성질체로서 또는 그의 혼합물로서 화학식 I 내지 화학식 IV의 화합물로 구성된 군으로부터 선택된 화합물, 또는 제약학적으로 허용 가능한 그의 염.〈화학식 I〉〈화학식 II〉〈화학식 III〉〈화학식 IV〉상기 식 중,Z1및 Z2는 독립적으로 -O-, -N(R10)- 또는 -OCH2-이고,R1및 R4는 각각 독립적으로 수소, 할로, 알킬, -OR10, -C(O)OR10, -C-(O)N(R10)R11, -N(R10)R11, -N(R10)C(O)R10, 또는 -N(H)S(O)2R13이고,R2는 -C(NH)NH2, -C(NH)N(H)OR10, -C(NH)N(H)C(O)OR13, -C(NH)N(H)C(O)R10, -C- (NH)N(H)S(O)2R13, 또는 -C(NH)N(H)C(O)N(H)R10이고,R3은 할로, 알킬, 할로알킬, 할로알콕시, 우레이도, 시아노, 구아니디노, -OR10, -C(NH)NH2, -C(NH)N(H)OR10, -C(O)N(R10)R11, -R12-C(O)N(R10)R11, -CH(OH)C-(O)N(R10)R11, -N(R10)R11, -R12-N(R10)R11, -C(O)OR10, R12-C(O)OR10, -N(R10)C(O)R10, (1,2)-테트라히드로피리미디닐(임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고,R5는 수소, 할로, 알킬, 시클로알킬, 할로알킬, 아릴, 아랄킬, 알킬티오, 히드록시, 메르캅토, 알콕시, 또는 -N(R10)R11이고,R6은 -(C(R7)(R8))n-R9(여기서, n은 1 내지 4임), 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)인데,여기서, 각 R7은 독립적으로 수소, 알킬, 알케닐, 알키닐, 할로알킬, 할로알케닐, 시클로알킬, 시클로알킬알킬, -C(O)OR10, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -C-(O)-R12-N(R10)R11, -R12-C(O)R10, -R12-C(O)N(R10)N(R10)R11, -R12-C(R10)(OR10)-R12-N(R10)R11, -C(R10)(OR10)C(O)OR11, -R12-C(R10)(C(O)OR10)2, -C(R10)(N(R10)R11)C(O)OR10, -R12-C(R10)(N(R10)R11)C(O)OR10, -C(R10)(OR10)R11, -R12-N(R10)R11, -R12-N(R10)C(O)OR13, -R12-N(R10)C(O)OR11, -R12-N(R10)C(NR10)R13, -R12-N(R10)S(O)2R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12-N(R10)C(NR10)N(R10)N(R10)R11, -R12-N(R10)-R12-C(R10)(N(R10)R11)C(O)OR10, -R12-N(R10)S(O)R11, -R12OR10, -R12-ON(R10)C(NR10)N(R10) R11, -R12-OS(O)2OR10, -R12-P(O)(OR10)R11, -R12-OP(O)(OR10)2, -R12-P(O)(OR10)2, -R12-SR10, -R12-S-R12-C(O)OR10, -R12-S-R12-N(R10)R11, -R12-S-R12-C(R10)(N(R10)R11)C(O)OR10, -R12-S-R12-N(R10)C(O)OR10, -R12-S-R12-N(R10)C(O)R10, -R12-S-S-R12-C(R10)(N(R10)R11)C(0)OR10, -R12-SC(O)N(R10)R11, -R12-SC(S)N(R10)R11, -R12-S(O)R10, -R12-S(O)2R13, -R12-S(O)OR10, -R12-S(O)2OR10, -R12-S(O)2N(R10)R11, -R12-S(O)(NR10)R11이거나,또는 각 R7은 아릴(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아랄킬(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 헤테로시클릴(임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 헤테로시클릴알킬(여기서, 헤테로시클릴 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C-(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아다만틸(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아다만틸알킬(여기서, 아다만틸 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S-(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이고,각 R8은 독립적으로 수소, 알킬, 시클로알킬, 또는 아릴이고,R9는 -C(O)OR10또는 -C(O)N(R10)R11이고,R10및 R11은 각각 독립적으로 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고,R12는 직쇄 또는 분지쇄 알킬렌이고,R13은 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이다.
- 제1항에 있어서, Z1및 Z2는 독립적으로 -O- 또는 -OCH2-이고;R1및 R4는 각각 독립적으로 수소, 할로 또는 -OR10이고;R2는 -C(NH)NH2, -C(NH)N(H)S(O)2R13, 또는 -C(NH)N(H)C(O)N(H)R10이고;R3은 우레이도, 구아니디노, -C(O)N(R10)R11, -N(R10)R11, -C(O)OR10, -N-(R10)C(O)R10, (1,2)-테트라히드로피리미디닐(임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고;R5는 수소, 할로, 알킬, 할로알킬, 아릴, 또는 아랄킬이고;R6은 알킬, 아릴, 아랄킬, 또는 -(C(R7)(R8))n-R9(여기서, n은 1임)이고;R7은 알킬, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -R12-C(R10)(C(O)OR10)2, -R12-N(R10)R11, -R12-N(R10)C(NR10)R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12OR10, -R12-OP(O)(OR10)2, -R12-SR10, -R12-S(O)2R13이거나,또는 R7은 아랄킬(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C-(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 R7은 헤테로시클릴알킬(여기서, 헤테로시클릴 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이고;R8은 독립적으로 수소 또는 알킬이고;R9는 -C(O)OR10또는 -C(O)N(R10)R11이고;R10및 R11은 각각 독립적으로 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고;R12는 직쇄 또는 분지쇄 알킬렌이고;R13은 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)인 화합물.
- 제2항에 있어서, Z1및 Z2는 각각 -O-이고;R1은 수소 또는 -OR10이고;R2는 -C(NH)NH2이고;R3은 -C(O)N(R10)R11, (1,2)-테트라히드로피리미디닐 (임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴 (임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐 (임의로 알킬에 의해 치환됨)이고;R4는 수소이고;R5는 알킬 또는 아랄킬이고;R6는 알킬, 아랄킬, 또는 -C(R7)(R8)-R9이고;R7은 알킬, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -R12-C(R10)(C(O)OR10)2, -R12-N(R10)R11, -R12-N(R10)C(NR10)R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12OR10, -R12-OP(O)(OR10)2, -R12-SR10, -R12-S(O)2R13이거나,또는 R7은 아랄킬(임의로 할로, 할로알킬, 히드록시, 및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 R7은 이미다졸릴알킬 또는 인돌릴알킬이고;R8은 수소 또는 알킬이고;R9는 -C(O)OR10또는 -C(O)N(R10)R11이고;R10및 R11은 각각 독립적으로 수소 또는 알킬이고;R12는 직쇄 또는 분지쇄 알킬렌이고;R13은 알킬 또는 아릴인 화합물.
- 제3항에 있어서, Z1및 Z2는 각각 -O-이고;R1은 수소이고;R2는 -C(NH)NH2이고;R3은 -C(O)N(R10)R11, (1,2)-테트라히드로피리미디닐 (임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴 (임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐 (임의로 알킬에 의해 치환됨)이고;R4는 수소이고;R5는 알킬이고;R6는 아랄킬 또는 -C(R7)(R8)-R9이고;R7은 알킬, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -R12-C(R10)(C(O)OR10)2, -R12-N(R10)R11, -R12-N(R10)C(NR10)R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12OR10, -R12-OP(O)(OR10)2, -R12-SR10, -R12-S(O)2R13이거나,또는 R7은 아랄킬(임의로 할로, 할로알킬, 히드록시, 및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 R7은 이미다졸릴알킬 또는 인돌릴알킬이고;R8은 수소 또는 알킬이고;R9는 -C(O)OR10또는 -C(O)N(R10)R11이고;R10및 R11은 각각 독립적으로 수소 또는 알킬이고;R12는 직쇄 또는 분지쇄의 알킬렌이고;R13은 알킬 또는 아릴인 화합물.
- 제4항에 있어서, R3은 -C(O)N(R10)R11, (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨) 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고;R4는 수소이고;R5는 알킬이고;R6는 아랄킬 또는 -C(R7)(R8)-R9이고;R7은 알킬, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -R12-C(R10)(C(O)OR10)2, -R12-N(R10)R11, -R12-N(R10)C(NR10)R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12OR10, -R12-OP(O)(OR10)2, -R12-SR10, -R12-S(O)2R13이고;R8은 수소이고;R9는 -C(O)OR10이고;R10및 R11은 각각 독립적으로 수소 또는 알킬이고;R12는 직쇄 또는 분지쇄의 알킬렌이고;R13은 알킬 또는 아릴인 화합물.
- 제5항에 있어서, R3은 -C(O)N(R10)R11이고;R4는 수소이고;R5는 메틸 또는 에틸이고;R6은 벤질이고;R10및 R11은 독립적으로 수소 또는 메틸인 화합물.
- 제6항에 있어서, R3은 -C(O)N(R10)R11(여기서, R10및 R11은 모두 메틸임)이고, R4는 수소이고, R5는 메틸이고, R6은 벤질인, 즉 2-(2-히드록시-5-아미디노페녹시)-6-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린인 화합물
- 제6항에 있어서, R3은 -C(O)N(R10)R11(여기서, R10및 R11은 모두 메틸임)이고, R4는 수소이고, R5는 메틸이고, R6은 벤질인, 즉 6-(2-히드록시-5-아미디노페녹시)-2-(3-디메틸아미노카르보닐페녹시)-8-메틸-9-벤질퓨린인 화합물.
- 단독 입체 이성질체로서 또는 그의 혼합물로서 화학식 I 내지 화학식 IV의 화합물로 구성된 군으로부터 선택된 화합물, 또는 제약학적으로 허용 가능한 그의 염의 치료적 유효량, 및 제약학적으로 허용 가능한 부형제를 포함하는, 혈전 활성의 특징을 갖는 질병 상태를 지닌 사람을 치료하는데 유용한 제약 조성물.〈화학식 I〉〈화학식 II〉〈화학식 III〉〈화학식 IV〉상기 식 중,Z1및 Z2는 독립적으로 -O-, -N(R10)- 또는 -OCH2-이고,R1및 R4는 각각 독립적으로 수소, 할로, 알킬, -OR10, -C(O)OR10, -C-(O)N(R10)R11, -N(R10)R11, -N(R10)C(O)R10, 또는 -N(H)S(O)2R13이고,R2는 -C(NH)NH2, -C(NH)N(H)OR10, -C(NH)N(H)C(O)OR13, -C(NH)N(H)C(O)R10, -C- (NH)N(H)S(O)2R13, 또는 -C(NH)N(H)C(O)N(H)R10이고,R3은 할로, 알킬, 할로알킬, 할로알콕시, 우레이도, 시아노, 구아니디노, -OR10, -C(NH)NH2, -C(NH)N(H)OR10, -C(O)N(R10)R11, -R12-C(O)N(R10)R11, -CH(OH)C-(O)N(R10)R11, -N(R10)R11, -R12-N(R10)R11, -C(O)OR10, R12-C(O)OR10, -N(R10)C(O)R10, (1,2)-테트라히드로피리미디닐(임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고,R5는 수소, 할로, 알킬, 시클로알킬, 할로알킬, 아릴, 아랄킬, 알킬티오, 히드록시, 메르캅토, 알콕시, 또는 -N(R10)R11이고,R6은 -(C(R7)(R8))n-R9(여기서, n은 1 내지 4임), 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)인데,여기서, 각 R7은 독립적으로 수소, 알킬, 알케닐, 알키닐, 할로알킬, 할로알케닐, 시클로알킬, 시클로알킬알킬, -C(O)OR10, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -C-(O)-R12-N(R10)R11, -R12-C(O)R10, -R12-C(O)N(R10)N(R10)R11, -R12-C(R10)(OR10)-R12-N(R10)R11, -C(R10)(OR10)C(O)OR11, -R12-C(R10)(C(O)OR10)2, -C(R10)(N(R10)R11)C(O)OR10, -R12-C(R10)(N(R10)R11)C(O)OR10, -C(R10)(OR10)R11, -R12-N(R10)R11, -R12-N(R10)C(O)OR13, -R12-N(R10)C(O)OR11, -R12-N(R10)C(NR10)R13, -R12-N(R10)S(O)2R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12-N(R10)C(NR10)N(R10)N(R10)R11, -R12-N(R10)-R12-C(R10)(N(R10)R11)C(O)OR10, -R12-N(R10)S(O)R11, -R12OR10, -R12-ON(R10)C(NR10)N(R10) R11, -R12-OS(O)2OR10, -R12-P(O)(OR10)R11, -R12-OP(O)(OR10)2, -R12-P(O)(OR10)2, -R12-SR10, -R12-S-R12-C(O)OR10, -R12-S-R12-N(R10)R11, -R12-S-R12-C(R10)(N(R10)R11)C(O)OR10, -R12-S-R12-N(R10)C(O)OR10, -R12-S-R12-N(R10)C(O)R10, -R12-S-S-R12-C(R10)(N(R10)R11)C(0)OR10, -R12-SC(O)N(R10)R11, -R12-SC(S)N(R10)R11, -R12-S(O)R10, -R12-S(O)2R13, -R12-S(O)OR10, -R12-S(O)2OR10, -R12-S(O)2N(R10)R11, -R12-S(O)(NR10)R11이거나,또는 각 R7은 아릴(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아랄킬(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 헤테로시클릴(임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 헤테로시클릴알킬(여기서, 헤테로시클릴 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C-(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아다만틸(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아다만틸알킬(여기서, 아다만틸 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S-(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이고,각 R8은 독립적으로 수소, 알킬, 시클로알킬, 또는 아릴이고,R9는 -C(O)OR10또는 -C(O)N(R10)R11이고,R10및 R11은 각각 독립적으로 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고,R12는 직쇄 또는 분지쇄 알킬렌이고,R13은 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이다.
- 단독 입체 이성질체로서 또는 그의 혼합물로서 화학식 I 내지 화학식 IV의 화합물로 구성된 군으로부터 선택된 화합물, 또는 제약학적으로 허용 가능한 그의 염의 치료적 유효량을 필요로하는 사람에게 투여하는 것을 포함하는, 혈전 활성의 특징을 갖는 질병 상태를 지닌 사람의 치료 방법.〈화학식 I〉〈화학식 II〉〈화학식 III〉〈화학식 IV〉상기 식 중,Z1및 Z2는 독립적으로 -O-, -N(R10)- 또는 -OCH2-이고,R1및 R4는 각각 독립적으로 수소, 할로, 알킬, -OR10, -C(O)OR10, -C-(O)N(R10)R11, -N(R10)R11, -N(R10)C(O)R10, 또는 -N(H)S(O)2R13이고,R2는 -C(NH)NH2, -C(NH)N(H)OR10, -C(NH)N(H)C(O)OR13, -C(NH)N(H)C(O)R10, -C- (NH)N(H)S(O)2R13, 또는 -C(NH)N(H)C(O)N(H)R10이고,R3은 할로, 알킬, 할로알킬, 할로알콕시, 우레이도, 시아노, 구아니디노, -OR10, -C(NH)NH2, -C(NH)N(H)OR10, -C(O)N(R10)R11, -R12-C(O)N(R10)R11, -CH(OH)C-(O)N(R10)R11, -N(R10)R11, -R12-N(R10)R11, -C(O)OR10, R12-C(O)OR10, -N(R10)C(O)R10, (1,2)-테트라히드로피리미디닐(임의로 알킬에 의해 치환됨), (1,2)-이미다졸릴(임의로 알킬에 의해 치환됨), 또는 (1,2)-이미다졸리닐(임의로 알킬에 의해 치환됨)이고,R5는 수소, 할로, 알킬, 시클로알킬, 할로알킬, 아릴, 아랄킬, 알킬티오, 히드록시, 메르캅토, 알콕시, 또는 -N(R10)R11이고,R6은 -(C(R7)(R8))n-R9(여기서, n은 1 내지 4임), 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)인데,여기서, 각 R7은 독립적으로 수소, 알킬, 알케닐, 알키닐, 할로알킬, 할로알케닐, 시클로알킬, 시클로알킬알킬, -C(O)OR10, -R12-C(O)OR10, -R12-C(O)N(R10)R11, -C-(O)-R12-N(R10)R11, -R12-C(O)R10, -R12-C(O)N(R10)N(R10)R11, -R12-C(R10)(OR10)-R12-N(R10)R11, -C(R10)(OR10)C(O)OR11, -R12-C(R10)(C(O)OR10)2, -C(R10)(N(R10)R11)C(O)OR10, -R12-C(R10)(N(R10)R11)C(O)OR10, -C(R10)(OR10)R11, -R12-N(R10)R11, -R12-N(R10)C(O)OR13, -R12-N(R10)C(O)OR11, -R12-N(R10)C(NR10)R13, -R12-N(R10)S(O)2R13, -R12-N(R10)C(O)N(R10)R11, -R12-N(R10)C(NR10)N(R10)R11, -R12-N(R10)C(NR10)N(R10)N(R10)R11, -R12-N(R10)-R12-C(R10)(N(R10)R11)C(O)OR10, -R12-N(R10)S(O)R11, -R12OR10, -R12-ON(R10)C(NR10)N(R10) R11, -R12-OS(O)2OR10, -R12-P(O)(OR10)R11, -R12-OP(O)(OR10)2, -R12-P(O)(OR10)2, -R12-SR10, -R12-S-R12-C(O)OR10, -R12-S-R12-N(R10)R11, -R12-S-R12-C(R10)(N(R10)R11)C(O)OR10, -R12-S-R12-N(R10)C(O)OR10, -R12-S-R12-N(R10)C(O)R10, -R12-S-S-R12-C(R10)(N(R10)R11)C(0)OR10, -R12-SC(O)N(R10)R11, -R12-SC(S)N(R10)R11, -R12-S(O)R10, -R12-S(O)2R13, -R12-S(O)OR10, -R12-S(O)2OR10, -R12-S(O)2N(R10)R11, -R12-S(O)(NR10)R11이거나,또는 각 R7은 아릴(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아랄킬(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -N(R10)R11, -C(O)OR10, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 헤테로시클릴(임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 헤테로시클릴알킬(여기서, 헤테로시클릴 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, 아랄킬, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C-(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아다만틸(임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이거나,또는 각 R7은 아다만틸알킬(여기서, 아다만틸 라디칼은 임의로 알킬, 할로, 할로알킬, 할로알콕시, -OR10, -SR10, -C(O)OR10, -N(R10)R11, -C(O)N(R10)R11, -S-(O)2OR10및 -OP(O)(OR10)2로 구성된 군으로부터 선택된 치환체 1종 이상으로 치환됨)이고,각 R8은 독립적으로 수소, 알킬, 시클로알킬, 또는 아릴이고,R9는 -C(O)OR10또는 -C(O)N(R10)R11이고,R10및 R11은 각각 독립적으로 수소, 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이고,R12는 직쇄 또는 분지쇄 알킬렌이고,R13은 알킬, 아릴(임의로 할로, 알킬, 히드록시, 알콕시, 아랄콕시, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨), 또는 아랄킬(임의로 할로, 알킬, 아릴, 히드록시, 알콕시, 아랄킬, 아미노, 디알킬아미노, 모노알킬아미노, 카르복시, 알콕시카르보닐, 아미노카르보닐, 모노알킬아미노카르보닐, 또는 디알킬아미노카르보닐에 의해 치환됨)이다.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8/689,979 | 1996-08-16 | ||
| US08/689,979 US5753635A (en) | 1996-08-16 | 1996-08-16 | Purine derivatives and their use as anti-coagulants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20000068177A true KR20000068177A (ko) | 2000-11-25 |
Family
ID=24770610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019997001289A KR20000068177A (ko) | 1996-08-16 | 1997-08-14 | 퓨린 유도체 및 항응혈제로서 그의 용도 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5753635A (ko) |
| EP (1) | EP0920430B1 (ko) |
| JP (1) | JP2000516242A (ko) |
| KR (1) | KR20000068177A (ko) |
| CN (1) | CN1096461C (ko) |
| AT (1) | ATE250606T1 (ko) |
| AU (1) | AU722631B2 (ko) |
| CA (1) | CA2262876A1 (ko) |
| CZ (1) | CZ50299A3 (ko) |
| DE (1) | DE69725151T2 (ko) |
| DK (1) | DK0920430T3 (ko) |
| ES (1) | ES2206746T3 (ko) |
| HK (1) | HK1020057A1 (ko) |
| HU (1) | HUP9902308A3 (ko) |
| IL (1) | IL128160A (ko) |
| NO (1) | NO314584B1 (ko) |
| NZ (1) | NZ333895A (ko) |
| PL (1) | PL331608A1 (ko) |
| PT (1) | PT920430E (ko) |
| RU (1) | RU2191778C2 (ko) |
| SK (1) | SK19399A3 (ko) |
| UA (1) | UA57746C2 (ko) |
| WO (1) | WO1998007725A1 (ko) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2214685C (en) | 1995-03-10 | 2008-05-20 | Berlex Laboratories, Inc. | Benzamidine derivatives their preparation and their use as anti-coagulants |
| ATE236161T1 (de) | 1995-11-01 | 2003-04-15 | Novartis Pharma Gmbh | Purinderivate und verfahren zu ihrer herstellung |
| US5994375A (en) | 1996-02-12 | 1999-11-30 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants |
| ZA971896B (en) * | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| KR20000036017A (ko) | 1996-09-12 | 2000-06-26 | 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 | 시클릭 아미노산 및 시클릭 히드록시산 유도체로 치환된 벤즈아 |
| US6004985A (en) | 1996-10-09 | 1999-12-21 | Berlex Laboratories, Inc. | Thio acid derived monocylic N-heterocyclics as anticoagulants |
| US6686364B2 (en) | 1997-12-08 | 2004-02-03 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| US6140351A (en) * | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| IL135536A0 (en) | 1997-12-19 | 2001-05-20 | Schering Ag | Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same |
| US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| US6127376A (en) | 1998-12-04 | 2000-10-03 | Berlex Laboratories, Inc. | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| CA2320730A1 (en) * | 1998-12-23 | 2000-07-06 | Renhua Li | Thrombin or factor xa inhibitors |
| GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| US6350761B1 (en) | 1999-07-30 | 2002-02-26 | Berlex Laboratories, Inc. | Benzenamine derivatives as anti-coagulants |
| NZ528216A (en) * | 2001-02-24 | 2006-12-22 | Boehringer Ingelheim Pharma | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DK1569912T3 (en) | 2002-12-03 | 2015-06-29 | Pharmacyclics Inc | 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors. |
| US7566707B2 (en) * | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE10355304A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
| US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
| US7179809B2 (en) * | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
| US7439370B2 (en) * | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| DE102004043944A1 (de) * | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004044221A1 (de) * | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004054054A1 (de) * | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| EP2057160A1 (en) * | 2006-08-08 | 2009-05-13 | Boehringer Ingelheim International GmbH | Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
| NZ576347A (en) * | 2006-10-27 | 2011-10-28 | Signal Pharm Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| KR101610005B1 (ko) * | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체 |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| EA031225B1 (ru) * | 2008-08-15 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы дпп-4 для заживления ран |
| EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
| JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
| EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| MX366629B (es) | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas. |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
| CN110300590A (zh) * | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| BR112021026410A2 (pt) | 2019-07-01 | 2022-02-08 | Tonix Pharma Ltd | Anticorpos anti-cd154 e usos dos mesmos |
| US20240059781A1 (en) | 2021-01-06 | 2024-02-22 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5922697B2 (ja) * | 1976-01-13 | 1984-05-28 | エーザイ株式会社 | ビス−（メタ−アミジノフエノキシ）−化合物 |
| ZA928276B (en) * | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
| WO1993015756A1 (en) * | 1992-02-14 | 1993-08-19 | Corvas International, Inc. | Inhibitors of thrombosis |
| DE4213919A1 (de) * | 1992-04-28 | 1993-11-04 | Thomae Gmbh Dr K | Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| AU675981B2 (en) * | 1992-12-02 | 1997-02-27 | Bristol-Myers Squibb Company | Guanidinyl-substituted heterocyclic thrombin inhibitors |
| WO1994013693A1 (en) * | 1992-12-15 | 1994-06-23 | Corvas International, Inc. | NOVEL INHIBITORS OF FACTOR Xa |
| US5332822A (en) * | 1992-12-24 | 1994-07-26 | Bristol-Myers Squibb Company | Heteroaromatic and thioheteroaromatic substituted sulfonamide thrombin inhibitors |
| JP3466614B2 (ja) * | 1993-02-12 | 2003-11-17 | コルバス・インターナショナル、インコーポレイテッド | 血栓症のインヒビター |
| IL115420A0 (en) * | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US5994375A (en) * | 1996-02-12 | 1999-11-30 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants |
-
1996
- 1996-08-16 US US08/689,979 patent/US5753635A/en not_active Expired - Fee Related
-
1997
- 1997-08-14 DK DK97938904T patent/DK0920430T3/da active
- 1997-08-14 CA CA002262876A patent/CA2262876A1/en not_active Abandoned
- 1997-08-14 RU RU99105119/04A patent/RU2191778C2/ru not_active IP Right Cessation
- 1997-08-14 SK SK193-99A patent/SK19399A3/sk unknown
- 1997-08-14 PL PL97331608A patent/PL331608A1/xx unknown
- 1997-08-14 NZ NZ333895A patent/NZ333895A/xx unknown
- 1997-08-14 AT AT97938904T patent/ATE250606T1/de not_active IP Right Cessation
- 1997-08-14 CN CN97197270A patent/CN1096461C/zh not_active Expired - Fee Related
- 1997-08-14 PT PT97938904T patent/PT920430E/pt unknown
- 1997-08-14 ES ES97938904T patent/ES2206746T3/es not_active Expired - Lifetime
- 1997-08-14 KR KR1019997001289A patent/KR20000068177A/ko not_active Application Discontinuation
- 1997-08-14 WO PCT/EP1997/004445 patent/WO1998007725A1/en not_active Application Discontinuation
- 1997-08-14 UA UA99031393A patent/UA57746C2/uk unknown
- 1997-08-14 IL IL12816097A patent/IL128160A/xx not_active IP Right Cessation
- 1997-08-14 DE DE69725151T patent/DE69725151T2/de not_active Expired - Fee Related
- 1997-08-14 EP EP97938904A patent/EP0920430B1/en not_active Expired - Lifetime
- 1997-08-14 JP JP10510377A patent/JP2000516242A/ja not_active Ceased
- 1997-08-14 HU HU9902308A patent/HUP9902308A3/hu unknown
- 1997-08-14 CZ CZ99502A patent/CZ50299A3/cs unknown
- 1997-08-14 AU AU41186/97A patent/AU722631B2/en not_active Ceased
-
1999
- 1999-02-12 NO NO19990673A patent/NO314584B1/no not_active IP Right Cessation
- 1999-11-18 HK HK99105313A patent/HK1020057A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0920430A1 (en) | 1999-06-09 |
| ATE250606T1 (de) | 2003-10-15 |
| JP2000516242A (ja) | 2000-12-05 |
| HK1020057A1 (en) | 2000-03-10 |
| IL128160A (en) | 2003-04-10 |
| IL128160A0 (en) | 1999-11-30 |
| NZ333895A (en) | 2000-07-28 |
| HUP9902308A2 (en) | 2000-07-28 |
| CN1228092A (zh) | 1999-09-08 |
| SK19399A3 (en) | 1999-08-06 |
| PL331608A1 (en) | 1999-08-02 |
| CN1096461C (zh) | 2002-12-18 |
| PT920430E (pt) | 2003-12-31 |
| DE69725151T2 (de) | 2004-06-09 |
| DK0920430T3 (da) | 2003-11-17 |
| WO1998007725A1 (en) | 1998-02-26 |
| US5753635A (en) | 1998-05-19 |
| NO990673L (no) | 1999-04-15 |
| CA2262876A1 (en) | 1998-02-26 |
| HUP9902308A3 (en) | 2000-08-28 |
| CZ50299A3 (cs) | 1999-06-16 |
| DE69725151D1 (de) | 2003-10-30 |
| NO314584B1 (no) | 2003-04-14 |
| ES2206746T3 (es) | 2004-05-16 |
| AU722631B2 (en) | 2000-08-10 |
| RU2191778C2 (ru) | 2002-10-27 |
| NO990673D0 (no) | 1999-02-12 |
| AU4118697A (en) | 1998-03-06 |
| EP0920430B1 (en) | 2003-09-24 |
| UA57746C2 (uk) | 2003-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20000068177A (ko) | 퓨린 유도체 및 항응혈제로서 그의 용도 | |
| US5693641A (en) | Bicyclic pyrimidine derivatives and their use as anti-coagulants | |
| US6150382A (en) | Thio acid derived monocyclic n-heterocyclics as anticoagulants | |
| US6008234A (en) | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants | |
| US6232325B1 (en) | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatves and their use as anti-coagulants | |
| AU715992B2 (en) | Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |